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ABSTRACT 
 
This thesis explores the roles of the gut hormones Peptide YY (PYY) and glucagon-like 
peptide 1 (GLP-1) in the modulation of human brain reward pathways utilising 
functional magnetic resonance imaging (fMRI). 
 
PYY and GLP-1 are co-released post-prandially and both have been shown to reduce 
appetite and inhibit food intake when administered to humans.  They have the 
potential to be developed into anti-obesity therapies, with the expectation that low-
dose combination therapy may provide more effective weight loss and limited side 
effects.  There are currently no safe and effective medications available to treat 
obesity, and yet this global health crisis continues unabated.  In this context, a study 
of the mechanisms by which gut hormones exert their anorectic effects, may guide 
the rational development of new drugs. 
 
To date, the effects of GLP-1 alone and the ways in which PYY and GLP-1 combine to 
modulate brain activity in humans are unknown.  This thesis contains a set of 
functional MRI experiments designed to determine these effects in healthy, fasted, 
normal-weight human subjects. Results are compared with the changes in brain 
activation patterns observed physiologically following a meal.   
 
For the first time in humans, I have demonstrated that, in conjunction with a 
comparable effect on lunchtime energy intake, combined infusion of PYY3-36 and 
GLP-17-36amide to fasted subjects results in a similar modulation of brain activity as 
observed following a large breakfast.  This supports the proposal that these 
hormones are major physiological mediators of satiety in humans. Both the fed state 
and the administration of anorectic gut hormones to fasted subjects, reduces 
activation in multiple brain reward regions in response to visual food-cues.  This 
confirms that circulating gut hormones modulate the hedonic processing of food.  
The lack of any obvious differential activation pattern between PYY3-36 and GLP-17-
36amide raises the possibility that they act at corticolimbic structures via a final 
common pathway.  
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1.1  The Problem of Obesity 
 
The problem of obesity has become a critical and global health concern. In 2005 the 
World Health Organisation estimated that 1.6 billion adults worldwide were 
overweight [body mass index (BMI) 25 to 30 kg/m2] and at least 400 million obese 
[BMI >30kg/m2].  By 2015 this is projected to rise to 2.3 billion and over 700 million 
respectively (WHO, 2006).  In the UK in 2010, 26.1% of all adults (aged over 16 years) 
and 16% of all children were classified as obese (Health Survey for England data, UK 
Department of Health). The medical costs associated with treatment of obesity-
related diseases in the NHS are estimated to increase by £1·9–2 billion/year by 2030 
(Wang et al., 2011). 
It is well established that overweight and obesity are independently linked to an 
increased risk of cardiovascular disease, and contribute to pre-established risks such 
as hypertension and dyslipidaemia (Dhaliwal and Welborn, 2009, Dyer et al., 1990).  
Obesity is the most important risk factor for the development of Type 2 diabetes 
mellitus, with all of its attendant risks of macrovascular disease, limb loss, blindness 
and renal failure (Colditz et al., 1995).  Obesity has also been causally linked to 
numerous cancers, obstructive sleep apnoea, musculoskeletal disorders, infertility, 
depression and many other morbidities (Kopelman, 2000).  The most recent 
epidemiological analysis suggests a reduction in life expectancy of 0.66 years for 
every BMI increase of 2 kg/m2 (Stewart et al., 2009). 
 
The fundamental cause of overweight and obesity is an imbalance between calories 
consumed and calories expended.  In normal adults, body weight remains relatively 
constant over decades, despite large short-term fluctuations in food intake and 
energy expenditure.  Central energy-homeostasis mechanisms sense deviations in 
nutrient intake or energy stores and act to conserve body weight at a set point, by 
altering metabolic rate or the sensation of hunger.  Overlaid on this is a higher brain 
reward network, aimed at reinforcing behaviours associated with a survival 
advantage, such as food consumption, by making them pleasurable. This central 
14 
 
control of appetite is achieved through a complex neural and hormonal signalling 
network which, according to the “thrifty gene” hypothesis, evolved over millions of 
years of relative food shortage and is therefore optimised towards energy 
conservation (Ravussin and Bogardus, 2000, Weinsier et al., 1998).  Set against this 
backdrop of physiological mechanisms designed to resist food deprivation, the global 
environmental shift towards readily-available energy-dense foods and sedentary 
lifestyles is fuelling the obesity pandemic. 
 
Lifestyle changes to reduce energy intake and increase energy output can promote 
weight loss, but the “obesogenic” forces of modernisation have proven much more 
difficult to overcome (Rennie and Jebb, 2005).  For most people, their weight-loss 
solution is not as simple as “eating less” and “moving more”. This urges scientists 
toward a better understanding of the regulation of human eating behaviour and 
energy homeostasis, with the aim of developing new therapies to treat obesity. 
 
 
1.2  Current Obesity Treatments 
 
1.2.1  Lifestyle 
 
There is compelling evidence that weight loss can reverse or attenuate many of the 
health consequences of obesity and improve life expectancy. A retrospective 
matched cohort study of obese subjects undergoing weight loss surgery, revealed a 
40% reduction in all-cause mortality, 92% reduction in diabetes deaths, 56% 
reduction in coronary artery disease deaths and a 60% reduction in cancer deaths 
secondary to weight loss (Adams et al., 2007, Adams et al., 2009). 
 
Unfortunately, lifestyle interventions alone rarely result in long term weight loss and 
the vast majority of dieters return to baseline weight within 3-5 years (Weiss et al., 
2007).  Even patients enrolled in randomised controlled trials have difficulty adhering 
to weight-reducing diets and typically achieve only very modest weight loss 
(Dansinger et al., 2005). 
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1.2.2  Medical Therapies 
Since even small, sustained reductions in weight can significantly improve 
cardiovascular risk (Pi-Sunyer et al., 2007), the US Food and Drug Administration 
(FDA) guidance for the approval of weight loss drugs recommends a 5% placebo-
corrected weight reduction that should be maintained for at least 12 months after 
treatment initiation.  With a target population for drug therapy set at BMI >30 (or 
>27 with co-morbidities), there is a huge market for weight-loss drugs.  However, 
there is currently only one licensed drug in the UK for the long term treatment of 
obesity - orlistat. 
Orlistat (Xenical, Roche Pharmaceuticals) irreversibly inhibits intestinal lipases 
required to hydrolyse dietary triglycerides into free fatty acids (FFAs), and so up to 
30% of ingested fat is not absorbed.  This is the reason for the most common adverse 
events, gastrointestinal discomfort and faecal urgency.  Meta-analysis of clinical 
trials indicate a mean weight loss for orlistat-treated patients of 2.89 kg above 
placebo over 12 months (Rucker et al., 2007). This mix of modest weight loss and 
often intolerable side effects leads to high attrition rates in users.  One survey of 
17,000 orlistat users reported rates of ongoing use of less than 10% at one year and 
2% at two years (Padwal et al., 2007).   
 
The history of weight-loss drugs is now littered with examples of agents which have 
been withdrawn due to dangerous side effects.  In general, such drugs have either 
caused an increase in energy expenditure via increased autonomic tone, resulting in 
raised cardiovascular risk, or have non-specifically targeted brain reward systems, 
resulting in negative side effects on mood and cognition.  The major examples are 
sibutramine and Rimonabant, which are briefly discussed here. 
 
Sibutramine (Reductil, Abbott Laboratories) is a selective noradrenaline and 
serotonin re-uptake inhibitor (SNRIs), which centrally modulates appetite and also 
increases energy expenditure through sympathetic activation.  Meta-analysis 
16 
 
revealed an average placebo-corrected weight loss of 4.5 kg in patients taking the 
drug and it gained widespread approval in the late 1990s (Rucker et al., 2007).  A 
decade later, interim analysis of the Sibutramine Cardiovascular Morbidity/Mortality 
Outcomes in Overweight or Obese Subjects at Risk of a Cardiovascular Event (SCOUT) 
trial, revealed a 16% increased risk of cardiovascular events in the sibutramine-
treated group (James et al., 2010).  By late 2010 the drug had been withdrawn from 
both the US and European markets. This followed in the wake of the withdrawal of 
Rimonabant from the European market in 2008. Rimonobant (Acomplia, Sanofi-
Aventis), a selective cannabinoid (CB1) receptor antagonist, had weight reducing 
effects via hedonic modulation of food intake in higher reward centres as well as 
interaction with the hypothalamic circuitry governing the homeostatic regulation of 
appetite.  In clinical trials, Rimonobant was associated with a 6.6 kg greater weight 
loss over placebo after a year (Van Gaal et al., 2005). However, within 2 years of 
post-marketing surveillance in Europe, it was withdrawn due to the discovery of an 
increased risk of depression and suicide in those taking the drug.  It never received 
FDA approval for usage in the US.   
 
In the light of these serious failures, anti-obesity agents currently in development are 
facing far more stringent pre-approval assessment.  The FDA has recently considered 
two new anti-obesity agents, following resubmissions from their manufacturers 
citing extra safety data or more restrictive prescribing guidance.  The first is a 
combination of the amphetamine-like drug phentermine and the anticonvulsant 
topiramate (Qnexa, Vivus).  Phase 3 trials have reported very impressive weight loss 
benefits of 14.2 kg over a year versus placebo (Gadde et al., 2011).  However, there 
is also a significant increase in cognitive disturbance and an elevation in heart rate 
seen with the drug, as well as evidence of teratogenicity limiting its use in women of 
childbearing potential.  The 5-HT2c receptor agonist Lorcaserin (Arena 
Pharmaceuticals) has been shown to produce more modest weight loss benefits of 
4.7 kg over a year against placebo, but was associated with a significantly increased 
incidence of heart valvulopathy (Smith et al., 2010). 
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1.2.3  Bariatric Surgery 
 
At present, the most effective means of significant and sustained weight loss for 
obese patients is bariatric surgery.  It is also the only treatment that has been shown 
to reduce mortality (Adams et al., 2007, Sjostrom et al., 2007).   
 
Broadly speaking, there are two major types of surgical intervention.  Gastric 
banding involves the insertion of an adjustable band around the upper portion of the 
stomach.  The degree of constriction can be varied.  Weight loss is achieved by 
limiting the quantity of food that can be comfortably ingested and by increasing 
satiety (Dixon et al., 2005).  Roux-en-Y gastric bypass (RYGB) involves the formation 
of a small stomach pouch and bypass of the proximal small bowel, with an end-
anastomosis of the jejunum to the small gastric pouch. The bypassed remnant drains 
via jejuno-jejunostomy, so that duodenal and pancreatic secretions can still enter the 
remainder of the small bowel. The RYGB was originally designed to cause 
malabsorption as well as restricting stomach size. However, the modern procedure 
allows a sufficient distance of small bowel to remain for fully efficient absorption.  
Nevertheless, RYGB results in much more weight loss (in the order of 30% of body 
mass loss) than restrictive procedures such as banding alone (around 20% loss) 
(Sjostrom et al., 2004, Olbers et al., 2006).  The RYGB is associated with other 
benefits too. After RYGB, patients reduce their relative intake of fat and refined 
carbohydrates (Halmi et al., 1981, Kenler et al., 1990) and have a reduced preference 
for sweet foods (Miras et al., 2012), whereas following banding procedures, patients 
display a greater preference for high-energy liquid foods such as milk-shakes (Brolin 
et al., 1994, Olbers et al., 2006). Secondly, RYGB results in a rapid improvement in 
insulin secretory function and often a resolution of Type 2 diabetes, well before 
significant weight loss has occurred (Kellum et al., 1990, Rubino et al., 2004, 
Wickremesekera et al., 2005). 
 
These advantages of RYGB are thought to be partly due to an alteration in the 
release profile of appetite-inhibiting gut hormones, such as glucagon-like peptide-1 
(GLP-1) and peptide YY (PYY), the post-prandial levels of which have been shown to 
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be elevated following gastric bypass surgery but not after gastric banding (le Roux et 
al., 2006a, Borg et al., 2006). The incretin effect of GLP-1, which acts at pancreatic 
beta cells to augment glucose-dependent insulin release, could explain some of the 
observed improvement in glucose tolerance.  More recent studies have also 
highlighted a vagally-mediated effect to reduce hepatic glucose output following the 
altered delivery of nutrients to the jejunum in bypass models (Breen et al., 2012). 
 
However, bypass surgery is costly, in many cases irreversible and associated with 
significant surgical and anaesthetic risks, including a 0.5% mortality rate (Marsk et 
al., 2008).  Despite recent calls for the procedure to be extended to leaner patients 
as a treatment for Type 2 diabetes and to perform the procedure early after 
diagnosis, when the chances of long term remission of diabetes are greater (Rubino 
et al., 2010), the balance of risks and benefits may not ultimately favour surgery for 
patients with less severe obesity.  Furthermore, limitations in financial and human 
resources restrict its availability, even for those with most to gain.  
 
There is therefore a huge incentive to develop safe pharmacological alternatives to 
surgery and the tantalising potential of achieving long-term weight loss using 
medicines based on gut hormones.  There is a clear need to improve our 
understanding of the pathophysiology of obesity and, in particular, the mechanisms 
by which gut hormones influence appetite, in order to guide the rational 
development of new drugs. 
 
 
1.3  Central Energy Balance and the Control of Appetite 
 
The systems governing food intake may be simplistically divided into “homeostatic” 
and non-homeostatic, or “hedonic”.  Energy homeostasis refers to the subconscious 
stabilization of body weight, by the transmission of information about the body’s 
energy status and the reciprocal modulation of appetite and metabolism.  However, 
palatability (flavour and appearance), social and emotional influences affect food 
intake in a manner which may over-ride these homeostatic mechanisms.  The non-
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homeostatic control of food intake is largely modulated by brain reward pathways, 
strongly influenced by past experience (memory and learning).  Although 
traditionally studied and described in greater detail here as two separate entities, 
the modern viewpoint is that these homeostatic and non-homeostatic pathways are 
in fact part of an overlapping appetitive network (Harrold et al., 2012).  This is 
schematically illustrated in Figure 1.1. 
 
1.3.1  Homeostatic Mechanisms Modulating Food Intake 
 
The crucial areas of the brain co-ordinating energy and body-weight homeostasis are 
the brainstem and hypothalamus.  Here, neural afferents and hormonal signals 
carrying peripheral information about the body’s energy stores and nutrient 
availability are integrated to regulate appetite and control energy expenditure 
(Schwartz et al., 2000).    
 
1.3.1.1  The Brainstem 
 
The brainstem is continuous with the spinal cord caudally.  Visceral vagal afferents 
terminate in its nucleus of the tractus solitarius (NTS).  The NTS together with the 
adjacent area postrema (AP) and dorsal motor nucleus of the vagus, comprise the 
dorsal vagal complex (DVC) (Fry et al., 2007).  The AP is a circumventricular organ, a 
select area within the CNS containing highly fenestrated microvasculature, which 
effectively keeps it outside of the blood-brain-barrier (BBB) and therefore a target 
for circulating hormones (Johnson and Gross, 1993).  The AP and NTS share 
reciprocal innervations.  Thus the DVC plays a fundamental role in relaying sensory 
and metabolic information from the periphery to the remainder of the CNS.     
 
1.3.1.2  The Hypothalamus 
 
Alongside numerous other homeostatic functions including thermoregulation, 
osmoregulation and coordination of the neuroendocrine axis, the hypothalamus has 
a central role in maintaining energy balance. It is situated symmetrically around the 
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midline in the floor and walls of the third ventricle.  Over forty distinct hypothalamic 
nuclei and subnuclei have been identified, along with extensive intra- and 
extrahypothalamic projections (Berthoud, 2002).  Broadly speaking, each half of the 
hypothalamus may be divided in the coronal plane into periventricular, medial and 
lateral areas. The hypothalamus is in close proximity to and shares extensive 
neuronal connections with another circumventricular organ, the median eminence, 
enabling it to respond rapidly to circulating factors.  The action of peripheral signals 
of energy balance on the hypothalamus to control food intake forms an important 
focus of current appetite research. 
 
The modern integrated hypothesis of central energy homeostasis centres on the 
crucial role of the arcuate nucleus of the hypothalamus (ARC).   This periventricular 
structure lies particularly close to the median eminence. Two discrete sets of 
neuronal populations have been described within the ARC which are thought to act 
in concert to regulate appetite.  Orexigenic neurones (ie those stimulating food 
intake) in the medial ARC express neuropeptide Y (NPY) and Agouti-related protein 
(AgRP).  Anorexigenic neurones (ie those inhibiting food intake) in the lateral ARC 
express alpha-melanocyte-stimulating hormone (α-MSH) derived from pro-
opiomelanocortin (POMC), and cocaine- and amphetamine-regulated transcript 
(CART) (Cone et al., 2001).  The relative tone of orexigenic and anorexigenic 
hypothalamic neurones is delicately altered by numerous neuroendocrine inputs 
(Figure 1.1).  The ARC projects efferents to the paraventricular nucleus (PVN) of the 
hypothalamus where responsive effects on energy expenditure arise, including 
changes in basal metabolic rate (via the thyroid axis), sympathetic outflow and 
thermoregulation (Cowley et al., 1999). The ARC also shares dense, reciprocal neural 
connections with the dorsal vagal complex of the brainstem (ter Horst and Luiten, 
1986).   
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Figure 1.1:   Schematic of the Neuroendocrine Network of Appetite Control.  
Circulating adipostat hormones, which signal long-term energy stores, and prandially 
released gut hormones, which signal short term nutrient status, are able to directly 
influence neuronal activity in key brain areas involved in energy homeostasis, the 
brainstem and hypothalamus.  Circulating gut hormones [such as peptide YY (PYY), 
glucagon-like peptide 1 (GLP-1), cholecystokinin (CCK), pancreatic polypeptide (PP), 
oxyntomodulin (OXM) and ghrelin] modulate gastrointestinal vagal sensory input 
into the brainstem.  They may also directly access the brainstem’s nucleus of the 
solitary tract (NTS) and hypothalamic arcuate nucleus (ARC) via areas deficient in 
blood brain barrier [the area postrema (AP) and median eminence (ME)].  Two major 
subpopulations of neuron in the ARC influence appetite.  Those which co-express 
neuropeptide Y (NPY) and Agouti-Related Protein (AgRP) are orexigenic, whereas 
those co-expressing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-
regulated transcript (CART) are anorexigenic.  AgRP antagonizes the effects of the 
POMC product, α-melanocyte-stimulating hormone (α-MSH).  Orchestrated within 
corticolimbic brain structures and superimposed on this homeostatic system of 
appetite control, are hedonic reward drives stimulated by sensory cues and possibly 
directly modulated by circulating factors too. 
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1.3.2  Non-Homeostatic Mechanisms Modulating Food Intake 
 
A fuller description of appetite regulation must make mention of how higher brain 
areas associated with reward, motivation, learning and memory interact with 
homeostatic drives.  Food consumption is said to be rewarding, in other words it 
produces positive emotions that augment the drive to obtain it.  In this setting, the 
salience of an object (or image or situation) is how much it stands out or how 
emotionally arousing it is.  Saliency detection is important for focusing the brain’s 
limited cognitive resources on the most pertinent of environmental stimuli, and 
facilitates learning. 
 
In general, reward is divided into two major psychological processes:  “liking” 
(hedonic impact) and “wanting” (incentive salience). 
 
The hedonic impact of an object describes its attractiveness.  The concept of reward 
is generally understood as the subjective sensation of pleasure.  However, pleasure 
is not merely contained in the intrinsic sensation of the stimulus, but the evolved 
ability of that stimulus to activate brain “liking” systems.   It can be shown that 
hedonic stimuli can subconsciously provoke implicit “liking” reactions (such as 
positive facial expressions in response to sweet taste) which can be measured 
physiologically.  Furthermore, it is possible to pharmacologically manipulate this 
hedonic response.  In rats, microinjection of mu opioid receptor antagonists into a 
part of the nucleus accumbens (a corticolimbic brain reward structure) increases the 
objective “liking” response to sweet taste without altering reward seeking behaviour 
(Pecina and Berridge, 2005).  In short, the nucleus accumbens (NAcc) contains a 
‘hedonic hotspot’ where neuronal activity is purely correlated with pleasure 
perception. 
 
However, “liking” without “wanting” is simply a triggered affective state. Hence 
pleasure must be translated into “wanting” in order for reward to influence 
behaviour. “Liking” is closer to a sensory process, “wanting” to motor action and 
both are needed together for full reward. 
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In this context, “wanting” is termed incentive salience, and describes the type of 
motivation that promotes approach toward and consumption of a reward.  Incentive 
salience should be distinguished from more conscious forms of desire. Our general 
understanding of the word wanting requires the definition of a goal or expected 
outcome.  Instead, incentive salience can be subconscious and, as in the case of 
addiction, can occur even when cognitively the desire is understood to be irrational 
or unsafe (Berridge et al., 2009).   
 
Past experience with specific foods forms an important contributor to the reward 
process.  Learning entrains conditioned stimuli, which predict the availability and 
motivational value of reward and in time themselves become triggers of incentive 
salience. In humans, vivid imagery of food is one such potent cue and simply 
imagining food can also elicit cravings (Tiggemann and Kemps, 2005).  It is believed 
that cue triggered urges incrementally contribute to long term overconsumption and 
ultimately obesity.  
  
1.3.2.1  Corticolimbic Regions of Interest Related to Food Reward Processing 
 
The neural correlates of the reward system are still being delineated.  Incentive 
salience depends largely on a widespread network of subcortical mesolimbic 
dopamine neurotransmission, with important structures including the dorsal and 
ventral striata (Ikemoto, 2007).  The coding of the reward value of sensory cues 
depends more on cortical brain areas such as the insula and orbitofrontal cortex 
(OFC) (Kringelbach, 2005).  In contrast, current knowledge suggests that hedonic 
valence is neurologically organized as islands of mu-opioid and cannabinoid receptor 
neurones, such as the hotspot previously described within the nucleus accumbens. 
The specific brain reward regions studied in this work are described in more detail 
below. 
 
 
 
24 
 
1.3.2.2  Amygdala 
 
The amygdala is a deep cortical structure located within the anterior lobe. It has 
strong connections with the orbitofrontal, prefrontal and visual cortices, the insula 
and nucleus accumbens (Amaral and Price, 1984, Morgane et al., 2005). It has a 
complicated neuronal structure and, as part of the limbic system, is involved in 
emotion, reward, motivation, learning, memory and attention (Murray, 2007).  More 
specifically in the setting of reward processing, the amygdala encodes the emotional 
intensity of both pleasant and aversive stimuli (Baxter and Murray, 2002, Zald, 2003).  
Functional imaging research has shown that the amygdala is reliably activated when 
viewing or tasting food (LaBar et al., 2001, Killgore et al., 2003, Fuhrer et al., 2008, 
Stoeckel et al., 2008, Goldstone et al., 2009). 
 
1.3.2.3  Nucleus Accumbens (NAcc) 
 
The NAcc comprises the main part of the ventral striatum and is a member of the 
basal ganglia.  It has a rich dopaminergic innervation originating from the midbrain 
and is highly involved in reward processing and addiction.  It is particularly activated 
by the perception of pleasant, emotionally arousing scenes. Whereas amygdala 
activation correlates with salience per se (positive or negative), the NAcc is 
selectively activated by stimuli with hedonic valence (Sabatinelli et al., 2007).  In the 
field of appetitive functional imaging, NAcc activity correlates positively with 
subjective liking ratings of food images in fasted healthy human volunteers (Farooqi 
et al., 2007). 
 
1.3.2.4  Orbitofrontal Cortex (OFC) 
 
The OFC lies on the ventral surface of the frontal part of the brain.  The human OFC 
plays an important role in encoding food reward. Numerous sensory pathways 
carrying olfactory, visual, gustatory, and somatosensory information converge on the 
OFC, where monitoring, learning and memory of the reward value of sensory cues is 
performed.  In line with this, the OFC is closely connected with the hippocampus and 
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other paralimbic structures involved with memory (Verhagen and Engelen, 2006).  
Neuroimaging studies frequently implicate the OFC in processing the reward value of 
food images in the fasted state (Small et al., 2007, Porubska et al., 2006, Stoeckel et 
al., 2008, Schur et al., 2009).  The observation that OFC activation decreases with 
sensory-specific satiety (when food is repeatedly consumed to a state of aversion) 
supports its particular role in encoding reward value (Kringelbach and Rolls, 2004).  
 
1.3.2.5  Insula  
 
The insula cortex is a cortical structure spanning the temporal and frontal lobes.  It is 
an important gustatory centre, involved in both sensory and reward taste 
processing, as well as modulating taste aversion (Welzl et al., 2001, James et al., 
2009).  The insula receives visceral sensory information from the brainstem and 
projects to the OFC, NAcc and amygdala.  Functional MRI studies confirm its role in 
gustatory processing (Kida et al., 2011) but human fMRI studies also reveal increased 
activation in the insula in response to many other food cues (St-Onge et al., 2005, 
Porubska et al., 2006, Fuhrer et al., 2008, Stice et al., 2008, Schur et al., 2009, Siep et 
al., 2009). 
 
1.3.2.6  Caudate and Putamen 
 
The caudate and putamen are two connected structures which together comprise 
the dorsal striatum. They are the main input nuclei of the basal ganglia, receiving 
convergent afferents from nearly all parts of the cortex.  Historically they have been 
studied for their role in coordinating motor functions, but there is now mounting 
evidence for parallel cognitive functions (Grahn et al., 2008).   
 
The caudate nucleus in particular coordinates incentive salience and goal-directed 
behaviours, particularly where the outcome is perceived as desirable (Balleine and 
O'Doherty, 2010).  Human fMRI studies correlate caudate activity during gustatory 
stimulation with subsequent hedonic evaluation and reveal that the caudate can be 
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activated by the expectation of preferred foods (Arana et al., 2003, Pelchat et al., 
2004). 
 
The putamen has a greater role in stimulus-response-outcome learning (Haruno and 
Kawato, 2006).  In human fMRI studies, putamen activity correlates with the 
acquisition of learned associations (Tricomi et al., 2009) and is also modulated by 
subjective ratings of appetite (Porubska et al., 2006). 
 
There are dense interconnections between the hypothalamus and all of these 
mesolimbic/cortical reward systems.  Exactly how the regulatory (hypothalamic) and 
reward (corticolimbic) centres interact with one another in the overall control of 
appetite remains to be fully understood.  “Hedonic eating” can override the satiety 
effect of positive energy balance signals within the hypothalamus (Saper et al., 
2002).  Conversely, hunger can enhance food reward, in part mediated by 
hypothalamic projections of orexin neurones on to the nucleus accumbens (Harris et 
al., 2005). The latest research, supported by finding in this thesis, suggests that 
circulating satiety hormones, originally discovered for their effects on the brainstem 
and hypothalamus, can modulate hedonic circuitry too (Malik et al., 2008, Batterham 
et al., 2007, Farooqi et al., 2007, Dickson et al., 2012). 
 
 
1.4  Peripheral Signals Regulating Food Intake 
 
Peripheral neural and hormonal feedback signals to the brain transmitting 
information about the body’s energy status are complex and incompletely 
understood.  In general, the vagus nerve serves as the neural component of the gut-
brain axis, conveying information about mechanical distension and the chemical 
poroperties of gut luminal contents. Peptide gut hormones released around a meal 
relay information about acute fluctuations in nutritional status, whereas adipostat 
hormones, related to fat stores, provide information about longer-term energy 
needs (Figure 1.1).  
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1.4.1  Adipostat Factors 
 
The observations that dieting and experimental overfeeding induce compensatory 
responses that tend to restore adiposity to baseline levels are consistent with the 
adipostat theory, or a set point for the homeostatic control of body fat mass (Havel, 
2001).  The major adipostat hormones are insulin, which has known centrally 
mediated anorectic effects  and average circulating levels which correlate with fat 
mass (Woods and Seeley, 2001), and leptin, described in greater detail below. 
 
1.4.1.1  Leptin 
 
The hormone leptin, protein product of the obese (ob) gene (Zhang et al., 1994), is 
synthesised in white adipose tissue and circulates at concentrations proportional to 
body fat mass (Maffei et al., 1995). Leptin stimulates anorexigenic neurones and 
inhibits orexigenic neurones in the ARC. CNS and peripheral administration of leptin 
to rodents results in inhibition of food intake and decreased body weight (Friedman 
and Halaas, 1998).  Conversely, administration of leptin during food restriction 
delays other neuroendocrine responses to starvation (Ahima et al., 1996). Thus, 
leptin is thought to act as a signal of adequate fat stores, with declining levels 
indicating the onset of negative energy balance. 
 
The ob/ob mouse is completely leptin-deficient.  The behavioural response to 
perceived starvation in these animals is profound hyperphagia and resultant obesity.  
Administration of exogenous leptin to ob/ob mice results in normalisation of food 
intake and body weight (Halaas et al., 1995, Pelleymounter et al., 1995).  Human 
cases of severe obesity secondary to leptin deficiency are extremely rare but, where 
identified, have been successfully treated with recombinant leptin, with the principal 
effect a reduction in hyperphagia (Farooqi et al., 1999). 
In contrast, the vast majority of obese patients are appropriately hyperleptinaemic 
and yet continue to maintain high body fat stores. Treating obese, non-leptin 
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deficient patients with leptin achieves only modest weight loss (Zelissen et al., 2005).  
This state of “leptin resistance” remains poorly understood.  Several mechanisms 
may contribute to the phenomenon. The two most credited hypotheses are a failure 
in the transport of circulating leptin to its targets in the brain (Banks and Farrell, 
2003) or downregulation of the intracellular components of the leptin receptor 
signalling cascade (Munzberg and Myers, 2005).  Thus the discovery of leptin 
produced a huge step in our understanding of energy homeostasis but as yet shows 
little promise as a therapeutic agent for obesity. 
 
1.4.2  Gut Hormones 
Adipostat factors act as signals of long-term energy stores but energy consumption 
can also be centrally modulated on a meal-by-meal basis by peptide hormones 
released from the gut.  Control of meal size is largely determined by the onset of 
satiety. There are a number of postprandially secreted hormones, including Peptide 
YY (PYY), Glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), cholecystokinin 
(CCK) and pancreatic polypeptide (PP), which enhance the sensation of satiety.  
Conversely, ghrelin is the only known gut hormone to stimulate ingestive behaviour, 
with peak circulating levels measurable in the fasting state. The two anorectic gut 
hormones investigated in this project, PYY and GLP-1, are presently discussed in 
greater detail. 
 
 
1.4.2.1  Peptide YY (PYY) 
 
PYY is a 36 amino acid peptide hormone originally isolated from porcine intestine 
and named for the presence of a tyrosine residue at each terminal (Tatemoto and 
Mutt, 1980).  It is produced in the enteroendocrine L cells of the gastrointestinal 
mucosa (Rindi et al., 2004).  PYY is released into the circulation within 15 minutes of 
ingestion of a meal in proportion to the number of calories ingested.  Plasma levels 
peak 1-2 hours later and remain elevated for up to 6 hours (Adrian et al., 1985). 
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The major circulating form of PYY is PYY3-36.  It is formed following cleavage of the 
amino-terminal tyrosine-proline dipeptide of PYY1-36 by the ubiquitous enzyme 
dipeptidyl peptidase IV (DPP-IV) (Eberlein et al., 1989, Mentlein et al., 1993).  PYY3-36 
is considered the active circulating form of the hormone, and is much more potent at 
reducing food intake or delaying gastric emptying in rodents than PYY1-36 (Chelikani 
et al., 2004).  As with other members of the PP-fold family of peptides [namely, 
neuropeptide Y (NPY) and pancreatic polypeptide (PP)], PYY binds to the Y-family of 
G-protein-coupled receptors.  PYY3-36 has a selective (nanomolar) affinity to the Y2 
receptor (Y2R) (Berglund et al., 2003). 
 
Endogenous PYY has long been understood to affect gastric motility and secretion, 
conceptualised as the mediator of the “ileal brake”, which decelerates gastric 
emptying in response to the arrival of nutrients in the distal small bowel (Pappas et 
al., 1985, Savage et al., 1987). This paracrine effect to delay gut transit time is partly 
responsible for the sensation of satiety that is induced by the hormone.  
 
More recently, PYY has additionally been shown to act in a neurohumoral manner on 
CNS appetite control centres.  PYY3-36 is now accepted as an appetite-inhibitory 
hormone based on the following evidence:  peripherally administered PYY3-36 at 
physiological concentrations results in a marked acute inhibition of food intake in 
multiple species (Batterham et al., 2002, Halatchev et al., 2004, Chelikani et al., 2006, 
Pittner et al., 2004, Koegler et al., 2005);  peripheral injection of PYY3-36 increases c-
fos expression, a marker of neuronal activation, in the arcuate nucleus of the 
hypothalamus (ARC) and low dose PYY3-36 administered directly into the ARC has an 
anorectic effect in rats (Batterham et al., 2002);  peripherally administered 
radiolabelled PYY3-36 binds at the median eminence in the CNS (Dumont et al., 2007), 
supporting the notion that circulating PYY gains access to the hypothalamus via this 
circumventricular organ.  In addition, PYY knockout mice are hyperphagic and obese, 
a phenotype which is reversed by exogenous replacement of the hormone, strongly 
supporting its physiological role in the control of food intake (Batterham et al., 
2006).  Y2 receptors probably mediate the actions of PYY3-36:  Y2 receptor-knockout 
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mice are unresponsive to the hormone (Batterham et al., 2002), and pre-treatment 
with a selective Y2 receptor antagonist, either by intra-ARC injection (Abbott et al., 
2005b) or by IP injection (Talsania et al., 2005), abolishes the anorectic effects of 
PYY3-36 in wild types. 
 
In humans who have been previously fasted from the day before, food intake at a 
buffet lunch was reduced by 36% following an intravenous infusion of PYY3-36 that 
achieved plasma levels similar to those measured physiologically after a meal 
(Batterham et al., 2002).  PYY may indeed be involved in the pathogenesis of obesity 
in humans. Obese subjects have been reported as having significantly lower levels of 
PYY compared to people with a normal BMI.  This finding has not always been 
reproduced, although others have reported a blunted postprandial release of PYY3-36 
in obese patients (Stock et al., 2005, le Roux et al., 2006b).  Importantly, there is no 
suggestion that, as for leptin, obesity is a PYY-resistant state (Pfluger et al., 2007). In 
a separate study, exogenous infusion of PYY3-36 resulted in a reduction in food intake 
by 30% in an obese group and 31% in a group of subjects with normal BMI 
(Batterham et al., 2003). 
 
Chronic exogenous administration of PYY3-36 to humans has not been reported.  
However, chronic administration to rodents has not always produced long lasting 
anorectic effects (Chelikani et al., 2006, Pittner et al., 2004, Reidelberger et al., 
2008), although there is some suggestion that the ongoing effects of PYY are masked 
by counter-regulatory mechanisms to prevent excessive body weight loss 
(Unniappan and Kieffer, 2008).  Nevertheless, there remains significant interest in 
the therapeutic potential of PYY as a weight-loss agent with the observation that 
basal and post-prandial levels are elevated in obese patients that have lost weight 
and experience altered taste preference following Roux-en-Y gastric bypass surgery 
(le Roux et al., 2006a, Miras et al., 2012).  In line with this, some gastrointestinal 
diseases associated with appetite and weight loss are also characterized by elevated 
PYY levels (El-Salhy et al., 2002).  
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Nastech and Merck developed a nasally administered form of human PYY3-36 to be 
taken with each meal, which reached phase 2 clinical trials in 2007.  The study was 
terminated after 24 weeks because of significant drop-out rates due to nausea and 
vomiting, which is a well described dose related adverse effect of PYY (and all other 
anorectic gut hormones) (Gantz et al., 2007).  It remains unclear to what extent the 
anorectic and nauseating effects of gut hormones are independent processes.  
However, it is generally understood that satiety in humans involves a spectrum of 
experience (ranging from extreme hunger at one end, through the onset of satiation 
during a meal, to feelings of fullness and then nausea at the other end), which is 
mirrored by the circulating concentrations of anorectic gut hormones.  In the Merck 
nasal PYY study the maximum plasma PYY concentration achieved was 105 pmol/L, 
which is much higher than the normal postprandial level of 50 pmol/L.  Furthermore, 
the time taken to reach this peak concentration was 18-26 minutes - much shorter 
than the slower and sustained physiological post-prandial rise.  Thus the high drop-
out due to nausea and the failure of nasal PYY to induce longer term appetite 
reduction and weight loss may have been due to the pharmacokinetics of this mode 
of delivery.   
 
 
1.4.2.2  Glucagon-like Peptide - 1 (GLP-1) 
 
GLP-1 is a cleavage product of the prohormone preproglucagon, which is expressed 
in the pancreas, brainstem and enteroendocrine L-cells. Preproglucagon is cleaved in 
a tissue-specific manner by prohormone convertases 1 and 2 (Mojsov et al., 1986).  
Glucagon is the principle expression product in the pancreatic islets, whereas GLP-1, 
GLP-2 and oxyntomodulin are produced in the CNS and intestine.   
The stimulus for GLP-1 secretion from the gut is food intake.  In humans, there is a 
biphasic secretion pattern initially within 10-15 minutes of meal ingestion followed 
by a second plateau phase at 30-60 minutes (Herrmann et al., 1995).  The active 
circulating forms of GLP-1 are GLP-17-36amide and GLP-17-37 (Orskov et al., 1993, Orskov 
et al., 1994).  Both are produced by post-translational cleavage of GLP-11-37 in the L-
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cells.  At pancreatic islets, GLP-1 acts as a potent incretin hormone.  It physiologically 
augments glucose-dependent insulin release and inhibits the secretion of glucagon. 
GLP-1 also modulates digestion by delaying gastric emptying (Naslund et al., 1999b, 
Kreymann et al., 1987, Gutniak et al., 1992). 
As with PYY, GLP-1 additionally acts as a neurohumoral satiety factor, inhibiting food 
intake in rats after either central or peripheral administration (Turton et al., 1996, 
Tang-Christensen et al., 1996, Larsen et al., 2001).  Central administration of the GLP-
1 receptor antagonist Exendin9-39 increases food intake, suggesting a physiological 
role for endogenous GLP-1 in appetite regulation (Turton et al., 1996).  These effects 
are likely to be centred on the brainstem and hypothalamus, where GLP-1 receptor 
gene expression is altered by fasting and refeeding (Zhou et al., 2003).  Peripherally 
administered GLP-1 causes neuronal activation in the ARC (Abbott et al., 2005a) and 
central administration causes neuronal activation in the PVN, nucleus of the tractus 
solitarius (NTS) and area postrema (AP) (Larsen et al., 1997, Rowland et al., 1997).  
GLP-1 probably also acts directly at the vagus nerve, whose sensory terminals 
express the GLP-1 receptor (Nakagawa et al., 2004), since the effect of peripherally 
administered GLP-1 on both energy intake and activation of ARC neurones is 
attenuated by either bilateral sub-diaphragmatic truncal vagotomy or bilateral 
transections of the brainstem-hypothalamus pathway (Abbott et al., 2005a). 
In both lean and obese humans, acute IV infusion of GLP-1 dose dependently 
reduces energy intake at a subsequent buffet meal, although the anorectic effects 
are not as potent as PYY at doses that mimic normal post-prandial circulating levels 
(Verdich et al., 2001).  Chronic SC administration results in weight loss and improved 
glycaemic control in patients with type 2 diabetes and after 5 days of subcutaneous 
GLP-1 injections, obese subjects reduced their cumulative calorie intake by 15% and 
lost 0.55 kg in weight (Naslund et al., 2004). There is some evidence that altered 
GLP-1 secretion may contribute to the pathogenesis of obesity in humans, since 
endogenous levels are inversely correlated with body mass but normalise with 
weight loss (Ranganath et al., 1996).  Higher circulating levels of the hormone are 
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measured in patients following RYGB, which may help to explain the early post-
operative improvement in glycaemic control that is frequently observed (le Roux et 
al., 2006a). 
 
GLP-1 based therapies have been successfully developed as treatments for Type 2 
diabetes, making use of the hormone’s incretin effect.  As with other peptide gut 
hormones, GLP-1 has an extremely short plasma half-life of 2 minutes.  In contrast to 
its effect on PYY1-36, DPP-IV N-terminal dipeptide cleavage rapidly and completely 
inactivates GLP-1, rendering the native hormone itself unviable as a drug (Kieffer et 
al., 1995).  There have been two successful approaches to this problem:  degradation 
resistant GLP-1 receptor (GLP-1R) agonists (incretin mimetics) and DPP-IV inhibitors. 
 
Exendin-4, a peptide with sequence homology to GLP-1 that was first purified from 
the venom of the Gila monster Heloderma suspectum, is a potent agonist at the GLP-
1 receptor and is resistant to degradation by DPP-IV.  It was developed into the drug 
exenatide (Byetta, Amylin / Eli Lilly), which was released in 2005 and now has 
extensive licensing for use as first line treatment in obese patients with Type 2 
diabetes mellitus or as an adjunct to all other oral antidiabetic agents and insulin.  As 
well as improvements in glycaemic control, exenatide is the first treatment for 
diabetes with proven weight loss benefits.  A meta-analysis of clinical trials reveals 
an average weight loss of 2.13 kg in exenatide treated groups compared to placebo, 
and a 4.76 kg weight loss compared with insulin (Amori et al., 2007).  Administration 
is by twice-daily SC injection, which constituted a barrier to widespread patient 
acceptance, and prompted the development of once-weekly exenatide (Bydureon®), 
now also approved for clinical use.  A second GLP-1 analogue has recently been 
introduced into clinical practice: liraglutide (Victoza, Novo Nordisk). Liraglutide is 
97% identical to the native human peptide, but is coupled at the position 26 lysine to 
a palmitoyl side chain, which promotes binding to albumin, thereby lengthening its 
half-life. In clinical studies, liraglutide shows evidence of slightly improved glycaemic 
control compared with exenatide and a similar weight loss profile (Feinglos et al., 
2005).  Currently coming through late-stage clinical trials, GSK have their own 
incretin mimetic albiglutide and Sanofi are developing lixisenatide, but Roche were 
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forced to halt the development of their drug taspoglutide, due to the emergence of 
severe hypersensitivity reactions during Phase III testing. 
 
The suitability of incretin-mimetics as mono-therapy for obesity in the absence of 
diabetes is under investigation.   Liraglutide is currently in late-stage trials to assess 
its efficacy in this setting. Open-label Phase II results revealed that 75% of non-
diabetic obese subjects receiving high dose liraglutide lost greater than 5% body 
weight and 35% over 10% (Astrup et al., 2009).  A 10% drop out rate due to side 
effects was largely due to nausea rather than severe hypoglycaemia.  In fact, at the 
doses used to treat diabetes, the commonest side effect with all GLP-1 analogues is 
nausea. The incidence ranges from 33% to 57% with exenatide compared with 0.4% 
to 9% in patients treated with insulin analogues (Barnett et al., 2007).  In general, 
this side effect can be ameliorated by early dose titration and eventually mitigates 
with continued use. 
 
In contrast to the incretin mimetics, DPP-IV inhibitors have gained less widespread 
usage in Type 2 diabetes.  In the UK at present there are three such drugs licenced, 
all available as once daily tablets, with no evidence that any one is more effective 
that the others at improving glycaemic control.  They are sitagliptin (Januvia, Merck 
& Co), vildagliptin (Galvus, Novartis) and saxagliptin (Onglyza, Bristol Myers Squibb).  
None of these drugs have weight-loss benefits.  This may be because DPP-IV modifies 
a multitude of peptides.  For example, whilst its action is to inactivate GLP-1, it also 
converts PYY1-36 to its active anorectic form PYY3-36.  Thus DPP-IV inhibition has a 
neutral effect on overall concentrations of active circulating anorectic peptides. 
 
 
1.4.2.3  The Potential of Combination Gut Hormone Treatments for Obesity 
 
The observations that the natural post-prandial sensation of satiety is mediated by 
the release of several gut hormones and that the superior weight loss effects of 
bariatric surgery may be mediated by alterations in numerous neuroendocrine 
factors, have led to the concept of combining multiple gut hormones or developing 
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dual agonists of gut hormone receptors as treatments for obesity (Moran and Dailey, 
2009).  This rationale is further supported by the notion that the dose limiting effects 
of nausea for each hormone can be offset by administering multiple agents at lower 
doses. 
 
Oxyntomodulin, a naturally occurring weak dual agonist of both the GLP-1 and 
glucagon receptors, has already been developed into a potential anti-obesity agent. 
Chronic administration of the native hormone to healthy overweight and obese 
volunteers resulted in a 2.3 kg weight loss compared with 0.5 kg weight reduction in 
placebo-treated controls (Wynne et al., 2005).  Its weight-loss effects are mediated 
both via a reduction in appetite and increase in energy expenditure (Cohen et al., 
2003, Dakin et al., 2002).  Animal studies with engineered and more potent 
combined agonists of the GLP-1 and glucagon receptors confirm this dual mode of 
action (Pocai et al., 2009). 
In human studies, administration of PYY3-36 and GLP-17-36 amide, at doses that are 
ineffective on their own, produces a significant reduction in ad libitum food intake 
when given together (Neary et al., 2005).  In the same paper, rodent studies 
confirmed that the combined peripheral administration of PYY3-36 and GLP-17-36 amide 
led to a reduction in food intake that was greater than that observed when either 
hormone was infused individually at twice the dose. In the ARC, no increase in c-fos 
expression was observed after individual low-dose administration PYY3-36 or GLP-17-36 
amide, but co-administration at the same doses led to significant activation. In another 
human study, coadministration of PYY3-36 and oxyntomodulin reduced energy intake 
by 42.7% in comparison with the saline control group, a significantly greater effect 
than that achieved with either hormone alone (Field et al., 2010). 
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1.5 The Use of Functional MRI to Investigate the Neuroendocrinology of 
Appetite 
 
The concepts of homeostatic and hedonic control of food intake, and the 
contribution of circulating satiety signals, represent a huge shift in our understanding 
of appetite regulation over the past two decades.  However, the precise pathways by 
which anorectic gut hormones exert their appetite-modulating effects, particularly in 
humans, are technically challenging to research and they remain unclear.  Recently, 
functional magnetic resonance imaging (fMRI) has become a popular and rapidly 
advancing tool for investigating CNS appetite pathways in humans, allowing for 
repeated measures in the same subject without exposure to ionising radiation. The 
earliest fMRI appetite studies explored differences in brain activation patterns 
between the normal fed and fasted state. This was followed by a cluster of studies 
exploring differences in food-cue invoked reward area activation between obese and 
lean populations. Most recently, fMRI studies have begun to investigate hormonal 
influences on appetitive brain processes and in relation to this, to explore functional 
neuroimaging outcomes following weight loss interventions. 
 
1.5.1  Principles of Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) utilises the behaviour of hydrogen nuclei, which 
consist of single protons that possess angular momentum (spin).  By virtue of this 
spin, each proton also possesses a magnetic dipole moment, the axis of which is the 
same as the spin axis.  When an external magnetic field (B0) is applied, the protons in 
tissue try to align with it, causing a net magnetic moment (termed the net 
magnetisation vector, NMV) parallel with B0. However, the angular momentum of 
the protons prevents complete alignment of the NMV with B0 and instead the 
protons precess around the field axis (commonly assigned to the z axis in 3D co-
ordinates).  
 
 
37 
 
Generation of MRI images requires application of a radiofrequency (RF) pulse at 90o 
to B0. This causes the NMV to flip into the transverse (x/y) plane (Figure 1.2 a). When 
the RF pulse is turned off, the NMV returns to a state of equilibrium with B0 (Figures 
1.2 b and c). This ‘relaxation’ results in changes to the magnetic field that can be 
detected through induction of current in a nearby receiver coil and converted to 
images. By slightly altering the strength of the magnetic field (and therefore the 
frequency of the emitted radiation) using gradient coils across the volume to be 
imaged, spatial information can be inferred. Gradient coils which vary along the x, y 
and z axes divide the subject being imaged into voxels, or cubic volumes, the 
dimensions of which define the image resolution.   
 
The T1 relaxation time is a time constant referring to the realignment of the NMV 
with B0 when the RF pulse is switched off (Figures 1.2 a-c). Simultaneous with this 
longitudinal relaxation, there is a (much quicker) de-phasing of individual precessing 
spins in the transverse plane (Figures 1.2 d-f). The time constant relating to this de-
phasing is termed T2. In practice, due to localised inhomogeneities in the external 
magnetic field, measured T2 is usually shorter than predicted for any particular 
tissue. This apparent T2 is referred to as T2
*.  T1 and T2 vary depending on the tissue 
being imaged. The MR signal obtained for a particular tissue therefore depends 
primarily on three intrinsic parameters: the proton density and the T1 and T2 
relaxation times.  Contrast in MR images originates from the differences in these 
properties between adjacent tissues. 
 
The repetition time (TR) is the time elapsed between successive RF excitation pulses. 
A short TR allows full realignment of the NMV with B0 of tissues with a short T1, but 
only partial recovery of tissues with a long T1. Full recovery is associated with a 
greater net signal following further flipping of the NMV by subsequent RF pulses. The 
echo delay time (TE) is the interval between the RF pulse and the first measurement. 
A short TR highlights T1 differences between tissues, whereas a short TE minimises 
T2 effects. Thus, with selection of appropriate TR and TE, it is possible to ‘weight’ the 
image to accentuate signal from certain tissue types. 
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Figure 1.2:  Schematic of T1 and T2 Relaxation.   
MRI utilises the behaviour of tissue protons within varying magnetic fields to 
produce signals which can be converted into images. The summated magnetic 
moments of all of the protons trying to align with the main external magnetic field of 
the scanner (referred to here as B0 and conventionally shown along the z axis in 3D 
coordinates), can be considered as a net magnetisation vector, NMV (red arrow).  A 
second magnetic field (in the form of a short radiofrequency RF pulse) is applied, 
which flips the NMV from alignment in the z direction into the x-y plane (1a).  Before 
application of the RF-pulse the amplitude in the z-axis is maximal while the 
amplitude in the x-y plane is zero. Just after application of the RF-pulse the 
amplitude in the z-axis is zero (1a) while the amplitude in the x-y plane is maximal 
(1d). During relaxation the amplitude in the z-axis will slowly increase (1 b and c) 
while the amplitude in the x-y plane slowly decreases (1 e and f).  T1 relaxation is the 
time taken for the z vector to regain in strength, whereas T2 relaxation is the time 
taken for the x-y vector to decay.  These changing magnetic vectors invoke their own 
RF signals, which are picked up by the receiver coils and interpreted into information 
about the tissues of the subject being scanned. 
 
39 
 
 
1.5.2  Principles of Functional Magnetic Resonance Imaging (fMRI) 
 
fMRI utilises adaptations of this classical MRI technique, such that brain activity can 
be examined rather than structure alone. Virtually all fMRI studies rely on a measure 
called blood-oxygenation-level dependent (BOLD) contrast, based on the fact that 
oxygenated and deoxygenated blood possess different magnetic properties. 
Increased neuronal activity in the brain elicits a local haemodynamic response, which 
causes an increase in blood flow greater than necessary for tissue demands.  This 
results in a locally reduced ratio of deoxyhaemoglobin to oxyhaemoglobin 
concentrations and the ensuing differences in local magnetic field inhomogeneities 
can be detected on a T2*-weighted imaging protocol (Ogawa et al., 1992).  The 
locally reduced ratio of deoxyhaemoglobin to oxyhaemoglobin leads to a longer T2*, 
producing increased image intensity in that region (1.3). BOLD-based protocols 
typically use magnetic gradients to generate the MR signal (gradient-echo imaging) 
and, as scanner and computational hardware has advanced, faster sequences have 
been developed to acquire large numbers of images in short spaces of time. Echo-
planar imaging (EPI), for example, is a technique whereby an entire 2-dimensional 
image can be attained by the rapid alteration of spatial gradients following a single 
RF pulse. In this way, the entire brain can now be functionally imaged within the 
same timeframe as the physiological changes of interest.  
 
fMRI image reconstruction results in the selected brain area divided into thousands 
of voxels, each assigned a signal intensity. Statistical analysis of each voxel, or cluster 
of voxels, ascertains whether the signal intensity is greater there compared with all 
others. Whilst this approach may be useful for exploratory studies, most fMRI 
experiments perform region of interest (ROI) analyses whereby the functional 
properties of a pre-determined set of voxels (corresponding to a priori anatomical 
areas of the brain) are analysed. Alternatively, resting state functional connectivity 
analysis can investigate the activational inter-relationships between different brain 
regions, allowing for the formation of distinct neuronal networks implicated in a co-
ordinated brain response (Biswal et al., 1997).  
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Figure 1.3:  The BOLD (Blood Oxygen Level Dependent) Effect. 
The increased metabolic demand from activated neurones results in an increase in 
oxygen consumption of around 10%.  This is physiologically overcompensated for by 
an increase in regional blood flow by over 30%.  As a result, the ratio of 
deoxygenated to oxygenated haemoglobin (Hb/HbO2) actually decreases in activated 
brain areas.  Oxyhaemoglobin (HbO2) is diamagnetic (ie has the same magnetic 
properties as surrounding tissue), whereas deoxyhaemoglobin (Hb) is paramagnetic 
and therefore distorts the local magnetic field.  The relative reduction in 
deoxyhaemoglobin in activated areas means that the magnetic field there is less 
distorted (longer T2*) and so the MRI signal is stronger.  Hence, the BOLD effect 
results in greater MRI signal from activated brain areas. 
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1.5.3  Summary of Human fMRI Studies of Appetite to Date 
 
All fMRI studies of human appetite have primarily examined corticolimbic reward 
areas, with some also reporting on the hypothalamus.  The commonest experimental 
paradigm is to present the subject with images of food or non-food items. It is well 
understood that whilst taste provides an immediate reward (or punishment) for 
consumed foods, the visual characteristics of food are quickly learned and become 
powerful cues, capable of influencing subsequent food-seeking behaviour.  In fact, in 
humans food selection is primarily guided by the visual system (Linne et al., 2002).  
Thus, showing food images is a useful way of examining appetitive reward circuitry. 
A subtraction analysis is performed to see whether the difference in regional brain 
activation between viewing images of food or non-food is altered in different 
physiological conditions (eg the fasted versus the fed state). 
 
fMRI studies investigating human appetite do indeed reveal greater activation by 
food than by non-food images in corticolimbic reward areas (van der Laan et al., 
2011).  However, due to differences in experimental design, concurrence between 
studies is moderate, with only a few regions consistently reported as task-
responsive, particularly the OFC, amygdala, insula and striatum.  The most frequently 
investigated factors that can modulate the brain response to food cues are hunger, 
the caloric content of the food images and BMI.  In general, a satiety-induced 
reduction in activity in these corticolimbic structures is reported (LaBar et al., 2001, 
Killgore et al., 2003, St-Onge et al., 2005, Fuhrer et al., 2008).  Reward areas are also 
more strongly activated in response to viewing high calorie versus low calorie foods 
(Schur et al., 2009, Siep et al., 2009), a difference which is amplified when hungry .  
Reward area activation, as measured with fMRI, tends to correlate positively with 
subjective appetite ratings (Porubska et al., 2006, Goldstone et al., 2009).  Studies 
investigating activation patterns in obese subjects have reported a hyper-reactive 
reward system, particularly to high calorie food cues (Rothemund et al., 2007, 
Stoeckel et al., 2008).  There is also some suggestion that obese individuals show 
greater responses to anticipated food consumption but weaker activation during 
actual consumption compared to lean individuals (Stice et al., 2008).  Interestingly, 
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recent imaging studies pre- and post- gastric bypass surgery, by which an average 
30% reduction in body weight had been achieved, have suggested that some of 
these aberrant reward activation patterns can be reversed with weight loss, with the 
suggestion that such changes may in part be mediated by alterations in post-
operative gut hormone levels (Ochner et al., 2011). In line with this, there have been 
a few fMRI studies which have directly examined the effects of exogenously 
administered hormones on the CNS.   
 
One study has shown that intranasal insulin administration (that is, direct central 
administration whilst maintaining euglycaemia) reduces BOLD fMRI activation (with 
respect to food images versus non-food images) in reward centres in normal adults 
(Guthoff et al., 2011).  This concurs with our understanding of insulin as an anorectic, 
adipostat factor. 
 
In two congenitally leptin deficient human subjects, daily subcutaneous leptin 
replacement reduced BOLD fMRI activation (in terms of the difference in activation 
between viewing food and non-food images) in striatal regions compared with the 
leptin deficient state (Farooqi et al., 2007). Another study in three leptin deficient 
patients, suggested regional differences in the way leptin modulates food reward, 
with some areas, such as the insula, being inhibited and others, like the prefrontal 
cortex, being activated by leptin (Baicy et al., 2007).  In normal, hyperleptinaemic 
obese subjects, weight loss results in increased activity in reward areas in response 
to visual food cues, which can be attenuated with leptin administration (Rosenbaum 
et al., 2008).  This suggests that weight loss leads to a state of relative leptin 
deficiency, which may be responsible for the rebound hyperphagia and subsequent 
weight gain observed in most dieters.  These early fMRI studies of the physiology of 
leptin were the first to suggest that circulating signals of energy stores interacted 
with hedonic as well as homeostatic systems. 
 
There are two examples of BOLD fMRI studies investigating the CNS effects of gut 
hormones.  In the first, intravenous infusion of PYY3-36 to healthy human subjects 
produced the expected acute reduction in food intake, and increased activity in the 
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hypothalamus and OFC (Batterham et al., 2007).  A later study demonstrated that in 
normal-weight human subjects, intravenous ghrelin infusion increased hunger 
ratings and also increased the BOLD fMRI signal change (between food and non-food 
visual cues) in multiple corticolimbic reward areas, compared with saline infusion 
(Malik et al., 2008).  
 
To date, there has been no fMRI study investigating the effects of GLP-1 infusion on 
its own, or any combination gut hormone administration on appetitive CNS activity. 
 
 
 
1.6  Hypothesis and Aims 
 
PYY3-36 and GLP-17-36 amide are both post-prandially released anorectic gut hormones.  
Previous co-administration studies in humans have shown that their effects on 
inhibition of food intake are additive.  However, the brain pathways which mediate 
these effects in humans are unknown.  The aim of this project from the outset was to 
utilise BOLD-based fMRI to investigate the CNS effects of PYY3-36 and GLP-17-36 amide 
administration, and to compare and contrast brain activation patterns between the 
fed and fasted state and following single or combined infusions of these hormones. 
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I hypothesise that: 
 
1. In subjects fasted overnight, subanorectic doses of PYY3-36 and GLP-17-36amide, 
when infused in combination, will reduce ad libitum energy intake at a 
subsequent buffet meal compared with saline. 
 
2. There will be increased BOLD fMRI signal in the fasted state compared to the 
fed state when viewing food images versus non-food images in key CNS 
reward areas.  
 
3. The effect of combined infusion of PYY3-36 and GLP-17-36 amide in fasted subjects 
will reduce the BOLD fMRI signal in key CNS reward areas, similar to that 
observed in the fed state.  
 
 
 
 
The aims of this project are: 
 
 
1. To establish doses of PYY3-36 and GLP-17-36 amide that are subanorectic alone 
but anorectic in combination compared with saline. 
 
2. To compare the functional MRI response to food versus non-food images in 
the fed state and the fasted state during infusion of saline.  
 
3. In the fasted state, to investigate the modulation of the food-salient 
functional MRI response by the single and combined administration of PYY3-36 
and GLP-17-36 amide. 
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CHAPTER 2 
 
 
Investigation of the Effects of Single 
and Combined Infusions of PYY3-36 
and GLP-17-36amide on Energy Intake 
in Healthy Humans. 
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2.1  INTRODUCTION 
 
Finding the correct dose of infused hormones to study was of the utmost importance 
for this neuroimaging study.  The primary aim was to find doses of PYY3-36 and GLP-
17-36 amide that are subanorectic alone but anorectic in combination.  This was 
attempted in order to create an experimental condition which more closely reflected 
the physiological post-prandial state, whereby satiety without nausea is mediated by 
the slow and sustained release of multiple gut hormones.   
 
Both PYY3-36 and GLP-17-36 amide are peptide hormones with short circulating half lives 
in the range of minutes, due to the activity of plasma proteases.  PYY3-36 has a 
circulating half-life of approximately 8 minutes and that of GLP-17-36 amide is only 2 
minutes (Lluis et al., 1989, Kieffer et al., 1995).  The therapeutic window for gut 
peptides is narrow and the anorectic effect and maximum tolerated dose is limited 
by the initiation of nausea and vomiting.  The onset of nausea is thought to be 
related not only to the peak plasma concentration achieved of the hormone, but also 
its rate of rise (Gantz et al., 2007).  Thus a large bolus dose, giving rise to an 
immediate sharp peak in plasma levels, is likely to cause vomiting.  This is of 
particular importance given that in the supine position and claustrophobic 
environment of the MRI scanner, nausea may be accentuated, and vomiting can lead 
to aspiration. Furthermore, it was important to avoid imaging aversive rather than 
anorectic brain activation. 
 
A dose verification experiment was therefore performed in volunteers recruited 
using the same inclusion criteria as for the subsequent imaging study.  These 
subjects would experience an identical gut hormone infusion protocol but not be 
scanned, and the purpose of this study was simply to ascertain the appropriate 
doses to be taken forward into the imaging sessions.   
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An unramped infusion protocol was planned, with the aim of a slow rise in infused 
hormone plasma concentration until a steady state was achieved.  The selection of 
doses to be tested (0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min GLP-17-36 amide) was 
based on the following review of literature in the field. 
 
Only one study has reported on the co-infusion of PYY3-36 and GLP-17-36 amide.  
Combined administration, each at a dose of 0.4 pmol/kg/min, significantly reduced 
energy intake by 27% compared to saline at an ad libitum buffet meal served 90 
minutes into the infusion. No nausea was reported in the group of 10 lean, healthy 
subjects. When 0.4 pmol/kg/min GLP-17-36 amide was administered singly, there was a 
non-significant 5% reduction in energy intake compared to saline at the ad libitum 
buffet meal.  0.4 pmol/kg/min PYY3-36 infusion on its own produced a 15% reduction 
in food intake (Neary et al., 2005). 
 
I decided to increase the dose of GLP-17-36 amide used in this study to 0.8 pmol/kg/min 
based on a meta-analysis of single GLP-17-36 amide infusion studies.  This revealed that 
a mean infusion rate of 0.89 pmol/kg/min GLP-17-36 amide across seven studies led to a 
13.2% reduction in energy intake at the ad libitum buffet meal compared with saline 
infusion (Verdich et al., 2001).  Although formal assessment of nausea ratings was 
only made in two of the studies included in the meta-analysis, none reported any 
nausea.  Thus it was predicted that this higher selected dose of GLP-17-36 amide would 
safely produce a similar reduction in food intake to PYY3-36. 
 
Studies reporting the effect of single infusion of PYY3-36 suggest it has a narrower 
therapeutic (ie anorectic but non-nauseating) window.  The very first study showing 
the anorectic effects of PYY3-36 in humans reported a 36% reduction in energy intake 
at an ad libitum buffet meal compared with saline infusion (Batterham et al., 2002).  
This was measured two hours after the termination of a 90 minute infusion of 0.8 
pmol/kg/min PYY3-36.  No nausea was reported in that study of 12 lean, healthy 
volunteers.  In a different study, no reduction in ad libitum energy intake was seen 
with an infusion of 0.2 pmol/kg/min PYY3-36, whereas a dose of 0.8 pmol/kg/min led 
to a 19% reduction in ad libitum energy intake (Sloth et al., 2007).  However, the 
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higher dose infusion had to be terminated due to severe nausea and abdominal pain 
in 5/9 subjects tested. In another PYY3-36 dose-response study of 16 subjects, 0.2 
pmol/kg/min did not produce any nausea, 0.4 pmol/kg/min led to nausea in 2 
subjects and a dose of 0.8 pmol/kg/min induced nausea in 4 subjects (Degen et al., 
2005).  Thus, in order to minimise the risk of nausea in this neuroimaging study, a 
dose of 0.3 pmol/kg/min PYY3-36 was chosen.  
 
In planning this study, consideration was also taken over the meal timing.  Firstly, the 
use of an MRI-compatible injector system to deliver the peptide infusion during the 
scan had to be taken into account, which constrained the protocol to allow for the 
test meal to be served only after the infusion had ended.  This is because the MRI-
compatible injector cannot be moved out of the scanner room, switching infusion 
pumps would have led to pharmacokinetic inconsistencies which such short-lived 
peptides and, finally, it was not possible to serve a meal in the scanner room.  The 
literature on human PYY3-36 infusion studies reported an interval of up to 2 hours 
between termination of the infusion and timing of the test meal, whilst still eliciting 
a significant reduction in food intake (Batterham et al., 2002). In contrast, many GLP-
17-36 amide infusion studies have continued to run the peptide infusion throughout the 
meal (Naslund et al., 1999a).  This is likely to reflect its shorter half-life.  I therefore 
decided to serve the test meal immediately after terminating the 90 minute gut 
hormone infusion, to ensure that the food intake effects were measured when 
plasma levels were close to peak. 
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2.2  METHODS 
 
2.2.1  Peptides 
 
Human PYY3-36 and GLP-17-36 amide was purchased from Bachem (St. Helens, UK). The 
identity and purity of each peptide was confirmed by matrix-assisted laser 
desorption ionisation-time of flight (MALDI-TOF) mass spectrometry, and by high-
pressure liquid chromatography (HPLC) (Bachem).  
 
Sterile 0.9% saline was purchased from Bayer (Haywards Heath, UK). Using an 
aseptic technique in a laminar flow cabinet, the peptides were dissolved in 0.9% 
saline, aliquoted into vials and freeze dried. Vials were randomly selected for 
microbiological examination and for the Limulus Amoebocyte Lysate test for 
pyrogen. The vials were sterile on bacterial and extended fungal culture 
(Department of Microbiology, Hammersmith Hospital, London) and the Limulus 
Amoebocyte Lysate tests (Associates of Cape Cod, Liverpool, UK) were within the 
safe range for human infusion. Further representative vials were randomly selected 
and sent for amino acid analysis by Alta Bioscience (Birmingham, UK). These results 
were used to calculate the actual peptide content of the vials and therefore the 
correction factor when calculating the dose of peptide to be administered to 
subjects.  
 
Toxicity studies were also performed using PYY3-36 and GLP-17-36 amide, at doses 
greater than 10 times the maximum intended for humans (in pmol/kg body weight), 
administered by IP injection to 20 mice, alongside a saline-administered control 
group. The mice were observed for evidence of abnormal behaviour. Half the 
animals in each group were sacrificed by CO2 asphyxiation after 48 hours, and the 
other half after 21 days. The lungs, heart, kidneys, liver, brain and reproductive 
organs of both sexes were dissected, fixed and sent for examination by an 
independent histopathologist who was blinded to treatment group. 
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2.2.2  Participants 
 
Healthy, normal-weight, non-smoking adults were recruited for the study by 
advertisement.   
 
Inclusion criteria for this research were: age 18 years or over, in good health, stable 
body weight for the preceding three months and BMI 19 – 25 kg/m2. Exclusion 
criteria were: smokers, recreational drug use, substance abuse, significant physical 
or psychiatric illness, regular medication other than contraceptives, and pregnancy. 
All subjects were screened and determined to be healthy by full medical history, 
physical examination, full blood count, urea and electrolytes, liver function tests, 
bone profile, random glucose, thyroid function tests and 12-lead electrocardiogram. 
Women of child-bearing age were advised to avoid pregnancy during the studies and 
underwent a urine test to exclude pregnancy prior to the start of each study visit. All 
potential subjects were screened to exclude those with disordered eating, as 
assessed by the SCOFF questionnaire, and those with a high level of restrained 
eating, as assessed by the standard Dutch Eating Behaviour Questionnaire. 
Volunteers also completed a three-day diet diary to determine their usual eating 
habits before acceptance into the studies. During the screening visit, a sample of the 
study meal was provided, and an assessment of palatability was made using a nine-
point hedonic scale. Subjects who disliked the study meal, or rated the study meal as 
‘like extremely’ were also excluded.   
 
The research (with the dose verification and imaging arms considered as a single 
project) was approved by the St Mary’s Research Ethics Committee (reference 
number 09/H0712/4). All subjects gave written informed consent, and the research 
was planned and performed in accordance with the Declaration of Helsinki.  
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2.2.3  Dose Verification Study: Effect of Intravenous Infusion of 0.3 
pmol/kg/min PYY3-36 and 0.8 pmol/kg/min GLP-17-36 amide on Energy Intake in 
Healthy Human Subjects. 
 
In order to verify that the doses of 0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min 
GLP-17-36 amide were subanorectic when administered individually, anorectic in 
combination and not nauseating in lean, healthy human subjects, six subjects (2 
male, 4 female) were recruited to test their effects on appetite and energy intake. 
 
The subjects attended for 5 study visits, each at least 3 days apart. They were asked 
to fast (permitted to drink only water) from 22:00h the evening before each study 
visit.  The volunteers standardised their diet (by eating the same evening meal at the 
same time the night before each study visit), abstained from alcohol and avoided 
strenuous exercise for 24 hours prior to each visit.  
 
The study was conducted in a single-blinded fashion. On their first visit, subjects 
always received an infusion of saline after an overnight fast. This protocol was 
identical to that used for the subsequent visits, and was intended to acclimatise the 
subject to the clinical environment and to experimental procedures.  Results from 
the first saline visit are not included in the analysis. Following the acclimatisation 
visit, subjects were assigned to receive each of the following in random order after 
an overnight fast: 
 
1. Saline infusion (the fasted, control visit) 
2. PYY3-36 infusion at 0.3 pmol/kg/min 
3. GLP-17-36 amide infusion at 0.8 pmol/kg/min 
4. Combined PYY3-36 + GLP-17-36 amide infusion, at 0.3 pmol/kg/min and 0.8 
pmol/kg/min respectively. 
 
Subjects arrived for each visit at 09:30 h (t= -60 min), when peripheral venous 
cannulae (20G) were inserted in both forearms; one for infusions and one for blood 
sampling. Subjects were encouraged to relax, but not fall asleep, by reading or 
52 
 
watching a DVD.  Time cues were removed from the study room to limit the 
potential effect of time awareness leading to food expectation and appetite 
alteration.   
 
The intravenous infusion started at 10:30 h (t = 0 min) and was delivered over 90 
minutes.  All syringes and lines used to deliver peptide were coated in Gelofusin® (B. 
Braun Medical Ltd, UK) for 20 minutes prior to preparation, to minimise adsorption 
of peptide to the plastic walls.  The actual vehicle for delivering peptide (also used on 
the “saline” infusion days) was a 10% solution of Gelofusin in 0.9% saline.  Vials of 
peptide were dissolved in 2.5ml vehicle, and drawn up in a single syringe up to a 
total volume of 60ml.  The first 10mls were slowly (over 5 minutes) purged through 
the delivery line before it was attached to a subject’s infusion cannula.  The amount 
of peptide added to the delivery syringe varied according to the weight-adjusted 
dose each subject received, such that the infusion rate was kept constant 
throughout at 20ml/hr (Graseby 3100 syringe driver, SIMS Graseby Ltd, Watford, 
UK).   
 
Six ml blood samples were collected at t = -30, 0, 15, 30, 45, 60, 75, 90 and 120 min. 
min, into lithium heparin-coated tubes (International Scientific Supplies Ltd, 
Bradford, UK) containing 1500 kallikrein inhibitor units (0.15 ml) aprotinin (Trasylol, 
Bayer Schering Pharma, Berlin, Germany). Samples immediately underwent 
centrifugation (4000 rpm for 10 minutes at 4°C), after which, plasma was separated 
immediately and stored at -20°C until analysis. Cannulae were flushed with 5 ml 
0.9% saline after collecting each blood sample. Immediately prior to collection of the 
subsequent sample, 1 ml dead-space blood was collected and discarded. 
 
At t = -30, 0, 15, 30, 45, 60, 75, 90 and 120 min., subjects completed a series of visual 
analogue scales (VAS) that rated hunger, satiety and nausea. The VAS scales 
consisted of 100 mm lines with text expressing the most positive and the most 
negative rating for each variable anchored at either end.  
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Haemodynamic parameters and blood glucose were measured during the studies.  
At t = -30, 0, 15, 30, 45, 60, 75, 90 and 120 min. the pulse and blood pressure of each 
subject was measured and a drop of blood was taken from each blood sample to 
check blood glucose on an Optimum Exceed blood glucose monitor (Abbott Diabetes 
Care, Maidenhead, Berks).   
 
The infusion was terminated after 90 minutes.  Thirty minutes after stopping the 
infusion (i.e. t= 120 min), subjects were offered a buffet meal and were asked to ‘eat 
until comfortably full’. The meal, which was provided to excess so that all appetites 
would be accommodated, was served in private over 20 minutes. It consisted of 
either a mild chicken tikka curry with rice (628 kJ/ 100g) or a vegetarian option of 
tomato and mozzarella pasta (507kJ /100g).  Each subject had previously decided 
which meal they preferred during their screening visit and were then served the 
same meal for each of their study visits. Food was weighed pre- and post-
consumption. Energy intake was calculated from the weight of food consumed. At 
the end of the meal, subjects were asked to rate the palatability of the food using a 
VAS. Subjects remained in the study room until t = 150 min.  
 
 
The protocol for the Dose Verification Study is summarised in Figure 2.1 
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Figure 2.1 - Protocol for Dose Verification Study: Effect of Intravenous Infusion of 
0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min GLP-17-36 amide on Energy Intake in 
Healthy Human Subjects. 
 
Following an overnight fast, six healthy, normal-weight subjects each received the 
following interventions, in random order, over 4 separate study days in a single-
blinded fashion: 
 
1. 90 minute saline infusion (fasted saline, control visit) 
2. 90 minute PYY3-36 infusion at 0.4 pmol/kg/min  
3. 90 minute GLP-17-36 infusion at 0.4 pmol/kg/min  
4. 90 minute combined PYY3-36 and GLP-17-36 infusion, at 0.3 pmol/kg/min and 0.8 
pmol/kg/min respectively. 
 
At every visit, an ad libitum buffet meal was served immediately after the infusion 
was discontinued in order to measure energy intake. Blood sampling (for PYY and 
GLP-1) and assessments of appetite (based on visual analogue scores (VAS)) was 
performed at the time-points indicated.  
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2.2.4  Plasma Hormone Radioimmunoassays 
 
2.2.4.1  Measurement of Total Plasma PYY 
Total PYY-like immunoreactivity was measured with a specific and sensitive in-house 
radioimmunoassay, previously established (Adrian et al., 1985).  The antiserum (Y21) 
was produced in rabbits against synthetic porcine PYY coupled to bovine serum 
albumin by glutaraldehyde and used at a final dilution of 1:50,000. This antibody 
cross-reacts fully with both PYY3-36 and PYY1-36, but not with pancreatic polypeptide, 
neuropeptide Y, or other known gastrointestinal hormones. The 125I PYY was 
prepared by the iodogen method and purified by high pressure liquid 
chromatography (HPLC). The specific activity of the 125I PYY label was 54 Bq/fmol. 
The assay was performed in total volume of 0.7 ml of 0.06 M phosphate buffer PH 
7.2 containing 0.3% bovine serum albumin (BSA). The assay was incubated for three 
days at 4oC before separation of the free and antibody bound label by sheep anti-
rabbit antibody. The detection limit of the assay was 2.5 pmol/l, with an intra-assay 
coefficient of variation of 5.8 % and inter-assay variation below 10%.  All samples 
were assayed in one assay to avoid inter-assay variation. 
 
2.2.4.2             Measurement of Total Plasma Amidated GLP-1 
 
GLP-1 like immunoreactivity was measured by a specific and sensitive in-house 
radioimmunoassay, previously established (Kreymann et al., 1987). The antibody was 
produced in rabbits against synthetic GLP-17-36amide coupled to BSA. The antibody cross 
reacted 100% with all amidated forms of GLP-1 [GLP-11-36amide, GLP-17-36amide and GLP-19-
36amide] but did not cross react with extended forms [GLP-11-37 and GLP-17-37] or any 
other known pancreatic or gastrointestinal peptide. 125I-GLP-1 was prepared by the 
iodogen method and purified by HPLC.  The specific activity of the 125I GLP-1 label 
was 48 Bq/fmol. The assay was performed in a total volume of 0.7 ml of 0.06 M 
sodium barbitone buffer (pH 8) containing 0.3 % BSA. The assay was incubated for 
three days at 4oC before separation of the free and antibody bound label by charcoal 
absorption. The limit of detection was 7.5 pmol/l, with an intra-assay variation of 
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5.4% and inter-assay variation below 10%.  All samples were assayed in one assay to 
avoid inter-assay variation 
 
Full details of all in-house RIA methods are given in Appendix II. 
 
2.2.5  Statistical Analysis 
 
Combined data are represented as the mean ± SEM. Comparisons of energy intake 
and ratings of meal were by repeated measures ANOVA with Tukey’s multiple 
comparison post-test and Dunnett’s comparison post-test against the fasted saline 
visit. VAS scores were adjusted for baseline and differences between t= 0 min and t= 
90 min compared by repeated measures non-parametric Friedman’s test with 
Dunn’s multiple comparison post-test. Comparisons of plasma gut hormone levels 
were by repeated measures ANOVA with Tukey’s multiple comparison post-test. 
Analyses were performed using Prism version 5.01 software (Graphpad Software, 
San Diego, CA, USA). 
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2.3  RESULTS 
 
Microbiological examination and Limulus Amoebocyte Lysate testing of 
representative peptide vials was unremarkable. Analysis by Alta Bioscience 
(Birmingham, UK) revealed that a representative 25 nmol vial of PYY3-36 actually 
contained 18.6 nmol and a representative 25 nmol vial of GLP-17-36 amide actually 
contained 25.4 nmol. Toxicity studies in mice were unremarkable (Appendix III).  
 
2.3.1  Effect of Intravenous Infusion of 0.3 pmol/kg/min PYY3-36 and 0.8 
pmol/kg/min GLP-17-36 amide on Energy Intake in Healthy Human Subjects. 
 
Six healthy subjects, 4 male and 2 female, average age 27.8 years and mean BMI 
21.4, completed the Dose Verification Study. The mean energy intake during the ad 
libitum buffet lunch was 3478 ± 838.4 kJ when they received saline, 3726 ± 804.5 kJ 
when they received the single infusion of 0.3 pmol/kg/min PYY3-36, 3334 ± 961.3 kJ 
when they received the single infusion of 0.8 pmol/kg/min GLP-17-36 amide  and 2359 ± 
825.7 kJ when they received the combined infusion of 0.3 pmol/kg/min PYY3-36  + 0.8 
pmol/kg/min GLP-17-36 amide. The difference in mean energy intake was statistically 
significant (P < 0.05) between the fasted saline and combination gut hormone visits. 
This is illustrated in Figure 2.2. 
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Figure 2.2 Analysis of Mean Ad Libitum Energy Intake in Dose Verification Study: Effect of 
Intravenous Infusion of 0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min GLP-17-36 amide on 
Energy Intake in Healthy Human Subjects. 
 
Six healthy subjects underwent 90 minute infusions of saline (Fast sal), 0.3 pmol/kg/min 
PYY3-36 (P 0.3), 0.8 pmol/kg/min GLP-17-36amide (G 0.8) and combined 0.3 pmol/kg/min PYY3-36 
+ 0.8 pmol/kg/min GLP-17-36amide (P 0.3 + G 0.8). All subjects were fasted overnight before 
each study visit.  An ad libitum buffet meal was served immediately after the infusion in 
order to measure energy intake.   * denotes P<0.05 for P 0.3 + G 0.8 vs all other groups. 
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2.3.2  VAS Analysis 
 
Combined infusion of 0.3 pmol/kg/min PYY3-36 + 0.8 pmol/kg/min GLP-17-36 amide 
resulted in a mean increase in VAS nausea score by 22.5 mm from t=0 min to   t= 90 
min. This was statistically significant when compared with the mean change in 
nausea score between t= 0 min and t= 90 min in other groups (P<0.05).  There were 
no reports of nausea with the single infusions (Figure 2.3 a).  Ratings of hunger and 
fullness changed as expected around the study meal, but were not affected by any of 
the gut hormone infusions (Figure 2.3 b/c).   
 
 
In the same study, mean rating (at t= 120 min) of how tasty subjects found the buffet 
lunch on a 100 mm VAS scale was 61 ± 9.4 mm when they received saline, 65.2 ± 
8.7mm  when they received the single infusion of 0.3 pmol/kg/min PYY3-36, 64.8 ± 7.8 
mm when they received the single infusion of 0.8 pmol/kg/min GLP-17-36 amide and 
56.7 ± 12.0 mm when they received the combined infusion of 0.3 pmol/kg/min PYY3-
36 + 0.8 pmol/kg/min GLP-17-36 amide. There was no significant difference between 
visits (P= 0.48, Figure 2.4).  
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Figure 2.3 a:  How nauseous do you feel right now?
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Figure 2.3 b:  How hungry do you feel right now?
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Figure 2.3 c:  How full do you feel right now?
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Figure 2.3   Analysis of VAS Ratings During Dose Verification Study. 
Six healthy subjects underwent infusions of saline (Fast sal), 0.3 pmol/kg/min PYY3-36 (PYY 
0.3), 0.8 pmol/kg/min GLP-17-36amide (GLP-1 0.8) and combined 0.3 pmol/kg/min PYY3-36 + 0.8 
pmol/kg/min GLP-17-36amide (PYY 0.3 + GLP-1 0.8). All subjects were fasted overnight before 
each study visit.  On each visit, the infusion was administered between t= 0 and t= 90 min, 
and lunch served immediately after. During the study, subjects completed 100 mm visual 
analogue scale questionnaires relating to nausea, hunger and fullness. Graphs are presented 
as change in score from baseline at t = -30 min.    * denotes P < 0.05 for P 0.4 + G 0.4 vs all 
other groups at the given timepoint.   
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Figure 2.4  Meal Palatability Rating Following Ad Libitum Lunch in Dose Verification Study   
 
Six healthy subjects underwent 90 minute infusions of saline (Fast sal), 0.3 pmol/kg/min 
PYY3-36 (P 0.3), 0.8 pmol/kg/min GLP-17-36amide (G 0.8) and combined 0.3 pmol/kg/min PYY3-36 
+ 0.8 pmol/kg/min GLP-17-36amide (P 0.3 + G 0.8). All subjects were fasted overnight before 
each study visit.  An ad libitum buffet meal was served immediately after the infusion and 
subjects retrospectively rated its palatability on a scale of 0-100. 
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2.3.3  Total Plasma PYY Levels in Dose Verification Study 
 
Mean plasma concentration of total PYY (from time points t= 15 min to t = 90 min) 
was 27.48 ± 1.7 pmol/L when saline was infused, 66.78 ± 9.0 pmol/L when 0.3 
pmol/kg/min PYY3-36 was infused,  20.5 ± 0.4 pmol/L when 0.8 pmol/kg/min GLP-17-36 
amide was infused, and 87.29 ± 8.8 pmol/L when the combination 0.3 pmol/kg/min 
PYY3-36 + 0.8 pmol/kg/min GLP-17-36 amide was infused. 
 
Peak mean plasma concentration of total PYY (during the entire study) was 33.26 
pmol/L when saline was infused (occurring at t = 30 min), 91.07 pmol/L when 0.3 
pmol/kg/min PYY3-36 was infused (occurring at t= 90 min), 33.3 pmol/L when 0.8 
pmol/kg/min GLP-17-36 amide was infused (occurring post-prandially at t = 120 min), 
and 106.5 pmol/L when combination 0.3 pmol/kg/min PYY3-36 + 0.8 pmol/kg/min 
GLP-17-36 amide was infused (occurring at t = 90 min).  
 
There was no significant difference between plasma concentration of total PYY 
achieved between saline and GLP-17-36 amide 0.8 pmol/kg/min infusions. Furthermore, 
there was no significant difference between mean plasma concentration of total PYY 
achieved when PYY3-36 was infused singly or in combination with GLP-17-36 amide. This 
was true for repeated measures analysis over the whole study (i.e. t = -60 to t = 120 
min) as well as for repeated measures analysis for samples analysed during the 
infusion period (t= 15 to t= 90 min).  Figure 2.5 shows the variation of plasma total 
PYY levels with time in the Dose Verification Study. 
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Figure 2.5  Plasma Total PYY Levels During Dose Verification Study. 
 
Six healthy subjects underwent infusions of saline , 0.3 pmol/kg/min PYY3-36 , 0.8 
pmol/kg/min GLP-17-36amide and combined 0.3 pmol/kg/min PYY3-36 + 0.8 
pmol/kg/min GLP-17-36amide . All subjects were fasted overnight before each study 
visit.  On each visit, the infusion was administered between t= 0 and t= 90 min, after 
which lunch was immediately served.  
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2.3.4  Total Plasma Amidated GLP-1 Levels in Dose Verification Study   
 
Mean plasma concentration of amidated GLP-1 (from time points t = 15 min to t = 90 
min) was 19.8 ± 0.2 pmol/L when saline was infused, 17.2 ± 0.5 pmol/L when 0.3 
pmol/kg/min PYY3-36 was infused, 58.9 ± 6.0 pmol/L when 0.8 pmol/kg/min GLP-17-36 
amide was infused, and 59.4 ± 5.7 pmol/L when the combination of 0.3 pmol/kg/min 
PYY3-36 + 0.8 pmol/kg/min GLP-17-36 amide was infused.  
 
Peak mean plasma concentration of total amidated GLP-1 (during the entire study) 
was 32.4 ± 4.7  pmol/L when saline was infused (occurring post-prandially at t = 120 
min), 26.3 ± 4.0  pmol/L when 0.3 pmol/kg/min PYY3-36 was infused (occurring post-
prandially at t= 120 min), 73.3 ± 6.7 pmol/L when 0.8 pmol/kg/min GLP-17-36 amide was 
infused (occurring at t= 90 min), and 73.0 ± 9.4 pmol/L pmol/L when the 
combination of 0.3 pmol/kg/min PYY3-36 + 0.8 pmol/kg/min GLP-17-36 amide was infused 
(occurring at t = 90 min).  
 
There was no significant difference between plasma concentration of total amidated 
GLP-1 achieved between saline and single PYY3-36 infusions. There was also no 
significant difference between mean plasma concentration of total amidated GLP-1 
achieved when GLP-17-36 amide was infused singly or in combination with PYY3-36. This 
was true for repeated measures analysis over the whole study (i.e. t = -60 to t = 120 
min) as well as for repeated measures analysis for samples analysed during the 
infusion period (t= 15 to t= 90 min). Figure 2.6 shows the variation of plasma total 
amidated GLP-1 levels with time in the Dose Verification Study. 
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Figure 2.6   Total Plasma Amidated GLP-1 During Dose Verification Study  
 
Six healthy subjects underwent infusions of saline , 0.3 pmol/kg/min PYY3-36 , 0.8 
pmol/kg/min GLP-17-36amide and combined 0.3 pmol/kg/min PYY3-36 + 0.8 
pmol/kg/min GLP-17-36amide . All subjects were fasted overnight before each study 
visit.  On each visit, the infusion was administered between t= 0 and t= 90 min, after 
which lunch was immediately served.  
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2.4  DISCUSSION 
 
 
The combined infusion of 0.3 pmol/kg/min PYY3-36 + 0.8 pmol/kg/min GLP-17-36 amide 
led to a statistically significant 32% reduction in ad libitum energy intake during the 
test meal compared with the control saline visit. This was associated with a small 
and tolerable rise in nausea ratings – notably only recorded on the written VAS 
scoresheets and never verbally reported during the infusions by any subject, or 
severe enough to necessitate discontinuation of the infusion. Single infusions of each 
of the hormones at these doses appeared to have no effect at all on subsequent 
energy intake in this small group of healthy volunteers, and also produced no 
nausea.   
  
A peak mean plasma total PYY concentration of 106.5 pmol/L and total GLP-1 level of 
73 pmol/L was achieved during the combined 0.3 pmol/kg/min PYY3-36 + 0.8 
pmol/kg/min GLP-17-36 amide infusion.  In the previously cited paper where 
combination 0.4 pmol/kg/min PYY3-36 + 0.4 pmol/kg/min GLP-17-36 amide were co-
infused, the peak circulating PYY and GLP-1 levels reported were 58.4 pmol/L and 
62.5 pmol/L respectively (Neary et al., 2005).  These discrepancies may be partly due 
to the fact that the doses used in this study were adjusted for the peptide content of 
the prepared vials.  Furthermore, there is likely to be a degree of inter-assay 
variation.  Circulating plasma hormone levels fell sharply (more so for GLP-1) back 
towards baseline within 30 minutes of discontinuation of the infusions, adding 
weight to the decision to serve the test meal immediately after termination of the 
infusion. 
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Although limited by small sample size, the results from this dose verification study 
were reassuring.  At the chosen doses of 0.3 pmol/kg/min PYY3-36 and 0.8 
pmol/kg/min GLP-17-36 amide, single gut hormone infusion was subanorectic, combined 
gut hormone infusion significantly reduced food intake without inducing serious 
nausea and the plasma levels achieved were in line with the literature.  These doses 
were taken forward into the functional neuroimaging study described in the next 
chapter.  
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CHAPTER 3  
 
 
Investigation of the Effects of single 
and Combined Administration of 
PYY3-36 and GLP-17-36 amide on Brain 
Appetite Centres using fMRI. 
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3.1  INTRODUCTION 
 
Blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) 
has recently been used as a tool to investigate the changes in brain activity 
associated with differences in nutritional status in humans. It is hoped that a clearer 
understand of brain appetite pathways will aid the rational design of effective anti-
obesity agents.  Activity of reward systems in the brain is increased in the fasted 
state compared to the fed state with presentation of food-relevant stimuli.  
However, there are only a few reports on the use of fMRI for characterization of 
human brain activity following the systemic administration of appetite-altering 
hormones. Intravenous infusion of PYY3-36 to human subjects modulates activity in 
brain regions mediating appetitive behaviour and leads to reduced food intake. 
However, there have been no human fMRI studies investigating the effects of 
administration of GLP-1, or co-administration of PYY and GLP-1 on brain activity in 
humans.  
 
In this work, I have used BOLD fMRI to investigate the changes in brain activity 
following single or combined administration of PYY3-36 and GLP-17-36amide in fasted 
healthy human subjects and compared the effects to those seen naturally following a 
meal. 
 
 
3.2  METHODS 
 
3.2.1  Peptides 
 
The same batch of peptides and corresponding dose calculations were used as for 
the Dose Verification Study (Section 2.2.1) 
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3.2.2  Participants 
 
For the imaging study, it was predicted that a sample size of 16 will have 90% power 
to detect a difference in mean food intake of 950 kJ assuming a standard deviation 
of differences of 1140, using a paired t test with a 0.05 two sided significance level.    
 
Inclusion and exclusion criteria for the imaging study and the screening protocol 
were identical to those adhered to for the preliminary Dose Verification Study 
(described in full detail in Section 2.2.2).  A copy of the volunteer information sheet 
for the study is given in Appendix IV. 
 
 
 
3.2.3  Study Protocol for the Gut Hormone fMRI study 
 
 
As for the dose verification study, volunteers were asked to fast (they were 
permitted to drink only water) from 22:00h the evening before each study visit.  
They standardised their diet (by eating the same evening meal at the same time the 
night before each study visit), abstained from alcohol and avoided strenuous 
exercise for 24 hours prior to each visit.  Study visits were separated by a minimum 
of three full days. 
 
The fMRI study was conducted in a single-blinded fashion. On their first visit, 
subjects always received an infusion of saline after an overnight fast. This protocol 
was identical to that used for the following fasted visits, and was intended to 
acclimatise the subject to the clinical environment and to experimental procedures.  
At the start of the acclimatisation visit, the nature of the MRI scan experience was 
explained to the volunteers.  This first scanning session also included an additional 
structural brain scan (2 minutes duration) to exclude organic disease and to act as an 
anatomical template for future functional analyses.  Functional data from the 
acclimatisation saline visit are not included in the analysis. 
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Following the first visit, subjects were randomly assigned to receive each of the 
following: 
 
1. Overnight fast followed by saline infusion (the fasted, control visit) 
2. Overnight fast followed by a set breakfast, then saline infusion (the fed visit) 
3. Overnight fast followed by PYY3-36 infusion at 0.3 pmol/kg/min 
4. Overnight fast followed by GLP-17-36 amide infusion at 0.8 pmol/kg/min  
5. Overnight fast followed by combined PYY3-36 and GLP-17-36 amide infusion, at 
0.3 pmol/kg/min and 0.8 pmol/kg/min respectively 
 
Subjects arrived for each visit at 09:00 h (t= -90 min). Peripheral venous cannulae 
were immediately inserted in both forearms and subjects could relax and read in a 
room next to the scanner until the preparation for the study had been completed. At 
that stage, a 100 cm long extension line was attached to the larger cannula so that 
blood samples could be taken without disturbing the subject during the scan.  During 
this period all time and food cues were removed from the room. 
 
On their fed visit, subjects received a 730 kcal set breakfast as described in Appendix 
V, which was served in a private area between 09:30 – 09:50 h (t= -60 to -40 min). At 
10:30 h (t= 0 min), the subject was taken into the scanning room and the 90 minute 
infusion started.   
 
All syringes and lines used to deliver peptide were coated in Gelofusin for twenty 
minutes as described for the Dose Verification Study.  The MEDRAD MR Injector 
Spectris Solaris EP (Seimens UK, Camberley, Surrey) pump was used to deliver the 
hormone infusions at a constant rate of 54ml/hr.  Vials of peptide were dissolved in 
2.5ml vehicle (10% Gelofusin in normal saline) and the amount of peptide added to 
the delivery syringes varied according to the weight-adjusted dose each subject 
received.  
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Six ml blood samples were collected at t= -60, 0, 15, 30, 45, 60, 75, 90 and 120 min 
and processed and stored as described in Section 2.2.3.  Three ml deadspace blood 
was collected and discarded at each sample point to account for the 100 cm long 
extension line.  
 
At t= -60, 0, 90, and 120 min, subjects completed a series of 100 mm visual analogue 
scores (VAS) that rated five food-related sensations (hunger, nausea, pleasantness to 
eat, how much one could eat, fullness), and four non-food related sensations 
(sleepiness, irritability, anxiety and warmth) (Appendix I). 
  
The pulse and blood pressure of each subject was measured at t= -60, 0, 15, 30, 60, 
75, 90, and 120 min. A drop of blood was taken from the t= -60, 0, 30, 60, 90 and 120 
min samples to check blood glucose with an Optimum Exceed blood glucose monitor 
(Abbott Diabetes Care, Maidenhead, Berks).   
 
Twenty minutes after the start of the infusion (i.e. t= 20 min), the 60 minute fMRI 
scan began.  Subjects lay supine in the scanner, with a specially designed head coil to 
optimise brain signal acquisition and padding to minimise head movements.  
Volunteers could verbally communicate with the radiographer, if required, at all 
times.  The subjects were requested to stay awake throughout, and they were asked 
about their general wellbeing during periodic breaks in image acquisition.   At the 
end of the scan, subjects were helped to sit up slowly, and stayed in the scanner 
room for a further 10 minutes until the infusion was stopped at t= 90 min.  The 
subject was then immediately led into a nearby private dining area where an ad 
libitum buffet meal (as described in Section 2.2.3) was served.  The lunch was 
provided in excess so that all appetites could be satisfied. Subjects were instructed 
to “eat until comfortably full”. Subjects were allowed to go home at t = 120 min.  
 
The protocol for the fRMI study is summarised in Figure 3.01. 
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 Figure 3.01 Protocol for Gut Hormone fMRI study 
 
Following an overnight fast, fifteen healthy, normal-weight subjects each received the 
following interventions, in random order, over 5 separate study days in a single-blinded 
fashion: 
 
1. 90 minute saline infusion (fasted saline, control visit) 
2. Standard breakfast, then 90 minute saline infusion (fed saline) 
3. 90 minute PYY3-36 infusion at 0.3 pmol/kg/min  
4. 90 minute GLP-17-36 infusion at 0.8 pmol/kg/min  
5. 90 minute combined PYY3-36 and GLP-17-36 infusion, at 0.3 pmol/kg/min and 0.8 
pmol/kg/min respectively. 
On each visit, subjects underwent a 60 min fMRI scan, which commenced 20 min after the 
start of the infusion. During the fMRI scan, a picture processing task was performed where 
images of food and non-food were shown. The mean % change in BOLD signal in pre-
specified brain regions of interest when viewing images of food compared to non-food were 
determined for each study day. An ad libitum buffet meal was served immediately after the 
infusion on all study days in order to measure energy intake. Blood sampling (for PYY and 
GLP-1) and assessments of appetite (based on visual analogue scores (VAS)) was performed 
at the time points shown. 
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3.2.4  BOLD fMRI Food Image Task  
 
During the fMRI scan, subjects were asked to watch and rate a series of colour 
images.  These visual stimuli were viewed via an angled mirror, which reflected 
images back-projected from a screen positioned in the bore of the magnet behind 
the subject’s head.  There were two sets of 75 images, alternated between each 
scanning session.  The 75 images that were shown during each scan were divided 
into three classes of 25 exemplars:  25 high-calorie foods, 25 low-calorie foods and 
25 non-food items (everyday objects eg watch, chair or scenery) (Figure 3.02).  The 
images appeared in blocks of 5 of the same exemplar, each image shown for 5 
seconds, and each 25 second block interspersed with periods of rest, during which 
time a blue octagon was projected.  Images from each category were presented in 
counterbalanced order across participants for the first three sessions, which was 
repeated for the final three sessions.  Non-food images were chosen as a positive 
control requiring similar perceptual analysis to food images but without any obvious 
affective or motivational value.  These images were imported from another 
appetitive fMRI study (Beaver et al., 2006), and revalidation of the salience ratings of 
these images was not formally repeated in this study group.   
 
The food image task paradigm allows for a subtraction analysis of the fMRI data.  In 
short, certain brain regions will be activated in response to food images more than 
non-food images.  The difference in regional brain activation between viewing 
images of food or non-food can be studied in different physiological conditions (eg 
the fasted state, the fed state or in the presence of exogenously administered 
anorectic hormones).  A larger difference entails a greater food-salient activation in 
that region under that condition. 
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Figure 3.02  Examples of Images Shown During the BOLD fMRI Food Image Task  
 
During the fMRI scan, subjects were asked to watch and rate a series of colour 
images. The images were divided into three classes of exemplars:  high-calorie foods 
(bottom row), low-calorie foods (middle row) and non-food items (everyday objects 
eg watch, chair or scenery, top row).  Non-food images were chosen as a positive 
control requiring similar perceptual analysis to food images but without any obvious 
affective or motivational value. Each image was shown for 5 seconds in blocks of 5 of 
the same exemplar, interspersed by short periods of rest.  25 images from each 
category were presented in counterbalanced order across participants for the first 
three sessions, which was repeated for the final three sessions.  In the ROI analysis, 
mean brain activation in response to presentation of blocks of food minus non-food 
images was calculated. 
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3.2.5  fMRI Data Acquisition 
 
T2*-weighted, dual echo, echo-planar images sensitive to BOLD contrast were 
acquired continuously on a 3T Siemens Tim Trio scanner with a 32-channel head coil 
(Siemens Healthcare, Erlangen, Germany). Each scan session consisted of 501 
volumes of 36-slice acquisition, angled ~300 coronally to the anterior-posterior 
commissural plane to minimize signal dropout in orbitofrontal and medial temporal 
regions (TR = 2000 ms; dual TEs = 13 and 31 ms; flip angle = 800, slice thickness= 3.0 
mm, matrix size = 64 × 64, and field of view = 225 × 225 mm2 for voxel size of 3.51 × 
3.51 × 3.0 mm). High-resolution T1-weighted anatomical scans were acquired with 
whole-brain coverage (208 slices) for each participant to facilitate fMRI image co-
registration, and ROI definition (TR = 3000 ms, TE = 3.66 ms, flip angle = 90, voxel size 
= 1 mm³). 
 
3.2.6  fMRI Data Analysis 
 
fMRI data were processed using FEAT (FMRI Expert Analysis Tool) Version 5.98, part 
of the FSL software package (www.fmrib.ox.ac.uk/fsl/).  The following pre-processing 
was applied: motion correction using MCFLIRT; fieldmap-based EPI unwarping using 
PRELUDE+FUGUE and non-brain removal using BET (Jenkinson et al., 2002, Jenkinson 
and Smith, 2001).  Data were high-pass filtered and spatially smoothed (5mm Full 
Width Half Maximum Gaussian kernel) to allow for gyral variability across subjects 
and to improve signal-to-noise ratio at the intra-subject level.  Individual sessions 
with greater than 3.5mm absolute head motion or severe stimulus-correlated 
motion (as exhibited by marked rim artefacts in the later intra-subject statistic maps) 
were excluded from further analysis. The echo planar functional images of each 
individual were then registered to the high-resolution anatomical (T1-weighted) scan 
using FLIRT, and overlaid on a standardized brain atlas (Monreal Neurological 
Institute, Quebec, Canada) in order to allow for comparisons across individuals.  
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A general linear model (GLM) was applied to detect task-related neural activation.  In 
essence, neural response is modelled by convolution of the haemodynamic response 
function with a boxcar (food image on/off) stimulus function, and subsequent 
random effects contrast analysis (high-calorie food vs. non-food, low-calorie food vs. 
non-food, food vs. non-food).  For each voxel, the GLM estimates a parameter, β, 
which represents the “goodness-of-fit” of the model at that voxel, relative to noise.  
The higher the β, the better the fit and therefore the more likely the measured MRI 
signal change over time in that voxel correlates with the stimulus.  A t-score is then 
calculated, which for each voxel is β / standard deviation of β.  This is converted to a 
z-score for whole brain analysis, with conventionally applied thresholds to decide 
which voxels have β scores high enough to qualify as “activations”. Since brain 
activations tend to happen in clusters of connected voxels, the statistical threshold is 
actually applied to clusters (ie cluster-corrected). 
 
Thus, the first stage of data analysis was the production of whole-brain z-statistic 
parametric maps.  A statistical threshold of P<0.001 uncorrected and cluster extent > 
5 voxels was used, while controlling the family-wise probability of type 1 error at 
p<0.05. The anatomical labelling of activations was checked with reference to 
neuroanatomical atlases.  The overlaid thresholded maps for the fed and fasted visits 
confirmed which areas of the brain were activated by the food image paradigm 
(“effect of task”).   
 
At this exploratory stage it was noted that when contrasting BOLD signal between 
high-calorie food images and low-calorie food images, the effect of task was less 
pronounced than when contrasting BOLD signal between all food images and non-
food images, although similar brain regions were implicated.  It was therefore 
decided that all subsequent ROI analysis be performed contrasting only combined 
food vs non-food images only.  
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3.2.7  ROI Analysis of fMRI Data 
 
The a priori ROIs chosen for this imaging project [amygdala, caudate, insula, nucleus 
accumbens (N Acc), orbitofrontal cortex (OFC) and putamen] were based on 
previous understanding of which parts of the corticolimbic reward network are 
particularly pertinent to the processing of visual food cues. 
 
All ROIs were defined as the conjunction between the full group main effect of task 
(food vs. non-food, using parametric testing at the level of spatially contiguous 
supra-thresholded clusters, while controlling the family-wise probability of type 1 
error at p<0.05, corrected – as described above) and the relevant anatomical region 
on a standard brain atlas. 
 
Using FSL’s ‘featquery’ tool, the mean % BOLD signal change was extracted for each 
ROI.  This is computed by scaling the relevant GLM contrast parameter estimate with 
the peak-to-peak regressor amplitude and normalising this ‘signal change’ factor 
with the global image mean.  Hence, whilst z-statistics do not convey the amplitude 
of activation, the extraction of % BOLD signal change allows for the description of 
how great the stimulus-induced regional activation was.  These estimates were 
averaged over right and left homologous regions, such that the report for each ROI is 
not lateralised. For each infusion, the null hypothesis tested was that the within-
subject difference between fasted saline, fed saline, PYY infusion, GLP-1 infusion or 
combined PYY + GLP-1 infusion in regional BOLD response to food images vs. non-
food images was zero, i.e. [the gut hormone infusion or fed saline BOLD response to 
food image exposures] – [fasted saline BOLD response to non-food image exposures] 
= ΔBOLD = 0.  
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3.2.8  Plasma Hormone Level Analysis 
 
 
‘Total’ PYY levels (measuring both the active form PYY3-36, and its inactive precursor 
PYY1-36) were measured using the in-house RIA described in Section 2.2.4.1 and 
detailed in Appendix II.   A second aliquot was run on a commercial 
radioimmunoassay (Millipore Corporation, MA, USA) with the following stated 
specificity:  human PYY3-36 100% and human PYY1-36 not detectable. This was in order 
to measure only ‘active’ PYY levels.  Details of the commercial PYY RIA are also given 
in Appendix II. 
 
 
‘Total’ amidated GLP-1 levels (that is GLP-11-36amide,  GLP-17-36amide and GLP-19-36amide) 
were measured using the in-house RIA described in Section 2.2.4.2 and detailed in 
Appendix  II.   ‘Active’ GLP-1 immunoreactivity was measured using a commercially 
available ELISA kit (Millipore Corporation, MA, USA), with the following specificities:  
GLP-17-36amide 100%,  GLP-17-37 72%,  GLP-11-36 OR GLP-11-37   <2%.  Details of the 
commercial GLP-1 ELISA kit are reproduced in Appendix II. 
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3.2.9  Statistical Analysis 
 
Combined data are represented as the mean ± SEM. Comparisons of energy intake 
and ratings of meal palatability were by repeated measures ANOVA with Tukey’s 
multiple comparison post-test and Dunnett’s comparison post-test against the fasted 
saline visit. VAS scores were adjusted for baseline and differences between t= 0 min 
and t= 90 min compared by repeated measures non-parametric Friedman’s test with 
Dunn’s multiple comparison post-test. Linear regression analysis was performed to 
assess correlation between nausea and energy intake over the whole study. 
Comparisons of plasma gut hormone levels during the infusion period (plasma 
samples from t=15 - 90 min inclusive) were by repeated measures ANOVA with 
Tukey’s multiple comparison post-test. The threshold for statistical significance in 
each case was set at p<0.05.  Analyses were performed using Prism version 5.01 
software (Graphpad Software, San Diego, CA, USA). 
 
The statistical model for the fMRI study was a repeated measures analysis of 
difference of means, between control (fasted saline) and each infusion session BOLD 
data. ROI analysis was performed using repeated measures ANOVA with Tukey’s 
multiple comparison post-test and Dunnett’s comparison post-test against the fasted 
saline visit.  Simple linear regression analysis was used to examine the relationship 
(Pearson correlation coefficient, r) between ROI BOLD signal change and VAS ratings, 
plasma gut hormone levels and energy intake at lunch. The threshold for statistical 
significance in each case was set at p<0.05. Analyses were performed outside FSL, 
using Prism version 5.01 software (Graphpad Software, San Diego, CA, USA). 
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3.3  RESULTS 
 
3.3.1  Participants 
 
16 healthy right-handed subjects (11 male, 5 female, mean age 29.5 years, range 21-
36 years, mean body mass index 22.1 kg/m2, range 18.3-25.1 kg/m2) were recruited 
and completed all 6 scanning sessions.  At the analysis stage, one male subject was 
excluded due to excessive head movement that caused gross image distortion, 
resulting in a complete dataset from 15 subjects for analysis. 
 
3.3.2  Energy Intake  
 
3.3.2.1  Energy Intake During Acclimatisation Visits 
 
Participants consumed significantly less energy at lunch on their initial 
acclimatisation visit compared with the subsequent, randomised fasted control visit, 
despite identical study protocols:  [Energy intake at ad libitum buffet lunch (kJ): 
fasted control, 4039 ± 399 vs. acclimatisation fasted saline, 3715 ± 419, p<0.05].   
 
3.3.2.2   Energy Intake During fMRI Study 
 
Consumption of the  standard breakfast by subjects before saline infusion (fed visit) 
led to a 23.5% ± 8.3% reduction in energy intake during the subsequent ad libitum 
buffet lunch, compared to when they received only saline infusion (fasted control 
visit):  [Energy intake at ad libitum buffet lunch (kJ): fasted control, 4039 ± 399 vs. 
fed, 3090 ± 335, p<0.01].  Infusion of PYY3-36, GLP-17-36amide or combined PYY3-36 and 
GLP-17-36amide to fasted subjects resulted in 12.3% ± 11.2%, 15.7% ± 7.5% and 27.0% ± 
9.4% reductions in energy intake, respectively, compared to the fasted control visit: 
[Energy intake at ad libitum buffet lunch (kJ): fasted control 4039 ± 399; PYY3-36 3542 
± 452; GLP-17-36amide 3407 ± 302; PYY3-36 + GLP-17-36amide 2950 ± 378].  The reduction in 
energy intake was significantly lower (p<0.001) relative to fasted saline only for the 
combined administration of hormone (Figure 3.03). 
82 
 
 
The additive effects of single infusions of PYY3-36 and GLP-17-36amide and the measured 
effects of the combined infusion of PYY3-36 and GLP-17-36amide on energy intake at the 
ad libitum lunch were comparable (Figure 3.04).  
 
 
3.3.2.3  Order Effect on Ad Libitum Energy Intake Across Visits 
 
The same lunch was provided at every study visit.  The caloric value of the food 
served at this buffet lunch was approximately 3000 kCal, but more food was 
available if required. None of the subjects consumed all of the food initially provided.  
 
Analysis of the mean energy intake (of the 15 subjects) during the ad libitum lunch 
across the 5 randomised visits is shown in Figure 3.05. Repeated measures ANOVA 
with Tukey’s post-test confirmed no evidence of habituation to the study meal.  
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Figure 3.03 Ad Libitum Lunch Energy Intake in fMRI Study by Condition 
 
Following an overnight fast, fifteen healthy, normal-weight subjects each received 
the following interventions, in random order, over 5 separate study days in a single-
blinded fashion: 
 
1. 90 minute saline infusion (fasted saline, control visit) 
2. Standard breakfast, then 90 minute saline infusion (fed saline) 
3. 90 minute PYY3-36 infusion at 0.3 pmol/kg/min  
4. 90 minute GLP-17-36 infusion at 0.8 pmol/kg/min  
5. 90 minute combined PYY3-36 and GLP-17-36 infusion, at 0.3 pmol/kg/min and 0.8 
pmol/kg/min respectively. 
An ad libitum buffet meal was served immediately after the infusion in order to 
measure energy intake on all study days. This graph shows the energy intake in 
kilojoules (kJ) during the buffet meal following each infusion. Data shown as mean ± 
SEM. ** denotes p<0.01 vs. fasted saline.  *** denotes p=0.0001 vs. fasted saline.  
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Figure 3.04 Reduction in Ad Libitum Lunch Energy Intake in fMRI Study for Each 
Condition Compared with Fasted Saline. 
 
This shows the reduction in energy intake in kilojoules (kJ) during the buffet lunch for 
each condition against the fasted saline (control) infusion. The arithmetic sum of the 
effects of individual infusions of PYY and GLP-1 (sum of PYY and GLP-1) are shown in 
the chequered box against the actual measured effect of the combined infusion (PYY 
+ GLP-1) at reducing food intake. 
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Figure 3.05  Order Effect of Visit Number on Ad Libitum Lunch Energy Intake in 
fMRI Study 
 
 
Following an overnight fast, fifteen healthy, normal-weight subjects each received 
the following interventions, in random order, over 5 separate study days in a single-
blinded fashion: 
 
1. 90 minute saline infusion (fasted saline, control visit) 
2. Standard breakfast, then 90 minute saline infusion (fed saline) 
3. 90 minute PYY3-36 infusion at 0.3 pmol/kg/min  
4. 90 minute GLP-17-36 infusion at 0.8 pmol/kg/min  
5. 90 minute combined PYY3-36 and GLP-17-36 infusion, at 0.3 pmol/kg/min and 
0.8 pmol/kg/min respectively. 
 
This graph shows the mean energy intake of the 15 subjects during the ad libitum 
lunch across the 5 randomised visits, by visit number not condition.  Results shown 
as mean +/- SEM.  Repeated measures ANOVA with Tukey’s post-test did not reveal 
any evidence that subjects ate progressively less during each subsequent visit as a 
result of habituation to the study meal. 
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3.3.3  VAS Results 
 
Visual analogue scores (VAS) by subjects confirmed that consumption of the 
standard breakfast significantly reduced subjective ratings of hunger, perceived 
pleasantness of eating more food and anticipated future consumption, as well as 
increasing a sense of “fullness”.  Similarly, in fasted subjects, combined infusion of 
PYY3-36 and GLP-17-36amide led to a small but significant reduction in hunger, perceived 
pleasantness of eating and anticipated food consumption, as well as increased 
“fullness” (Figure 3.06 A-D).   
 
Eleven out of the fifteen subjects also reported mild nausea with the combined 
infusion of PYY3-36 and GLP-17-36amide (Figure 3.07 A), but there was no correlation 
between nausea ratings during the infusion and subsequent energy intake during the 
ad libitum buffet meal (p= 0.23, r2 = 0.02, Figure 3.07 B). No subject verbally 
reported the nausea during the scan or withdrew from the study as a result of it.  By 
contrast, the single infusions of PYY3-36 or GLP-17-36amide were not associated with any 
significant changes in subjective feelings of hunger, perceived pleasantness of eating, 
anticipated food consumption, “fullness” or nausea (Figure 3.06 A-D and 3.07 A). 
 
There was no difference in food palatability ratings across all visits, as judged by the 
VAS score for “How tasty was the meal” taken immediately after lunch (Figure 3.08). 
Non-food related VAS scores (sleepiness, irritability, anxiety and warmth) did not 
alter significantly during any study (Figure 3.09 A-D). 
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Figure 3.07  Analysis of Nausea Related Visual Analogue Score (VAS) Parameters 
from t=-60 to t=90 min During each Infusion for the Gut Hormone fMRI Study. 
 
During each study subjects completed 100 mm visual analogue scale questionnaires 
relating to nausea (A). The change in VAS scores from baseline (t=-60 min) to the end 
of the infusion (t= 90 min) are shown. e denotes p<0.0001 for PYY+GLP-1 vs. all other 
groups. Across all infusions, there was no correlation between nausea and energy 
intake (p=0.23, r2 = 0.02) (B).   
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Figure 3.08 Meal Palatability Rating Following Ad Libitum Lunch in Gut Hormone 
fMRI Study. 
 
An ad libitum buffet meal was served immediately after the infusion at the end of 
every study visit.  Subjects retrospectively rated its palatability on a visual analogue 
scale of 0-100 in response to the question “How tasty was the meal”.  Results shown 
as mean +/- SEM.  Repeated measures ANOVA with Tukey’s post-test did not reveal 
any evidence of taste aversion.  
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3.3.4  Physiological Measurements  
 
There were no physiologically significant or sustained changes in systolic and diastolic blood 
pressure, pulse or blood glucose after hormone or placebo administration (Figure 3.10 A-D).  
Blood glucose measurements at t=0 (ie at the start of the saline infusion) were non-
significantly higher on the fed visit compared with on the fasted visit (mean blood glucose 
(mmol/L):  fasted control visit, 5.49 +/- 0.09 vs fed visit 6.05 +/- 0.28), a difference whch 
became even less pronounced by t=30 min. 
 
No significant adverse events were experienced by any of the subjects. 
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3.3.5  Plasma PYY and GLP-1 Levels Measured in the fMRI study 
 
3.3.5.1  Plasma Levels of Total PYY and Total (Amidated) GLP-1 
 
The in-house RIA measured total plasma levels of PYY (that is, PYY3-36 and PYY1-36) 
and total plasma levels of amidated GLP-1 (that is, GLP-11-36amide, GLP-17-36amide and 
GLP-19-36amide) over the course of the study.  These are shown in Figure 3.11.   
 
PYY3-36 infusion increased total plasma PYY levels to a peak of 78.8 +/- 6.7 pmol/L on 
the PYY3-36 infusion day and 93.5 +/- 8.4 pmol/L on the PYY3-36 and GLP-17-36amide 
infusion day. There was no significant difference between total plasma 
concentrations of PYY achieved when PYY3-36 was infused singly or in combination 
with GLP-17-36amide. There was no significant difference between mean total plasma 
concentrations of PYY during saline or GLP-17-36amide infusions (Figure 3.11 A).  
 
Analogously, GLP-17-36amide infusion resulted in an increase in total amidated plasma 
GLP-1 levels to a peak of 47.2 +/- 5.2 pmol/L on the GLP-17-36amide infusion day and 
51.2 +/- 5.0 pmol/L on the PYY3-36 and GLP-17-36amide infusion day. There was no 
significant difference between mean total plasma concentrations of GLP-1 achieved 
when GLP-17-36amide was infused singly or in combination with PYY3-36. There was no 
significant difference between mean total plasma concentrations of GLP-1 during the 
saline or PYY3-36 infusions (Figure 3.11 B).  
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Figure 3.11  Plasma Levels of Total PYY and Total (Amidated) GLP-1 in the fMRI Study 
 
On each study visit, the hormone infusion was administered between t= 0 and t= 90 min.  
Figure 3.11 A shows plasma total PYY levels (that is, PYY3-36 and PYY1-36). Figure 3.11 B shows 
plasma total amidated GLP-1 levels (that is, GLP-11-36amide, GLP-17-36amide and GLP-19-36amide) 
over the course of the study.    Data shown as mean +/- SEM 
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3.3.5.2  Plasma Levels of Active PYY and Active GLP-1 
 
In order to confirm that the fMRI signal changes were related to active circulating 
hormone and that the total plasma levels measured on the in-house RIAs described 
above were not primarily immunoreactive but biologically inactive breakdown 
products, a second aliquot of plasma from each subject was tested for active forms 
of both PYY and GLP-1. 
 
The commercial PYY RIA measured only the active circulating form of the hormone 
(that is, PYY3-36).  These results are shown in Figure 3.12 A.  Peak circulating levels of 
active PYY reached 59.8 +/- 3.7 pmol/L on the PYY3-36 infusion day and 63.6 +/- 2.7 
pmol/L on the PYY3-36 and GLP-17-36amide infusion day. There was no significant 
difference between these peaks.  There was also no significant difference between 
mean active PYY plasma concentrations during saline or GLP-17-36amide infusions. 
 
The commercial GLP-1 ELISA measured only active forms of the hormone (that is, 
GLP-17-36amide and GLP-17-37).  GLP-17-36amide infusion resulted in peak active GLP-1 
levels of 13.2 +/- 2.6 pmol/L on the GLP-17-36amide infusion day and 14.5 +/- 2.0 
pmol/L on the PYY3-36 and GLP-17-36amide infusion day.  There was no significant 
difference between these peaks.  There was also no significant difference between 
mean active GLP-1 plasma concentrations during saline or PYY3-36 infusions (Figure 
3.12 B). 
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Figure 3.12 Plasma levels of Active PYY and Active GLP-1 in the fMRI Study 
 
On each study visit, the hormone infusion was administered between t= 0 and t= 90 min.  
Figure 3.12 A shows plasma active PYY levels (that is, PYY3-36 only). Figure 3.12 B shows 
plasma active GLP-1 levels (that is, GLP-11-36amide and GLP-17-37) over the course of the study.   
Data shown as mean +/- SEM. 
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3.3.6  fMRI Analysis  
 
3.3.6.1  Whole Brain Activation with Presentation of Food-Salient Visual 
Stimuli (Effect of Task Analysis). 
 
Overlaid whole-brain maps of brain regions activated by food images (compared 
with non-food images) for the fasted saline and fed saline visits, thresholded at z > 
2.3 and p < 0.05, are shown in Figure 3.13.  A list of the anatomically defined task-
activated areas is given in Table 3.1.  All of the a priori chosen ROIs showed 
significant food-salient activation on this analysis, and are highlighted at the end of 
Table 3.1. 
 
It was not possible to demonstrate task-responsive signal changes in either the 
brainstem or hypothalamus, despite the following efforts to improve the probability 
of acquiring interpretable data (not shown): 
 
• fieldmap-based EPI unwarping during the image pre-processing phase, 
• re-analysing the MRI data weighted towards the first echo time (13 ms) 
rather than the second echo (31 ms), as for the rest of the image analysis, 
• reducing the statistical thresholding to z>1.6 on the effect of task maps. 
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Figure 3.13  Thresholded Effect of Task Maps 
 
During each infusion, a BOLD fMRI scan was performed, incorporating a picture 
processing task where images of food and non-food were shown. For the fasted 
saline and fed saline infusions, a whole brain map of brain regions activated (z-
statistics colour coded on the right-hand bar) by food images (compared with non-
food images) is shown.  Z indicates distance (mm) superior or inferior to the inter-
commissural plane in standard stereotactic space. Clusters were thresholded by 
means of parametric testing at the level of spatially contiguous supra-thresholded 
clusters, simultaneously controlling the family-wise probability of type 1 error at 
p<0.05, corrected. 
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Brain region 
MNI Coordinates of local 
maxima (mm) 
Max 
z-
score 
  X Y Z   
L Occipital -46 -68 -8 5.93 
R Occipital 16 -98 20 5.78 
L Inferior frontal gyrus/ frontal pole -44 38 12 5.42 
Posterior cingulate 0 -34 26 4.51 
R Paracingulate gyrus 8 12 42 4 
L Paracingulate gyrus -8 18 40 3.87 
L Superior frontal gyrus -18 2 54 3.79 
R Lateral occipital 32 -62 36 5.16 
R Posterior supramarginal gyrus 44 -40 44 3.98 
R Anterior supramarginal gyrus 52 -30 42 3.92 
R Angular gyrus 32 -48 32 3.91 
R Precentral gyrus 50 8 28 4.41 
R Inferior frontal gyrus 56 10 12 3.91 
R Middle frontal gyrus 48 14 42 2.38 
     L Amygdala -24 -4 -18 3.73 
R Amygdala 22 0 -18 3.76 
L Caudate -18 14 10 2.53 
R Caudate 18 4 20 3.33 
L Orbitofrontal cortex -34 34 2 3.8 
R Orbitofrontal cortex 26 36 -14 4.12 
L Insula -38 -6 4 5.09 
R Insula 40 8 -12 5.07 
L Putamen -20 4 8 3.01 
R Putamen 18 16 -6 3.42 
L Nucleus accumbens -14 16 -6 2.42 
R Nucleus accumbens 16 16 -8 3 
 
Table 3.1:  Local Maxima where ∆ BOLD (when subjects viewed images of food 
compared with when they viewed images of non-food) was Significantly Greater 
than Zero.  
 
Imaging measures (cluster peaks meeting a criterion of p<0.05, z >2.3) for saline 
infusion (in the fed and fasted state) are shown.  For each area, the MNI (Montreal 
National Institute) atlas co-ordinate where peak activation occurred is listed.  The a 
priori ROIs are highlighted in bold in the second half of the table 
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3.3.6.2   Amalgamated Region of Interest % BOLD Signal Change (food images 
minus non-food images) by Intervention. 
 
 
The effects of feeding, PYY3-36, GLP-17-36amide and combined PYY3-36 + GLP-17-36amide on 
changes in mean % BOLD signal in the total brain volume represented by the 
amalgamated 6 a priori selected ROIs is shown in Figure 3.14.  When fasted subjects 
(during the saline, control visit) viewed images of food compared with when they 
viewed images of non-food, there was significantly greater MRI signal in all of the 
ROIs tested (Table 3.1).  This % BOLD signal change for food minus non-food images 
was significantly attenuated (p<0.001) after administration of PYY3-36 or after co-
administration of PYY3-36 + GLP-17-36amide. There was a non-significant reduction in the 
mean % BOLD signal change in the amalgamated ROIs following feeding or after GLP-
17-36amide administration compared to fasted control.  
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Figure 3.14  Amalgamated Region of Interest % BOLD Signal Change (food images 
minus non-food images) by Intervention. 
 
The mean % BOLD signal change (food images minus non-food images) across all 6 
ROIs studied (amygdala, insula, caudate, nucleus accumbens, orbitofrontal cortex 
and putamen), is shown for each of the interventions.  Data are shown as mean ± 
SEM. ** p<0.01, *** p<0.001.  
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3.3.6.3    Individual Region of Interest Analysis by Intervention. 
 
The mean % change in BOLD signal in subjects after feeding, PYY3-36, GLP-17-36amide 
and combined PYY3-36 + GLP-17-36amide infusion across the individual a priori selected 
ROIs (left and right hemisphere data combined) is shown in Figure 3.15.  Following 
correction for multiple comparisons, only the insula showed a statistically significant 
reduction in signal compared to the fasted, saline visit for the fed, PYY3-36 and 
combined PYY3-36 + GLP-17-36amide conditions.  However, there was general pattern of 
a reduction in BOLD signal for all conditions in all ROIs against the fasted control 
visit.  Tables 3.2 (a-f) detail peak activations for each of the interventions (feeding, 
PYY3-36 infusion, GLP-17-36 amide and PYY3-36+GLP-17-36 amide) for each ROI. 
 
The reduction in mean % BOLD signal change with the combined infusion of PYY and 
GLP-1 was similar to the arithmetically summed reduction in mean % BOLD signal 
changes after individual administrations of the two hormones (Figure 3.16). 
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Tables 3.2 (a-f)   Peak Activation Coordinates for Each Comparator Condition by 
Region of Interest 
 
Imaging measures (cluster peaks meeting a criterion of p<0.05, z >1.6) for all treatment 
contrasts in each ROI are shown. Cluster peaks where there was greatest difference in mean 
% change in BOLD signal (when viewing images of food versus non-food) in subjects after 
feeding, PYY3-36, GLP-17-36 amide or combined PYY3-36 & GLP-17-36 amide infusion are given for each 
comparator condition.  Where there was no significant ΔBOLD, n/a is inserted.  MNI 
(Montreal National Institute brain atlas) co-ordinates are shown in millimetres.  The number 
of contiguous voxels exceeding threshold activation is given in the first column (voxels) and 
the z-score (Max z) for that cluster of activation given in the end column.   
 
Table 3.2a 
AMYGDALA  
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 94 -12 -2 -20 2.48 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 6 14 0 -18 2.28 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 2 -20 -7 -16 1.81 
PYY>Fasted saline 0 n/a n/a n/a n/a 
PYY<Fasted saline 5 -21 0 -18 1.92 
 
Table 3.2b 
CAUDATE 
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 11 -1 -5 19 2.08 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 9 2 19 4 1.96 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 13 5 0 16 2.23 
PYY>Fasted saline 7 -16 -11 22 1.77 
PYY<Fasted saline 46 15 20 4 2.45 
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Table 3.3 c 
INSULA 
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 796 2 4 -5 3.13 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 734 0 9 -2 3.07 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 265 16 7 -6 2.43 
PYY>Fasted saline 4 -17 -13 14 1.86 
PYY<Fasted saline 1198 4 7 4 3.15 
 
Table 3.3 d 
NUCLEUS ACCUMBENS 
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 5 -11 12 -11 1.88 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 26 -4 12 -10 3.02 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 0 n/a n/a n/a n/a 
PYY>Fasted saline 0 n/a n/a n/a n/a 
PYY<Fasted saline 53 -7 14 -9 2.91 
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Table 3.3 e 
ORBITOFRONTAL CORTEX 
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 22 -7 63 -12 1.91 
PYY+GLP-1<Fasted saline 628 -12 30 -18 2.83 
Fed saline>Fasted saline 305 -12 48 -16 2.38 
Fed saline<Fasted saline 207 -10 21 -12 2.35 
GLP-1>Fasted saline 133 -21 53 -12 2.31 
GLP-1<Fasted saline 90 23 25 -7 2.56 
PYY>Fasted saline 24 -32 29 -18 2.06 
PYY<Fasted saline 594 -2 26 -13 2.72 
 
 
Table 3.3 f 
PUTAMEN 
(FOOD MINUS NON-
FOOD) CLUSTER 
MNI CO-ORDINATES OF 
CLUSTER PEAK (mm) 
COMPARISON 
Voxels 
(n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 3 10 9 -11 1.87 
Fed saline>Fasted saline 5 8 -15 2 1.76 
Fed saline<Fasted saline 200 -11 11 -4 2.83 
GLP-1>Fasted saline 5 32 -8 2 1.75 
GLP-1<Fasted saline 5 6 3 1 1.79 
PYY>Fasted saline 10 30 -13 4 1.94 
PYY<Fasted saline 269 4 12 -5 2.76 
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Figure 3.16 Summed Reduction in Mean % BOLD Signal Change in ROIs with 
Individual Administration of PYY3-36 and GLP-17-36amide, Compared with the 
Reduction in Mean % BOLD Signal Change Measured after Combined 
Administration of PYY3-36 and GLP-17-36amide.  
 
The reduction in mean % BOLD signal change when subjects viewed images of food 
compared with when they viewed images of non-food compared with Fasted saline 
is expressed as a sum of the effects of individual PYY3-36 and GLP-17-36amide 
infusion(lilac bars). This is compared with the actual measured reduction in mean % 
BOLD signal change compared with Fasted saline for the combination infusion 
(purple bars). Data are shown for individual ROIs (amygdala, insula, caudate, nucleus 
accumbens, orbitofrontal cortex and putamen). 
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3.3.6.4  Regression Analysis of ROI MRI Signal with VAS Scores, Gut Hormone 
Levels and Energy Intake. 
 
There was no correlation between changes in nausea ratings on the VAS scores over 
the time course of the infusion and the change in BOLD signal for any of the 
interventions (fasting, feeding, PYY3-36 infusion, GLP-17-36 amide and PYY3-36+GLP-17-36 
amide) in any of the 6 ROIs.  This was analysed by plotting each subject’s change in 
nausea VAS score (t=90 mins minus t=0 mins) against their % change in BOLD signal 
for each ROI and every experimental condition. 
 
There was no correlation between changes in plasma gut hormone levels and the 
change in BOLD signal for any of the interventions (fasting, feeding, PYY3-36 infusion, 
GLP-17-36 amide and PYY3-36+GLP-17-36 amide) in any of the 6 ROIs.  This was analysed by 
plotting each subject’s area under the curve (AUC) for total and active hormone 
levels over the course of the infusion against their % change in BOLD signal for each 
ROI and every experimental condition. 
 
There was no correlation between change in BOLD signal for any of the interventions 
(fasting, feeding, PYY3-36 infusion, GLP-17-36 amide and PYY3-36+GLP-17-36 amide) in any of 
the 6 ROIs and subsequent energy intake at the buffet lunch.  This was analysed by 
plotting each subject’s ad libitum energy intake at lunch against their % change in 
BOLD signal for each ROI and every experimental condition. 
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3.4  DISCUSSION 
 
3.4.1  The Effects of Combination PYY3-36 and GLP-17-36amide Infusion on 
Energy Intake in Humans  
 
When analysing the effects of gut hormone infusion on appetite, it is always 
important to consider two potential confounders before making conclusions about 
the intervention on energy intake.  The first is anxiety, which has been shown to be 
increased (alongside increased stress hormone levels) on initial study visits 
(Chandarana et al., 2009).  Acute stress can cause an acute anorectic response via 
inhibition of hypothalamic NPY signalling, an effect which masked many early 
attempts to recreate the anorectic effects of exogenously administered PYY3-36 
(Abbott et al., 2006).  In support of this, the average energy intake on the 
acclimatisation visit in this study was 8% lower than that on the fasted saline 
(control) visit, despite an identical protocol.   
 
It is also important to consider an order effect on food intake across visits, with the 
possibility of subjects being progressively less enticed by the meal, resulting in lower 
energy intake at each subsequent visit. Following the initial acclimatisation visit, the 
remaining visits in this study were randomised in terms of the infusion administered 
(fasted saline, fed saline, PYY3-36, GLP-17-36 amide, PYY3-36 + GLP-17-36 amide). Therefore, 
one would expect an even distribution of individual interventions across all five study 
visits, which would counterbalance any possible order effects on average energy 
intake. Reassuringly, statistical analysis of the mean energy intake (of the 15 
subjects) during the ad libitum lunch across the five randomised visits (using a 
repeated measures ANOVA), revealed no evidence of such an order effect.   
 
This study demonstrated a 27% reduction in ad libitum energy intake during a buffet 
lunch following co-administration of 0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min 
GLP-17-36amide over 90 minutes, compared with saline-treated controls.  Single 
infusions of these doses of PYY3-36 and GLP-17-36amide produce smaller reductions in ad 
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libitum energy intake. The arithmetically summed effect of the single hormones was 
similar to the reduction in energy intake measured following combined infusion.  
Thus, whilst it is not possible to make firm conclusions about whether the effects of 
dual hormone infusion within this dose range are additive (or, indeed, synergistic), 
co-administration of PYY3-36 and GLP-17-36amide did not appear to lead to loss of effect 
of either individual hormone.  
 
The doses initially chosen for this study were based on previously reported studies, 
as described in Chapter 2.  However, variations in the technical details of infusion 
administration results in considerable differences between studies in plasma 
concentrations and biological effects for a given dose.  This is also partly a reflection 
of the very narrow therapeutic window in which gut hormones are able to exert an 
anorectic effect without nausea.  The earlier dose verification study was not 
designed to produce exhaustive dose-response information for each of the 
hormones alone or in combination, but rather to validate the informed choice of 
doses to safely take forward in the scanning stage. 
 
With this limited information however, it is still possible to suggest that co-
administration of low doses of PYY3-36 and GLP-17-36amide can avoid the nausea that 
would result from an equivalently anorectic dose of either hormone alone. It follows 
that combination treatment may offer greater efficacy than treatment with a single 
agent.  Since PYY3-36 is a selective agonist at the Y2 receptor, and GLP-17-36amide at the 
GLP-1 receptor, it is reasonable to predict that each hormone may have a separate 
effect on central appetite-regulatory areas.  This would allow a significant anorectic 
effect to occur without elevating plasma concentrations of either hormone to levels 
sufficient to produce nausea.  In this study, the combined gut hormone infusion did 
produce a significant increase in overall nausea scores by the end of the infusion 
compared to saline. However, in all cases the nausea was mild and tolerable.  In 
other studies, larger doses of PYY3-36 producing comparable reductions in food intake 
as achieved here with low dose combination infusion, are reported to induce severe 
nausea and vomiting (Sloth et al., 2007).  By comparison, the consumption of a large 
(but in no circumstance nauseating) breakfast in this study resulted in a 23% 
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reduction in food intake at lunch.  This physiological satiety effect is mediated by the 
slow, sustained secretion of numerous gut hormones at much lower concentrations 
than achieved with experimental infusions.   
 
Total hormone concentrations are more commonly reported in the literature and 
allow for more meaningful comparison with existing relevant data.  In this study, 
combined infusion of PYY3-36 and GLP-17-36 amide resulted in a mean total PYY 
concentration of 70 pmol/l and a mean total GLP-1 concentration of 43 pmol/l. The 
circulating levels of PYY and GLP-1 following breakfast were 33 pmol/l and 22 pmol/l 
respectively. In fact, the levels achieved with combined infusion in this study are 
much more comparable to concentrations measured in patients after bariatric 
surgery. Le Roux et al. found a mean 90 min post-prandial total PYY level of 40 
pmol/l and a mean 30 min post-prandial total GLP-1 level of 47 pmol/l in post-RYGB 
patients (le Roux et al., 2006a).  Therefore, although circulating levels achieved in 
this study may be regarded as supraphysiological within the normal population, they 
may be of greater functional relevance when considering the key role of PYY and 
GLP-1 in patients who have undergone gastric bypass surgery. This is important 
when taking into consideration the view that PYY and GLP-1 are implicated in 
mediating reduced appetite and promoting weight loss following gastric bypass.   
 
3.4.2   The Effects of Combination PYY3-36 and GLP-17-36amide Infusion on 
Subjective Appetite Ratings 
VAS scores provided by each subject revealed that consumption of the standard 
breakfast significantly reduced subjective ratings of hunger, perceived pleasantness 
of eating more food and anticipated future consumption, as well as increasing a 
sense of “fullness” compared to the fasted state.  The same subjects when fasted but 
receiving combined infusion of PYY3-36 and GLP-17-36amide reported smaller but still 
significant reductions in hunger, perceived pleasantness of eating and anticipated 
food consumption, as well as increased “fullness” compared to the fasted saline 
control visit.  These findings support previous reports that nutritional state impacts 
on the appeal and pleasantness of food (Uher et al., 2006, Stoeckel et al., 2007).  
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They also provide novel evidence that combination gut hormone infusion can mimic 
this phenomenon.  It has also been previously suggested that the palatability of food 
is reduced in the fed compared with the fasted state (Berridge, 1991).  However, 
retrospective rating of how tasty the lunch was in this study, revealed that whilst 
dual gut hormone infusion mirrored the appetite-reducing effects of physiological 
satiety (i.e. the fed state), it did not produce taste aversion. 
 
Overall, these findings add support to an anti-obesity pharmacotherapy based on the 
combination of PYY3-36 and GLP-17-36amide, which is likely to be efficacious and well-
tolerated. 
 
 
3.4.3   The Effects of Combination PYY3-36 and GLP-17-36amide Infusion on 
Haemodynamic and Glycaemic Parameters. 
Throughout every study visit, regular checks of blood pressure and blood glucose 
were recorded.  This was primarily to ascertain patient well-being but also for the 
following specific considerations: 
1. GLP-1 is an incretin hormone, capable of stimulating glucose-induced insulin 
secretion (Kreymann et al., 1987, Kim and Egan, 2008).  Since the exogenous 
infusion of the hormone was given only to subjects in the fasted state, it was 
not anticipated that it would incur any significant reduction in plasma glucose 
concentrations during the study, and this was confirmed on the data analysis. 
2. PP-fold peptides, particularly NPY acting via vascular smooth muscle Y1 
receptors, have long been known to exert vasoconstrictive effects 
(Wahlestedt and Reis, 1993). Y2 receptors have also been shown to more 
modestly potentiate angiotensin II–mediated renal vasoconstriction 
(Dubinion et al., 2006).  There were no effects of exogenous PYY3-36 infusion 
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on blood pressure and pulse during this study, in concurrence with other 
studies infusing near-physiological concentrations of the hormone 
(Batterham et al., 2002, Field et al., 2010).  
3.4.4   The Effects of Combination PYY3-36 and GLP-17-36amide Infusion on 
Brain Appetite Pathways in Humans as Studied using fMRI 
For the first time in humans, this study has shown that combined infusion of PYY3-36 
and GLP-17-36amide results in a similar modulation of brain activity as observed 
following a meal.  This is consistent with expectations that these hormones are 
important physiological mediators of post-prandial satiety.  In general, both the fed 
state and the administration of anorectic gut hormones to fasted subjects, reduces 
activation in brain reward regions in response to visual food-cues.  Numerous cross-
sectional studies have causally linked lack of breakfast consumption with increased 
daily fat intake, increased general consumption of high fat snacks and greater weight 
gain (Rampersaud et al., 2005, Masheb and Grilo, 2006, Timlin et al., 2008).  Others 
have reported that fasting leads to impulsive eating and weight re-gain in obese 
individuals on weight-reduction programmes (Schlundt et al., 1992). The 
neuroimaging findings here suggest that fasting heightens brain reward system 
activity in response to food cues, and that this can be dampened by feeding or the 
administration of anorectic gut hormones.   
Following rigorous statistical correction, the insula cortex was the brain area most 
significantly modulated by consumption of a meal and also by gut hormone infusion.  
This is much to do with the fact that the insula is the largest of the ROIs studied, 
situated at the interface of homeostatic and cognitive systems and involved in 
gauging the salience of external stimuli and initiating appropriate behavioural 
reactions.  Less robust, yet reproducible reductions in food-cue invoked activation 
compared to the fasting state were also seen in all of the other ROIs following meal 
consumption or gut hormone infusion, with the sole exception of the amygdala.  In 
this study, the physiological fed state appeared to make the amygdala more 
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responsive to food cues compared to when hungry, contrary to the findings of the 
earliest fed/fasted fMRI studies (LaBar et al., 2001, Morris and Dolan, 2001).  This 
may be the result of a statistical aberration, since with all gut hormone infusions 
food-invoked activation of the amygdala was attenuated as would be expected.   
 
A comparison of the arithmetically summed results of single infusions of PYY3-36 and 
GLP-17-36amide with the measured results from the combined infusion revealed no 
significant difference in the effect on % BOLD signal change in any ROI.  This mirrored 
the food intake analysis, which also suggested that the combined effects of the 
hormones were not counteractive.  However, only in the amygdala did the combined 
infusion produce less of a reduction in neuronal activity than the summed effect of 
the single hormones.  This observation did not reach statistical significance, and is 
likely to be due to normal inter-subject variation.  However, it is interesting to 
consider that these very slight aberrations in the behaviour of the amygdala may be 
representing the fact that it is playing a role in detecting some of the aversive (that 
is, nauseating) effects of gut hormone infusion.  On the other hand, a formal 
regression analysis did not show a significant correlation with amygdala activity and 
the (narrow range of) subjective nausea scores reported by the subjects.  This study 
was not designed to investigate the central mechanisms by which gut hormones 
switch from being anorectic to nauseating, although this clearly remains an area of 
great interest to those developing tolerable yet maximally effective 
pharmacotherapies. 
 
When PYY3-36 alone was infused in the fasted state, the pattern of signal change in 
brain reward ROIs was similar to that observed after feeding, with consistent 
reductions in mean % BOLD signal change across all brain reward ROIs. Reductions in 
signal change were most prominent (relative to the fed state) in the insula, nucleus 
accumbens and the OFC, consistent with a previous fMRI study of the effects of 
single infusion of PYY3-36.  As previously mentioned, PP-fold peptides have been 
reported as having vasoconstrictive effects, albeit largely mediated via the Y1 
receptor (to which PYY3-36 does not bind strongly) and not demonstrated in cerebral 
vasculature.  Nevertheless, the potential of any hormonal or even nutritional 
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manipulation to non-specifically alter BOLD response should always be considered.  
Previous studies have shown that caffeine reduces cerebral perfusion and increases 
BOLD signal intensity in response to visual stimulation (Laurienti et al., 2002).  No 
such effects have been reported for PYY3-36.   In fact, in this study, PYY3-36 (in line with 
the fed state) comparatively reduced BOLD signal intensity in all of the ROIs 
examined and did not produce any difference in activation pattern in the visual 
(occipital) cortex. 
 
Infusion of GLP-17-36amide alone led to consistent reductions in mean % BOLD signal 
change compared with fasted saline across all of the selected ROIs, in a pattern that 
most closely resembled the fed state.  Consistent and perhaps more profound 
reductions in mean % BOLD signal change, relative to infusion of saline alone, across 
all of the selected ROIs were also observed following combination infusion of PYY3-36 
and GLP-17-36amide.  As before, the insula appeared particularly sensitive to hormonal 
modulation. 
 
The lack of any obvious differential activation pattern between PYY3-36 and GLP-17-
36amide within the ROIs I studied here raises the question whether these hormones 
may be acting at the level of higher reward centres via a final common pathway. It is 
feasible that, having stimulated Y2 and GLP-1 receptors respectively in the brainstem 
and/or hypothalamus, circulating PYY3-36 and GLP-17-36amide have no direct effect on 
deeper (corticolimbic) brain structures and that the activation patterns seen 
represent input by upward projections from the hypothalamus.  In this, and most 
other fMRI studies utilising pictures of food, no effect of task activation was found in 
the hypothalamus.  This is most likely due to the technical limitations of 
hypothalamic imaging using BOLD-based techniques, which are discussed in full 
detail in the next section.  However, there are some other lines of evidence, to 
suggest that circulating gut hormones may directly influence reward pathways.  In 
rodents and humans both the Y2 and GLP-1 receptors are expressed in corticolimbic 
regions, although less densely than in the brainstem and hypothalamus (Gehlert et 
al., 1996, Stanic et al., 2006, Merchenthaler et al., 1999).  In rats, peripheral exendin-
4 (a potent and long-lasting GLP-1 mimetic) attenuates motivated (reward–seeking) 
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behaviour, an effect which is abolished by stereotactic injection of GLP-1 receptor 
antagonists into the NAcc (Dickson et al., 2012).   In other rodent studies, leptin has 
been shown to bind to amygdala-projecting ventral tegmental area dopamine 
neurons (the ventral tegmentum or VTA is another corticolimbic reward structure) 
(Leshan et al., 2010), and intra-VTA injection of ghrelin increases feeding (Skibicka et 
al., 2011).  It also remains untested as to whether, by directly modulating 
corticolimbic dopaminergic transmission, gut hormones have an effect on the 
pleasure perception of other rewards.  If they do, they may have a potential role in 
the treatment of drug addiction.  If their role is exclusively to modulate the 
perception of food cues, then the negative side effects on mood which have 
hampered other anti-obesity agents will not be an issue for gut-hormone based 
therapies. 
 
 
3.4.5  Limitations of fMRI 
 
It is pertinent to mention here that there are some inherent limitations when using 
BOLD-based fMRI to study homeostatic areas. The brainstem is difficult to visualise 
due to its proximity to large blood vessels and tendency to oscillatory image 
degradation with the cardiac cycle.  The hypothalamus has proven even more elusive 
due to its small size (approximately 5-8 mm in diameter) and its situation adjacent to 
the frontal skull sinuses.  T2*-weighted protocols, like BOLD fMRI, are particularly 
susceptible to signal loss as a result external magnetic field distortions around these 
air-tissue boundaries (Ojemann et al., 1997).  Furthermore, using the hungry, fasted 
state as an example, the net hypothalamic signal resulting from the activation of 
orexigenic nuclei and inhibition of anorexigenic nuclei may be very small, as 
opposing intrahypothalamic signals beyond the spatial resolution of the scanner 
cancel each other out.  It is also possible that the hypothalamus is not responsive to 
visual cues per se such that even if it were possible to image it, the visual-task 
paradigm is not an appropriate tool for eliciting differential hypothalamic activation.  
Thus, the current BOLD fMRI task-based paradigm is limited to the detailed analysis 
only of higher brain areas.  Even in this setting, although fMRI has provided novel 
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evidence that corticolimbic reward regions are modulated by circulating factors, 
there remains uncertainty as to which of these structures are directly responsive to 
the effects of gut hormones and which activations are correlates (as a result of 
spreading network activation) or consequences (e.g. motor functions related to the 
food-seeking response to reward). 
 
From the outset of this project, it was opted to perform an a priori ROI analysis of 
the fMRI data.  The major reason for this was to control for Type I error by limiting 
the number of statistical tests to a few ROIs. The thresholded effect-of-task map in 
the exploratory analysis was compiled only from the fed and fasted scans.  This 
provided information about which parts of the brain are activated specifically in 
response to food-image cues in physiological settings.  The previously selected ROIs 
were reassuringly all confirmed as task-responsive.  However, it is possible that areas 
of the brain which are not food responsive in the fed or fasted state, but become so 
when supraphysiological doses of gut hormones are administered, were missed.  
Similarly, by looking at the modulatory effects of gut hormone infusion on food-
responsive brain activation only in these pre-selected ROIs, it is not possible to 
conclude the brain-wide effects of PYY3-36 and GLP-17-36amide. 
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 CHAPTER 4 
 
GENERAL DISCUSSION 
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4.1 Summary of the Effects of PYY3-36 and GLP-17-36 amide on Appetite and Brain 
Reward Pathways Reported in this Thesis. 
 
This study has confirmed that co-administration of 0.3 pmol/kg/min PYY3-36 and 0.8 
pmol/kg/min GLP-17-36amide over 90 minutes to subjects fasted overnight, results in 
similar reductions in ad libitum energy intake during a subsequent buffet lunch as in 
subjects who have been fed a large breakfast. Single infusions of these doses of PYY3-
36 and GLP-17-36amide produce smaller reductions in ad libitum energy intake. The 
arithmetically summed effect of the single hormones was similar to the reduction in 
energy intake measured following combined infusion.   
 
For the first time in humans, this study has also shown that, in conjunction with a 
comparable effect on appetite and energy intake, combined infusion of PYY3-36 and 
GLP-17-36amide results in a similar modulation of brain activity as observed following a 
meal.  Both the fed state and the administration of anorectic gut hormones to fasted 
subjects, reduces activation in multiple brain reward regions in response to visual 
food-cues.  Simplistically, anorectic gut hormones make food seem less appealing.  In 
all instances (except for the amygdala in the fed state), either feeding or the 
administration of anorectic gut hormones to fasted individual, resulted in a 
reduction in neuronal activity in response to visual food cues in all of the reward 
ROIs studied.  The effects of combined gut hormone infusion on brain activation 
patterns are not significantly different from their arithmetically combined effects 
when administered alone.  Of the a priori chosen ROIs, the insula was most 
significantly modulated by either feeding or gut hormone infusion.  There was no 
obvious differential activation pattern between any of the conditions studied, but a 
suggestion that the OFC and NAcc are particularly sensitive to the effects of PYY3-36. 
Since the direct central effects of circulating gut hormones in humans can only be 
studied using functional imaging, it is useful to compare the findings in this work 
with other fMRI studies that have explored the neuroendocrinology of appetite.  At 
this point, it is important to point out that direct comparison between studies is not 
always possible, due to differences in study design.  The separate effects of 
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methodological and physiological factors on between-study variations have yet to be 
elucidated.  A recent meta-analysis reported that concurrence between studies on 
the brain response to viewing pictures of food was moderate: at best 41% (seven out 
of seventeen studies) concurred significantly activated clusters for the contrast 
between food and non-  food (van der Laan et al., 2011).  fMRI relies on the 
measurement of small signal changes amongst large inter-subject differences.  
Appetite pathways and the reward system in general are intricately tuned by 
numerous genetic, developmental, psychological, environmental and hormonal 
influences.  For example, in the study reported in this thesis, it was not possible to 
elicit differential neuronal activation patterns between high and low calorie foods.  
This may be because the food images used in this study were imported from another 
study into the effects of personality on reward drive (Beaver et al., 2006), and were 
not separately validated (in terms of palatability ratings) for this specific set of 
volunteers.  With this caveat, the following sections discuss some of the findings of 
this project in the context of fMRI studies which have investigated the effects of 
nutritional status, appetite-altering hormones, obesity and reward system 
responsiveness in patients pre- and post- gastric bypass. 
 
 
4.2. Comparison with fMRI Studies of Hunger and Satiety 
 
The earliest imaging studies into appetite confirmed the notion that, in humans, 
images of food can trigger the brain’s reward system and that the motivational 
potency of this trigger is greater in the fasted state.  Such differences in activation 
patterns have variously been attributed to a number of physiological differences 
between the fed and fasted state, such as changes in concentrations of gut 
hormones (PYY, GLP-1, ghrelin, CCK and insulin) and vagal afferents conveying 
information about gut distension, although none have formally correlated them. 
 
In 2001, LaBar et al reported on 9 healthy subjects, who underwent an initial whole-
brain fMRI after an 8 hour fast, followed by another post-meal scan one hour later. A 
follow up study was performed on 8 subjects who were fed a meal before the first of 
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the two scans, to rule out the potential of habituation effects in the first group. The 
subjects were presented with food and non-food images during each scan and 
subtraction analysis was performed (LaBar et al., 2001).  The authors’ hypothesis 
that variation in the state of hunger would modulate the response of the amygdala 
and anatomically related corticolimbic structures was borne out in a ROI analysis, 
which revealed satiety-induced reduction in activity in the amygdala, 
parahippocampal gyrus and fusiform gyrus. They suggested that the amygdala, with 
its extensive neural connections with the hypothalamus and higher brain centres, 
was in a pivotal position for integrating response to visual food stimuli in the context 
of nutritional status.  However, they also noted that their study was under-powered 
to detect similar satiety-induced changes in many other ROIs studied. As previously 
mentioned, the findings of amygdala activation in this thesis differ from those 
reported elsewhere, a likely consequence of normal population variation. 
 
In 2003, Killgore et al used a different approach by scanning satiated recruits who 
were presented with pictures of high calorie, low calorie and non-food items.  
Irrespective of calorific content, food images caused greater activation than non-
food images in the amygdala, hippocampus and ventromedial prefrontal cortex 
(Killgore et al., 2003).  The authors of that paper pointed out the importance of these 
areas in the expectation and evaluation of reward. High-calorie foods caused 
particular activation of the medial and dorsolateral prefrontal cortex, understood to 
be involved in evaluating stimulus relevance within the current affective state of the 
individual. In contrast, low calorie foods resulted in lesser activation of these reward 
areas per se, and greater activation in somatosensory areas, with a suggestion from 
the authors that this was due to a lesser cephalic phase response by classical 
conditioning to images of less appealing foods.  In 2005, Killgore published a 
reanalysis of this study data, using an ROI approach (specifically, a sub-analysis of the 
OFC) and correlated BOLD activity with BMI. It was reported that for the high calorie 
minus non-food contrast, there was a significant negative correlation between BMI 
and BOLD signal in the OFC (Killgore and Yurgelun-Todd, 2005).  In other words, as 
BMI increases, activity in the OFC becomes less food-responsive. It was not possible 
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to extend these findings to the obese population, since the subjects studied were all 
within the normal weight range.   
 
In 2005 St-Onge et al published the only fMRI study to date where fasted individuals 
were exposed to four different stimuli: visual food, visual non-food, tactile food and 
tactile non-food. In an uncorrected whole brain analysis they reported that the 
anterior cingulate, superior temporal gyrus, hippocampus and insula were 
significantly activated to a greater extent during the presentation of foods (whether 
seen or felt) over non-food items (St-Onge et al., 2005). 
 
In 2006, Porubska et al published the results of an fMRI study of 12 normal-weight 
fasted subjects. Visual food stimuli (in contrast to non-food images) activated the 
insular and orbitofrontal cortices, with a positive modulation of insula activity 
induced by subjective ratings of appetite (Porubska et al., 2006).  Following on from 
this, Fuhrer et al in 2008 studied 12 healthy male volunteers undergoing two 
separate scanning sessions – one when fasted overnight and the other immediately 
after a large meal.  They performed a whole brain, uncorrected analysis of the data 
and particularly noted significantly enhanced activity within the OFC when hungry 
(Fuhrer et al., 2008). In 2009, Schur et al performed a study of ten normal weight, 
fed subjects viewing images of fattening food, non-fattening food and non-food 
items. These food images were specifically chosen based on whether the food was 
perceived to be compatible with an effort to lose weight (another example of 
marked variation in experimental design). In a ROI analysis, this was the first study to 
report increased hypothalamic activation when viewing pictures of fattening food 
compared with non-food items, although this finding did not extend to other 
comparisons (ie fattening vs non-fattening or all food vs non-food).  They also found 
increased activation in the amygdala, insula and OFC when viewing fattening foods 
compared with non-food items (Schur et al., 2009).  Also in 2009, Siep et al. reported 
increased activity in the amygdala and OFC in response to viewing high calorie versus 
low calorie food images, but only when their subjects were fasted (Siep et al., 2009).  
Their experimental protocol allowed for the further observation that this increased 
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activity in the amygdala and OFC was only evident when participants explicitly 
evaluated foods but not when their concentration was diverted elsewhere. 
 
 
4.3  Comparison with fMRI Studies of Other Appetite-Modulating Hormones.  
 
It is perhaps most appropriate to interpret the results presented in this thesis 
alongside those of similar human fMRI studies investigating neuronal effects of 
appetite-modulating hormones. Such studies have also tended to measure BOLD 
signal change when viewing food-related images in the presence or absence of the 
hormone being studied. There is general concurrence that circulating appetite-
altering hormones affect reward processing of food cues, with the directionality of 
neuronal effects dependent on whether the hormone under scrutiny is anorectic or 
orexigenic. 
 
In two congenitally leptin deficient human subjects, daily subcutaneous leptin 
replacement reduced BOLD fMRI activation when viewing food vs. non-food images 
in the nucleus accumbens, caudate, putamen and globus pallidus (Farooqi et al., 
2007).  These findings have been recently extended to healthy subjects, in whom 
there is positive correlation between plasma leptin concentration and fMRI BOLD 
response in ventral striatal regions during the presentation of visual food cues 
(Grosshans et al., 2012).  Similar activation changes following infusion of PYY3-36 and 
GLP-17-36amide have been shown in this project.  However, there were also notable 
differences, with PYY3-36 and GLP-17-36amide apparently having much greater effects on 
the insula and OFC.  This implies that leptin, compared with PYY3-36 and GLP-17-36amide, 
modulates distinct neural networks, which may be related to the longer-term 
anorectic signalling by the adipokine leptin, relative to the more acute anorectic 
effects of post-prandially released gut hormones.   
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There has been one earlier human fMRI investigation of the effects of PYY3-36.  
Batterham et al. showed that in fasted, lean, healthy individuals, energy intake at 
lunch was predicted by the modulation of OFC signal following PYY3-36 infusion, but 
not with saline infusion, when subsequent food intake was better correlated with 
changes in hypothalamic signal (Batterham et al., 2007).  It was postulated that the 
presence of PYY3-36 switches regulation of food intake from a homeostatic brain 
region (hypothalamus) to a hedonic one (OFC). However, differences in methodology 
used (Batterham et al. tested for changes in resting state BOLD fMRI, compared with 
the task-activated BOLD fMRI data presented here) confound direct comparisons 
between the studies.  Nevertheless, the particular sensitivity of the OFC to PYY in 
both studies is striking.  Other fMRI studies have also demonstrated that compared 
to low-calorie food pictures, viewing high-calorie food stimuli induces a greater 
activation in the OFC (Killgore et al., 2003, Siep et al., 2009, Frank et al., 2010) and 
that and the change in appeal bias towards high-calorie foods is positively correlated 
with OFC activation (Goldstone et al., 2009). An early meta-analysis of neuroimaging 
data has shown that activity in the OFC is related to the monitoring and learning of 
reward value of reinforcers (Kringelbach and Rolls, 2004). The latest research has 
suggested that the OFC can be divided into specific functional subregions. For 
example, the reward value of a reinforcer is assigned in more lateral parts of the 
OFC, where it can be modulated by hunger and other internal states (van der Laan et 
al., 2011). 
 
 
The best direct comparison can be made with a recent study which investigated the 
effects of ghrelin, the only known gut hormone which acutely increases food intake, 
on brain activity in normal-weight humans (Malik et al., 2008). Intravenous ghrelin 
infusion increased food-image invoked BOLD activation in the amygdala, OFC, insula, 
visual areas and striatum. The hypothalamus was not reported.  Those results are 
directly mirrored by the negative modulatory effects of PYY3-36 and GLP-17-36amide 
reported here, suggestive of a CNS reward network, which when activated by 
ghrelin, mediates hunger and when inhibited by the anorectic gut hormones PYY3-36 
and GLP-17-36amide, mediates satiety.  
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4.4  Comparison with fMRI Studies of Appetite Pathways in Obesity. 
 
The majority of fMRI studies in overweight volunteers have sought to investigate 
evidence of aberrant brain appetite signalling with increasing BMI, although it is 
frequently impossible to tell whether these changes are the cause or effect of 
obesity.  Psychologists have pondered the question of obesity as a consequence of 
“food addiction” for many years.  One concept of addiction holds hypo-dopaminergic 
functioning (Reward Deficiency Syndrome - RDS) in brain reward pathways as a key 
risk factor (Blum et al., 2000).  As such, food is used as a form of self-medication to 
boost hedonic capacity.  In line with this, nuclear imaging studies have revealed a 
reduction in striatal dopamine receptor density in overweight subjects (Wang et al., 
2001, Volkow et al., 2008).  However, tolerance to reward is well known to cause 
down regulation of dopamine receptors in brain reward regions, and a competing 
theory is that individuals at risk of obesity actually have a hyper-reactive reward 
system to start with.  These individuals initially experience greater reward from food 
intake, which drives overeating that subsequently results in a tachyphylaxis of 
dopamine signalling in response to food intake (Stice et al., 2011b).   
 
In general, fMRI studies investigating the differential reward system activation 
patterns when looking at high calorie foods between obese and normal weight 
subjects have shown significantly greater activation in the obese group in several 
brain regions implicated in food reward. In 2007, Rothemund et al studied 13 obese 
and 13 normal weight women who had been fasted for at least 90 minutes. 
Increasing BMI positively predicted BOLD activation of the dorsal striatum (caudate / 
putamen), anterior insula, claustrum, posterior cingulate, post-central cortex and 
lateral OFC. This specifically pertained to the contrast between viewing high calorie 
food images versus non-food images (Rothemund et al., 2007).  A further ROI-based 
study by Stoeckel et al in 12 obese and 12 normal weight women demonstrated that 
pictures of high calorie foods (versus non-food) produced greater activation in the 
obese group compared with controls in several brain regions, including the ventral 
and dorsal striatum, insula, anterior cingulate cortex, amygdala, OFC, hippocampus, 
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ventral pallidum and medial prefrontal cortex (Stoeckel et al., 2008).  A later 
functional connectivity analysis of the same scans indicated that obese women 
displayed a relative deficiency in the amgdala’s modulation of the OFC and ventral 
striatum, along with excessive modulation of the ventral striatum by the OFC 
(Stoeckel et al., 2009).  In 2012, Scharmuller et al confirmed that obese participants 
showed greater insula activation than the lean participants during the passive 
viewing of food cues. Moreover, the obese group displayed stronger dorsolateral 
prefrontal cortex involvement when attempting to attenuate food-elicited craving 
(Scharmuller et al., 2012).  Collectively, these results support enhanced food cue 
reactivity as playing a role in the pathophysiology of obesity. 
 
Other studies have shown that obese individuals respond differently to satiation 
compared with normal weight individuals. A ROI-based study by Martin et al 
measured fMRI BOLD activation pre-and post prandially (following a 500 kCal meal) 
in response to pictures of food (a combination of high calorie and low calorie images) 
and non-food in 10 obese and 10 healthy weight adults. During the pre-meal 
condition, obese subjects showed increased activation in the anterior cingulate and 
medial prefrontal cortex, compared to healthy weight controls.  During the post-
meal condition, obese participants also showed greater BOLD activation in the 
medial prefrontal cortex compared with healthy weight controls (Martin et al., 
2010). A recent study by Dimitropoulos et al of 22 overweight / obese males and 16 
normal weight males showed that before eating, obese subjects showed greater 
response to food images (versus non-food images) compared with normal weight 
subjects in the anterior prefrontal regions.  Post-prandially, the obese group 
demonstrated increased response to all food images (versus non-food) compared 
with normal weight individuals in frontal, temporal and limbic regions. Specific 
greater activation to high calorie foods was seen in the obese group compared with 
normal weight individuals in the lateral OFC, caudate and anterior cingulate cortex 
(Dimitropoulos et al., 2012). 
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In 2008, Stice et al used fRMI to compare brain activity in 7 obese and 11 lean 
adolescent girls during the anticipated receipt of chocolate milkshake, during actual 
receipt of the milkshake, during anticipated receipt of a tasteless control solution 
and during actual receipt of the tasteless control solution. In response to anticipated 
receipt and actual receipt of the chocolate milkshake (versus the tasteless solution), 
obese adolescent girls showed greater BOLD activation bilaterally in the anterior and 
mid insula, frontal operculum, parietal operculum and rolandic operculum compared 
with lean adolescent girls. However, the obese girls displayed lower BOLD activation 
in the caudate in response to actual consumption of the milkshake (versus the 
tasteless solution) compared with the lean girls. From these results, the authors 
suggested that obese individuals show greater salience-associated responses from 
anticipated food consumption in gustatory and somatosensory regions, but weaker 
activation in the caudate during actual consumption compared to lean individuals 
(Stice et al., 2008).  It was postulated that this reflects increased anticipatory food 
reward but reduced consummatory food reward in obesity, which may contribute to 
overeating. In a later study by the same group, 8 women who gained > 2.5% increase 
in BMI over a 6 month period showed reduced striatal BOLD fMRI response to 
chocolate milkshake consumption (versus a tasteless control solution) compared 
with 12 women who demonstrated stable weight (Stice et al., 2010).  However, in 
their most recent study, it was reported that normal-weight adolescents at high-risk 
versus low-risk for future obesity showed greater activation in the dorsal striatum in 
response to palatable food receipt (Stice et al., 2011a). These results reinforce the 
consensus hypothesis that both reward centre hyper-reactivity and a subsequently 
reduced sensitivity of striatal reward circuitry (probably due to the down regulation 
of dopamine D2 receptors as a result of overeating), contribute to the 
pathophysiology of obesity. 
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4.5   Comparison with fMRI Studies Pre- and Post- Gastric Bypass Surgery 
 
As previously mentioned, the plasma gut hormone concentrations achieved in this 
study of 0.3 pmol/kg/min PYY3-36 and 0.8 pmol/kg/min GLP-17-36amide were 
comparable to those measured post-prandially in patients who have undergone 
gastric bypass surgery. 
 
The mechanisms behind the weight loss seen following Roux-en-Y bypass surgery 
remain to be fully elucidated, but are thought to be due to a number of additional 
neurohormonal causes (Tadross and le Roux, 2009).  These include elevated post-
operative levels of endogenous anorectic gut hormones such as PYY and GLP-1 (le 
Roux et al., 2006a), increases in energy expenditure and metabolic rate (Nestoridi et 
al., 2012), changes in taste preference away from calorie dense foods (Miras et al., 
2012), increased bile acid delivery to the ileum (Patti et al., 2009) and changes in gut 
microbiota (Li et al., 2011).  Recent studies imaging appetite in patients before and 
after weight loss are important in helping us to understand some of the CNS 
mediated effects, with the potential translational application of one day being able 
to identify those patients who will respond best to bypass surgery. 
 
In 2011 van de Sande-Lee et al. performed fMRI studies on 8 lean control subjects 
and 13 obese patients pre- and post- Roux-en-Y gastric bypass, by which an average 
30% reduction in body weight had been achieved (van de Sande-Lee et al., 2011).  
Using a resting state BOLD fMRI paradigm focusing on a mid-saggital slice only, they 
reported a high level of functional connectivity between the hypothalamus and the 
orbitofrontal and somatosensory cortices that was absent in obese subjects, but re-
established with post-operative weight loss. 
  
In the same year, a ROI-based study of 10 obese female patients 1 month pre- and 
post- Roux-en-Y gastric bypass, revealed an attenuation of fMRI BOLD signal (when 
viewing high-calorie versus low-calorie food images) in the ventral tegmental area, 
ventral striatum, putamen, lentiform nucleus, posterior cingulate and dorsomedial 
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prefrontal cortex following the bypass procedure (Ochner et al., 2011).  A 
subsequent analysis of the same cohort of pre- and post- Roux-en-Y gastric bypass 
patients revealed that of postoperative changes in mesolimbic reward pathway 
response predicted changes in the desire to eat (wanting), but not liking, for high- 
versus low-calorie foods (Ochner et al., 2012).  Although circulating gut hormone 
levels were not measured, the authors speculated that post-surgical reductions in 
the orexigenic hormone ghrelin could have explained their imaging observations. 
The concurrence with the findings of the work in this thesis, suggest that elevated 
PYY3-36 and GLP-17-36amide levels may also be implicated. 
 
4.6  Future Work 
4.6.1 Clarifying the Effect of Stress on Appetite Pathways as Measured by fMRI  
 
In this project, each subject underwent an initial acclimatisation visit, with a scanning 
protocol identical to that of the subsequent saline control visit.  This was performed 
because acute stress is well documented as having an anorectic effect of its own in 
appetite studies and, accordingly, data from this first visit was not included in the 
analysis presented in this thesis.   
 
The exclusion of food intake data taken from the first visit in (non-imaging) appetite 
studies is now standard.  However, it is less common for fMRI studies in other fields 
to incorporate an acclimatisation visit.  This is particularly important when 
considering the hypothalamus as a ROI, since its paraventricular nucleus plays a 
major role in generating the adaptive autonomic, behavioural, and hormonal 
responses to stress (Sawchenko et al., 1996).  More generally, stress may also have a 
non-specific effect on fMRI results, as acute stress has been shown to cause changes 
in haematocrit (Patterson et al., 1995), which affects the source of the BOLD signal. 
In addition, the effect of blood sampling on cortisol concentrations, a measure of 
stress, has been shown to be highly variable (Meeran et al., 1993), which suggests 
that the effects of stress on the fMRI response will vary between subjects too.  
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To clarify some of these issues, it will be interesting to analyse the acclimatisation 
visit data.  By comparing the acclimatisation visit activation patterns against those 
from the proper control saline visit, alongside plasma cortisol values, it will be 
possible to elicit novel information about the effects of acute stress on activity in 
brain appetite pathways.  
 
4.6.2 Analysing Resting State BOLD and Arterial Spin Labelling Data  
 
During the 60 minute scanning session performed in this dual gut hormone infusion 
study, three scanning protocols were applied, of which only the task-based BOLD 
results have been fully analysed and reported here.  An additional resting state BOLD 
scan and arterial spin labelling (ASL) scan were also performed at every visit.  The 
datasets from these additional scans are currently being analysed and will hopefully 
continue to provide new information about the central mode of action of PYY and 
GLP-1 as follows: 
 
1. The resting-state BOLD analysis will provide information about the functional 
connectivity of specific brain areas in the absence of any particular external 
stimulus or food cue.  Since there is no effect of task analysis required for 
resting state scans, it is hoped that hypothalamic signal may be interpretable.  
It is anticipated that the functional connectivity of ROIs that are known to be 
important in food processing will be altered or modulated in the presence of 
anorectic hormones. 
2. The ASL protocol does not rely on the BOLD effect at all, but rather is an 
imaging process which magnetically “tags” protons (with a short RF pulse) as 
they are travelling in the neck arteries, and follows their course into ROIs 
within the brain.  This allows for a quantification of cerebral blood flow, with 
the assumption that greater flow occurs in activated areas.  Should the lack of 
hypothalamic signal be related to technical limitations of T2*-weighted BOLD 
imaging, then it is anticipated that a T1-weighted ASL protocol will overcome 
these (Wong et al., 1997). 
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4.6.3 Investigating the CNS-Mediated Mechanisms of Weight Loss and Metabolic 
Improvement Following Bariatric Surgery 
 
An exciting extension of this project will be to further investigate the mechanism of 
action of gastric bypass surgery.  As previously mentioned, the strongest hypothesis 
at present is that the majority of its positive effects on appetite, energy and 
expenditure and glycaemic control are as the result of enhanced anorectic gut 
hormone profiles following the procedure.  By comparing groups who have either 
lost weight via surgery, combined chronic gut hormone therapy or caloric restriction 
alone, fMRI provides the best means of investigating how the modulation of CNS 
appetite pathways mediates outcome. 
 
4.7  Concluding Comment 
 
In this thesis, I have characterised the effects of single and combined administration 
of PYY3-36 and GLP-17-36 amide on brain BOLD fMRI activations in humans and shown for 
the first time that these hormones modulate brain reward centre activity to an 
extent and pattern similar to that observed physiologically after a meal. These 
findings provide direct evidence that the concerted action of gut hormones in the 
brain could explain post-prandial satiety. It therefore seems plausible that the 
administration of combined anorectic gut hormones may provide an effective future 
medical alternative to a surgical gastric bypass procedure to treat obesity. 
Meanwhile, it remains to be fully elucidated whether the corticolimbic effects of gut 
hormones are direct or secondary to hypothalamic projection, and many other 
questions about the brain-wide and dose-response effects of anorectic gut 
hormones remain unanswered.   As imaging technologies continue to evolve, it 
seems likely that future fMRI studies will continue to help unravel the complicated 
neuroendocrine network involved in human appetite control. 
 
 
132 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX 1 – VISUAL ANALOGUE SCALES  
 
 
 
 
 
How hungry do you feel right now? 
 
  NOT AT ALL         EXTREMELY 
 
 
 
 
 
How nauseous do you feel right now? 
 
  NOT AT ALL         EXTREMELY 
SICK 
 
 
 
 
 
How pleasant would it be to eat right now? 
 
  NOT AT ALL         EXTREMELY 
 
 
 
 
 
How much do you think you could eat right now? 
 
NOTHING        
     A LARGE AMOUNT 
 
 
 
 
 
How full do you feel right now? 
 
  NOT AT ALL  
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       EXTREMELY 
  
 
How tasty was the meal? 
 
  NOT AT ALL  
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       EXTREMELY 
  
 
 
How warm do you feel right now? 
 
   VERY COLD         VERY HOT 
 
 
 
 
 
 
 
How irritable do you feel right now? 
 
  NOT AT ALL         EXTREMELY 
 
 
 
 
 
 
 
How anxious do you feel right now? 
 
 NOT AT ALL         EXTREMELY 
 
 
 
 
 
 
    
How sleepy do you feel right now? 
 
  NOT AT ALL 
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       EXTREMELY 
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APPENDIX II – RADIOIMMUNOASSAY AND ELISA DETAILS 
 
 
 
All in-house radioimmunoassays (RIAs) used to measure ‘total’ PYY and ‘total 
amidated’ GLP-1 plasma levels were derived and maintained by Professor MA Ghatei 
(Professor of Regulatory Peptides, Metabolic Medicine, Faculty of Medicine, Imperial 
College).  All reagents and materials other than peptides were supplied by Sigma.  
 
General Principles of a Radioimmunoassay 
 
RIA is a technique that allows the detection and measurement of biological 
substances at very low concentrations from tissue or plasma samples. This method 
relies on the competition between radioactively-labelled and unlabelled antigen for 
a specific number of antibody binding sites. When the unlabelled antigen in 
standards or samples and a fixed amount of labelled antigen are allowed to react 
with a constant and limiting amount of antibody, decreasing amounts of labelled 
antigen are bound to the antibody as the amount of unlabelled antigen is increased.  
The RIA is incubated for at least 72 hours at 4°C in order for this reaction to reach 
equilibrium, according to the equation:  
 
*Ag + Ab + Ag *AgAb + AgAb  
 
Ag = unlabelled antigen  
*Ag = radiolabelled antigen  
Ab = antibody  
 
Separation of the bound from the free antigen is achieved by addition of either 
dextran-coated charcoal (free label is contained in the charcoal pellet following 
centrifugation, as for the in-house total amidated GLP-1 assay) or using a primary-
secondary antibody complex (free label is contained in the supernatant following 
centrifugation, as for the in-house total PYY assay). After separation, the bound and 
free components are measured in a γ-counter and the data used to construct a 
standard curve. By reference to the standard curve, the concentration of the 
unknown samples can be calculated. 
 
To measure and correct for baseline drift, tubes with no sample (‘zero’ tubes) are 
placed at regular intervals throughout the assay and standard curves are performed 
at the beginning and end of each assay. Samples of plasma with known spiked 
quantities of peptide (low, medium and high concentration) are also added for 
quality control.  The general structure of the RIA is outlined in the table below, which 
shows the content of the tubes according to their designation.  
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TUBE NUMBER   DESIGNATION 
1-2  Non-specific binding  
3-4  ½ X  
5-6  2 X  
7-8  Zero  
9-10  Zero  
11-12  Standard 1  
13-14  Standard 2  
15-16  Standard 3  
17-18  Standard 4  
19-20  Standard 5  
21-22  Standard 6  
23-24  Standard 7  
25-26  Standard 8  
27-28  Standard 9  
29-30  Standard 10  
31-34  Zero  
35- ….  Samples  
Zeros  Two zeros between each new 
subject/visit  
Standard curve  
Final two tubes  Excess  
 
 
Quality control is essential in RIA.  The following tubes are important for the 
assessment of the quality for the label, antibody and overall performance of the 
assay:  
Non-specific binding: low binding indicates adequate label integrity.  
½ X: assesses if greater sensitivity could be achieved by adding half the volume of 
label.  
 
2 X: assesses if greater sensitivity could be achieved by adding double the volume of 
label.  
 
Zero tubes: allows assessment of assay drift.  
 
Excess antibody: assesses the immunological integrity of the labelled peptide.  
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Detailed Methods for Preparation of the Iodinated Radioactive Labelled Tracers 
 
All tracers were made in house by Prof M. Ghatei (Dept. of Investigative Medicine, Imperial 
College London). Peptides were iodinated using the iodogen method (Wood et al., 
1981)and purified by HPLC using a C18 column (Waters, Milford, CT, USA). In brief, the 
iodogen method adds a 125I molecule onto a tyrosine residue in an oxidative reaction. 
Iodogen reagent (1,3,4,6,-tetrachloro-3α,6α-diphenylglycoluril; Pierce Chemical Co., 
Rockford, IL, USA) is reacted with Na125I to oxidise the 125I to the reactive iodine state, 
which subsequently incorporates into available tyrosine residues. The iodogen method 
requires the reaction (peptide in 0.2 M phosphate buffer, 37 MBq Na125I, 23 nmol iodogen 
reagent) to be incubated at 22°C before the reaction products are purified by reverse-
phase HPLC using a NovaPak C18 column (Millipore, Milford, MA, USA). The column was 
equilibrated for 10 minutes with 15% (v/v) acetonitrile (AcN) solution in water containing 
0.05% (v/v) trifluoroacetic acid (TFA), at a flow rate of 1 ml/min. The concentration of AcN 
was then gradually increased to 20-45% over the following 80 minutes and maintained at 
the final concentration of 45% for the next 10 minutes. Fractions were collected every 1.5 
minutes into tubes containing 1 ml 20 mM HEPES, pH 11.0 (to neutralise the acidity of the 
collected fractions) and 0.3% (v/v) bovine serum albumin (BSA) (ICN Biochemicals Inc, Costa 
Mesa, CA, USA). The fractions were tested in an RIA and used at 1500 cpm/tube. 
 
Details of the In-House ‘Total’ PYY Assay 
 
Plasma PYY3-36 was measured using a specific and sensitive RIA.  The assay was performed 
using 0.06 M phosphate buffer with 0.3% BSA at a total volume of 700μl per tube and a 
sample volume of 1–100μl. 125I-PYY was prepared by the iodogen method (detailed above) 
and purified by HPLC.  The antiserum (Y21) was raised in rabbits against synthetic porcine 
PYY1-36 (Bachem Ltd. U.K), coupled to BSA, and used at a final dilution of 1:50,000. The Y21 
antibody is specific for the C-terminal of PYY and reacts fully with human PYY1-36 and PYY3-36 
and does not cross-react with PP, NPY or other known gut hormones. A Standard 
concentration of 1pmol/ml was used for PYY3-36.  The intra- and inter-assay coefficients of 
variation were 6% and 10% respectively. 
 
Details of the In-House ‘Total Amidated’ GLP-1 Assay 
 
GLP-1- like immunoreactivity was measured by a specific and sensitive in-house 
radioimmunoassay.  The antibody was produced in rabbits against GLP-1 coupled to bovine 
serum albumin. The antibody cross reacted 100% with all amidated forms of GLP-1 but did 
not cross react with glycine extended forms [GLP-11-37 and GLP-17-37] or any other known 
pancreatic or gastrointestinal peptide. 125I-GLP-1 was prepared by the iodogen method 
(detailed above) and purified by HPLC.  The specific activity of the 125I GLP-1 label was 48 
Bq/fmol. The assay was performed in a total volume of 0.7 ml of 0.06 M sodium barbitone 
buffer (pH 8) containing 0.3 % BSA.  The assay was incubated for three days at 4oC before 
separation of the free and antibody bound label by charcoal absorption. The limit of 
detection was 7.5 pmol/l with an intra-assay variation of 5.4% and inter-assay variation less 
than 10%.  
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Commercial Assays Used 
 
In order to ensure that the signal changes detected on BOLD fMRI were related to 
changes in the concentration of circulating active hormone levels, a second aliquot 
of plasma was tested on commercial kits to measure active PYY (ie PYY3-36) and 
active GLP-1 (ie GLP-17-36amide and GLP-17-37) only. 
 
These kits were acquired from Merck Millipore (Billerica, MA, USA).  Weblinks are 
provided for access to the manufacturer’s full guide, and a shortened summary of 
the product characteristics are reproduced below. 
 
 
MILLIPORE HUMAN PYY3-36  SPECIFIC RIA KIT 
 
http://www.millipore.com/userguides/tech1/proto_pyy-67hk 
 
I. INTENDED USE 
Millipore's PYY (3-36) Radioimmunoassay (RIA) Kit utilizes an antibody, which 
recognizes only the 3-36 form of Human PYY (3-36). Sensitivity of 20 pg/mL can easily 
be achieved when using a 100μl serum or plasma sample in a two-day, 
disequilibrium assay.  
 
II. PRINCIPLES OF PROCEDURE 
In radioimmunoassay, a fixed concentration of labelled tracer antigen is incubated 
with a constant dilution of antiserum such that the concentration of antigen binding 
sites on the antibody is limited, for example, only 40%-50% of the total tracer 
concentration may be bound by antibody. If unlabeled antigen is added to this 
system, there is competition between labelled tracer and unlabelled antigen for the 
limited and constant number of binding sites on the antibody. Thus, the amount of 
tracer bound to antibody will decrease as the concentration of unlabeled antigen 
increases. This can be measured after separating antibody-bound from free tracer 
and counting one or the other, or both fractions. A standard curve is set up with 
increasing concentrations of standard unlabelled antigen and from this curve the 
amount of antigen in unknown samples can be calculated. Thus, the four basic 
necessities for a radioimmunoassay system are: a specific antiserum to the antigen 
to be measured, the availability of a radioactive labelled form of the antigen, a 
method whereby antibody-bound tracer can be separated from the unbound tracer, 
and finally, an instrument to count radioactivity. 
 
The Millipore PYY (3-36) assay utilizes 125I-labeled PYY and a PYY (3-36) antiserum to 
determine the level of PYY (3-36) in serum, plasma or tissue culture media by the 
double antibody/PEG technique. 
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MILLIPORE Glucagon-Like Peptide-1 (Active) ELISA Kit 
 
http://www.millipore.com/userguides/tech1/proto_eglp-35k 
 
I. INTENDED USE 
This kit is for non-radioactive quantification of biologically active forms of Glucagon-
Like Peptide-1 [i.e. GLP-1 (7-36 amide) and GLP-1 (7-37)] in plasma and other 
biological media. It is highly specific for the immunologic measurement of active 
GLP-1 and will not detect other forms of GLP-1 (e.g., 1-36 amide, 1-37, 9-36 amide, 
or 9-37). The GLP-1 sequence is highly conserved between the species, with no 
sequence variation occurring at all in mammals.  
 
II. PRINCIPLES OF PROCEDURE 
This assay is based, sequentially, on: 1) capture of active GLP-1 from sample by a 
monoclonal antibody, immobilized in the wells of a microwell plate, that binds 
specifically to the N-terminal region of active GLP-1 molecule, 2) washing to remove 
unbound materials, 3) binding of an anti GLP-1-alkaline phosphatase detection 
conjugate to the immobilized GLP-1, 4) washing off unbound conjugate, and 5 ) 
quantification of bound detection conjugate by adding MUP (methyl umbelliferyl 
phosphate) which in the presence of alkaline phosphatase forms the fluorescent 
product umbelliferone. Since the amount of fluorescence generated is directly 
proportional to the concentration of active GLP-1 in the unknown sample, the latter 
can be derived by interpolation from a reference curve generated in the same assay 
with reference standards of known concentrations of active GLP-1. 
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APPENDIX III – MOUSE HISTOPATHOLOGY REPORTS FOR PYY AND GLP-1 TOXICOLOGY 
STUDY 
 
 
Toxicity studies were performed using the prepared batches of PYY3-36 and GLP-17-36 amide, at 
doses greater than 10 times the maximum intended for humans (in pmol/kg body weight), 
administered by IP injection to 20 mice, alongside a saline-administered control group. The 
mice were observed for evidence of abnormal behaviour for 4 hours post injection. Half the 
animals in each group were sacrificed by CO2 asphyxiation after 48 hours, and the other half 
after 21 days. The lungs, heart, kidneys, liver, brain and reproductive organs of both sexes 
were dissected, fixed and sent for examination by an independent histopathologist, blinded 
to treatment group.. 
 
GROUP 1 – SALINE TREATED 
 
1. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
2. Normal lungs, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunners 
glands, normal pancreas with normal islets, normal colon. 
 
3. Normal lungs, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunners 
glands, normal pancreas with normal islets, normal colon. 
 
4. Normal lungs, fragment of normal thymus gland, normal trachea, normal 
oesophagus, normal heart, normal brain, normal spleen, normal liver, normal 
kidney, normal stomach, normal duodenum with Brunners glands, normal pancreas 
with normal islets, normal colon. 
 
5. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
6. Normal lungs, normal trachea, normal oesophagus, normal heart, the brain has 
prominence of both lateral ventricles although the third ventricle is not dilated. This 
may be an incidental finding. There is no cellular reaction. The choroid plexus 
appears normal. Normal spleen, normal liver, normal kidney, normal stomach, 
normal duodenum with Brunners glands, normal pancreas with normal islets, 
normal colon. 
 
7. Normal lungs, normal trachea, normal heart, normal spleen, normal liver, normal 
kidney, normal stomach, normal duodenum with Brunners glands, normal pancreas 
with normal islets, normal colon. There may be subtle ventricular dilatation in the 
brain although preparation is suboptimal. 
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8. Normal lungs, normal heart, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. There is possible mild bilateral ventricular dilatation. 
 
9. Normal lungs, normal trachea, normal oesophagus, normal heart, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunners 
glands, normal pancreas with normal islets, normal colon. There is possible 
ventricular dilatation although orientation is not optimal and the lateral ventricles 
were not well visualised 
 
10. Normal lungs, normal heart, normal brain, normal spleen, normal liver, normal 
kidney, normal stomach, normal duodenum with Brunners glands, normal pancreas 
with normal islets, normal colon. 
 
 
 
GROUP 2 - PYY3-36 TREATED 
 
11. Normal lungs with normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart, normal brain, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. 
 
12. Normal lungs, normal trachea with normal thyroid gland, normal oesophagus, 
normal heart, normal brain, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. 
 
13. Normal lungs, normal thymus gland, normal oesophagus, normal heart, normal 
brain, normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunners glands, normal pancreas with normal islets, normal colon. 
 
14. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
15. Normal lungs and normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart., normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunners glands, normal pancreas with normal islets, normal colon. 
The brain may have slight assymmetric ventricular dilatation although the fourth 
ventricle appears relatively normal 
 
16. Normal lungs and normal hilar lymph node, normal trachea, normal heart, normal 
brain, normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunners glands, normal pancreas with normal islets, normal colon. 
 
17. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
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18. Normal lungs, normal heart, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. There appears to be mild bilateral ventricular dilatation 
 
19. Normal lungs with normal hilar lymph node, normal trachea, normal heart, normal 
brain (although preparation is suboptimal and it's impossible to exclude a minor 
degree of ventricular dilatation), normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. 
 
20. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
 
GROUP 3 – GLP-17-36amide TREATED  
 
 
21. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
22. Normal lungs, normal bronchi, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
23. Normal lungs with normal hilar lymph node, normal trachea with normal thyroid and 
parathyroid glands, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunners 
glands, normal pancreas with normal islets, normal colon. 
 
24. Normal lungs with normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart, normal brain, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. 
 
25. Normal lungs, normal trachea, normal oesophagus, normal heart, the brain appears 
to have an assymmetric dilatation of lateral ventricle although this may be a 
consequence of orientation. Normal will spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunners glands, normal pancreas with normal 
islets, normal colon. 
 
26. Normal lungs, normal trachea, normal oesophagus, normal heart, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunners 
glands, normal pancreas with normal islets, normal colon. There appears to be mild 
dilatation of the lateral and third ventricle although there is no cellular reaction. 
brain, normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunners glands, normal pancreas with normal islets, normal colon. 
is possibly subtle dilatation of the lateral ventricles although the third ventricle 
appears relatively normal. 
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27. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. There is 
possibly subtle dilatation of the lateral ventricles although the third ventricle 
appears relatively normal. 
 
28. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
29. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum 
with Brunners glands, normal pancreas with normal islets, normal colon. 
 
30. Normal lungs, normal thymus gland, normal trachea, normal oesophagus, normal 
heart, normal brain, normal spleen, normal liver, normal kidney, normal stomach, 
normal duodenum with Brunners glands, normal pancreas with normal islets, 
normal colon. 
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APPENDIX IV - INFORMATION SHEET FOR HEALTHY VOLUNTEERS 
 
 
 
 
Department of Investigative 
Medicine 
Division of Investigative Science 
Imperial College London 
 
6th Floor Commonwealth 
Building 
Imperial College London at 
Hammersmith Campus 
Du Cane Road, London W12 
ONN, UK 
Tel: +44 (0)20 8383 2820  Fax: 
+44 (0)20 8383 8320 
 
 
Ref number 09/H0712/4  
12/02/2010  Version 04 
 
 
TITLE 
 
A Functional Magnetic Resonance Imaging Study of the Differential Effects of Glucagon-
like Peptide-1 and Peptide YY on Regional Brain Activity in Appetite Control.  
 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with friends, relatives and your GP 
if you wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
If you do decide to take part, please let us know beforehand if you have been involved in any 
other study during the last year. You are free to withdraw at any time without explanation. 
Thank you for reading this. 
 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
Healthy people release a variety of different hormones from the gut into the blood stream.  
The timing of these hormones being released depends on whether you are hungry or have 
recently had a meal.  Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are two examples 
of hormones which are naturally released after a meal.  We know that these hormones 
signal to the brain to reduce hunger.  This study is designed to see just how these hormones 
interact with the brain to signal appetite, using a safe brain scan called functional magnetic 
resonance imaging (fMRI).  It will be an important step towards understanding how we 
regulate our food intake and will aid the development of medicines to treat obesity.  
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WHY HAVE I BEEN CHOSEN? 
 
Healthy individuals are being recruited to take part in this study.  
 
You should not take part in this study if you:  
1) have any illnesses which we feel make you unsuitable  
2) take any medication which we feel makes you unsuitable 
3) are pregnant or breast feeding 
4) have given blood in the last three months 
 
It is important that you should not become pregnant during the course of the study or for 
one month following the study, as the effects of gut hormones in pregnancy are not known. 
It is therefore important that you have adequate and reliable contraception during this 
period. 
 
 
DO I HAVE TO TAKE PART? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason.  
 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
 
Screening visit 
If you agree to take part in this study, you will be invited for a screening visit. Prior to the 
screening visit, you will be asked to complete a few short questionnaires about your eating 
habits, personality and an MRI safety checklist. Please bring these with you to the screening 
visit.  
During the screening visit itself, you will first be asked some questions regarding your 
general health and medications you may be taking. You will then have your height and 
weight taken, be examined by one of the research doctors and have a blood test (no more 
than 20ml blood - equivalent to just over a tablespoon), a pregnancy test (if female) and a 
heart recording (ECG). You will also be asked to taste a sample of the lunch that you will be 
receiving on the study days.   
 
As long as these medical checks are satisfactory and you are still happy to participate, you 
will then be asked to attend for the first study visit. 
 
Number of visits 
You will be asked to attend as an outpatient the GSK-Imperial College Clinical Imaging Centre 
at Hammersmith Hospital on another 6 occasions following your screening interview, each 
separated by at least 3 days. These will be completed on dates convenient to you and the 
investigators, but should usually be completed within a maximum of 3 months. 
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Study design 
We are interested in studying the effects of the gut hormones glucagon-like peptide 1 (GLP-
1) and peptide YY (PYY).  Both of these hormones are normally released from the gut after a 
meal and are known to reduce appetite.  These naturally occurring hormones have been 
given to hundreds of human volunteers in the past with no reports of serious adverse 
events. These two hormones have also been safely given in combination to human 
volunteers and it was found that their appetite-inhibitory effects were additive. 
On each study visit you will be asked to have nothing to eat and only water to drink from 10 
pm on the evening before the study. You will be asked to attend at 9 o’clock in the morning 
and each visit will last around 3.5 hours. You will be asked to abstain from alcohol and 
strenuous exercise for 24 hours before the visit. We will also ask you to keep a record of all 
food and drink consumed for one day before the visit, the day of the visit and for one day 
afterwards. You will also have a pregnancy test on each visit (if female).  
 
 
 
When you arrive on the morning of the visit you will have a small plastic cannula tube 
inserted into a vein in each arm.  A vein is the type of blood vessel commonly used for taking 
blood samples. You may feel some discomfort whilst the cannulas are being inserted. After 
they have been inserted, one will be used to take blood samples. The other cannula will be 
used to administer the infusion of hormone or saline as a drip. 
 
 
At the start of the visit we will ask you to score how you are feeling (e.g. rating your hunger) 
by placing a mark on a line called a visual analogue scale. You will then either be given a 
moderate size breakfast to eat over 20 mins (on one of the study visits), or asked to continue 
fasting until lunchtime (on the other five study visits).  
 
 
Over the course of each study visit, blood samples will be taken painlessly from one of the 
cannula tubes.  The total amount of blood taken on each study visit will not be more than 
80ml (about 5 tablespoonfuls). The total amount of blood taken over all your visits will not 
be more than 500 ml (a little less than a pint and the same amount taken when making a 
single donation of blood for blood transfusion).  Whilst waiting for the scan you will also be 
asked to complete further visual analogue scales to rate how you are feeling.  During these 
visits you will be seated or lying on a couch, and can read or watch television when not 
having the scan. 
 
 
Approximately 90 mins after arriving, the infusion drip will begin. 20 mins after starting the 
infusion, you will have a magnetic resonance imaging (MRI) brain scan. We envisage that the 
scan will take approximately 60 mins. The scan will enable us to look at the structure and 
activity of your brain. During the functional brain scans we look at the activity of the brain at 
rest and while you look at a variety of pictures on a screen in front of you.  We will also ask 
you to perform simple tasks like pressing a button, reading, listening, speaking, recalling, 
thinking about words or numbers. You will be asked to respond to images projected on the 
screen in front of you. 
 
 
We will make every attempt to ensure that you are comfortable and relaxed inside the 
scanner.  You will be able to communicate directly with us throughout the entire scan.  You 
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will be given a chance to get used to lying inside the scanner before we start.  During the 
scan you will be allowed to take a break at any stage should you feel like one. 
 
 
The first study visit will help you acclimatise to the experience of the scan.  During this visit, 
the infusion will be a saline solution only. The saline is a placebo or dummy treatment that is 
commonly used in studies of this nature. It contains no active ingredient and is not expected 
to alter your appetite. 
 
 
 
On the following five visits you will receive one each of these infusions (in random order): 
 
a. An infusion of saline only.   
 
b. An infusion of saline only.  
 
 
c. An infusion of the hormone PYY.  The PYY infusion will commence 20 mins before 
the start of the scan and will continue for 90 mins. 
 
d. An infusion of the hormone GLP-1.  The GLP-1 infusion will commence 20 mins 
before the start of the scan and will continue for 90 mins. 
 
e. An infusion of the hormones PYY and GLP-1 together. This combined infusion will 
commence 20 mins before the start of the scan and will continue for 90 mins. 
 
On one of these five visits you will receive a breakfast.  On all of the other visits, you will be 
asked to remain fasting until after the scan. 
 
This is a randomised, single-blind trial. This means that after the initial acclimatisation visit, 
the remaining five visits can occur in any random order.  Furthermore, on any given study 
day you will not know whether you are being given hormone or saline.  The research doctor 
will know what you are receiving and will be monitoring your heart rate and blood pressure 
throughout the study. 
 
At the end of the brain scan you will be taken back to the nearby seating area. At the end of 
the infusion, you will be presented with a buffet meal and you will be asked to eat as much 
as you want of the meal until you feel comfortably full.  Before you leave you will also be 
asked to perform a recall exercise.  We will show you a selection of pictures and ask you 
which ones you recognise as being shown to you when you were in the scanner. 
 
Approximately 10 mins after the buffet meal, a final blood sample will be taken, after which 
you will be free to go home (about 3.5 hours after the cannulas were originally inserted).  At 
the end of the final visit you will also be asked to score how much you usually like to eat the 
foods in the pictures we showed you during the scans. 
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WHAT DO I HAVE TO DO? 
 
The only restrictions on your lifestyle are that you will be asked to have nothing to eat and 
only water to drink from 10pm on the night before the study days. You will need to keep a 
record of all food and drinks consumed in the three days before every study and for the 
twenty-four hours afterwards. For twenty-four hours before each study meal you will be 
asked to refrain from taking strenuous exercise and drinking alcohol. 
 
Female volunteers should have adequate contraception for the period of the study and for 
one month afterwards as the effects of gut hormones in pregnancy are not known. 
Pregnancy tests will be carried out to confirm that women of child bearing age are not 
pregnant on the morning before each study infusion. 
 
   
WHAT IS THE DRUG THAT IS BEING TESTED? 
 
PYY and GLP-1 are found naturally in the circulation of all healthy people. Both of these gut 
hormones have been used in several other studies in our department and worldwide, in men 
and women, without harmful effects. We have calculated the doses of PYY and GLP-1 that 
you will be given as the smallest possible dose known to induce changes in appetite, based 
on previous studies.  You will not be given a dose of hormone that will cause the level in 
your body to exceed levels found naturally.  
 
The MRI scans are being performed at the GSK Clinical Imaging Centre at Hammersmith 
Hospital.  This unit has been funded by GlaxoSmithKline in conjunction with Imperial College 
London, alongside a ten-year research agreement for medical imaging. This particular study 
is being run by doctors and scientists from Imperial College London.  
 
WHAT ARE THE SIDE EFFECTS OF TAKING PART? 
 
From our previous studies we do not expect any significant side effects.  Rarely, volunteers 
have experienced nausea after receiving these hormones.  This effect subsides very quickly 
when the drip is stopped.  You will always be able to communicate with one of the research 
doctors, even whilst you are in the scanner.  You can ask for the study to stop at any time, 
even without giving a reason. 
It is also possible, although very unlikely, that an unforeseen side effect occurs.  If this 
happens, the study will be stopped.  During the study, at least one experienced doctor will 
monitor you closely at all times. If you suffer from any ill effects during the study you should 
report them to the doctor monitoring you immediately. If you suffer from any ill effects 
afterwards you should report them to one of the research doctors on the 24 hour contact 
number given to you or when you next see them.  
 
MRI is a diagnostic body scanning technique, which is used in hospitals worldwide to create 
images of the inside of the body. MRI has been used safely for several decades and has no 
known side-effects.  
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WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? 
 
Gut hormones have been administered in several studies by our laboratory and therefore we 
do not anticipate any problems with the infusions. Insertion of the cannula (drip) into your 
arms on each of the study days may cause minor discomfort or superficial bruising. 
Magnetic resonance imaging (MRI) is a procedure that allows doctors to look inside the body 
by using a scanner that sends out a strong magnetic field and radio waves. MRI does not use 
X-rays. This procedure is used routinely for medical care and is very safe for most people, 
but you will be monitored during the entire MRI scan in case any problems do occur. The 
risks of having an MRI scan are:  
 
• The MRI scanner contains a very strong magnet. Therefore, you will not be able to have 
the MRI if you have any type of metal implanted in your body, for example, any pacing 
device (such as a heart pacemaker), any metal in your eyes, or certain types of heart 
valves or brain aneurysm clips. Someone will ask you questions about this before you 
have the MRI. 
 
• There is not much room inside the MRI scanner. You may be uncomfortable if you do not 
like to be in close spaces (“claustrophobia”). During the procedure, you will be able to 
talk to and hear the MRI staff through a speaker and earphone system, and, in the event 
of an emergency, you can tell them to stop the scan immediately. You will be closely 
monitored and repeatedly checked on to make sure you are as comfortable as possible. 
While your head is in the scanner, we will support it, so you can’t move it. If this upsets 
you, you will be able to signal and speak to the investigator and stop the scan through 
the use of a radio system and a signalling button. You will have the opportunity during 
the first MRI scan to ensure that you can tolerate having the scan before the next five 
scans are done. 
 
• The MRI produces a “hammering noise”. You will wear earplugs and headphones to 
prevent discomfort or damage to hearing. The headphones will also allow you to be able 
to hear us talk to you. 
 
• You will be fully awake during the MRI scan and will not be sedated at any time. We will 
make every effort to ensure your comfort during this experiment.  You will be 
communicating with us all the time you are in the scanner and you can ask for a break 
from the scanner at any time. 
 
It should be noted that the MRI brain scan cannot be viewed as a comprehensive health 
screening procedure. However, vary rarely, unexpected information can be detected which 
may warrant further investigation. In this event, you will be informed and a report will be 
sent to your GP, who will arrange further tests and coordinate your further care. In the rare 
event that we find a significant abnormality on your structural brain scan on the first visit 
this may exclude you from continuing with the rest of the study. 
 
 
It is possible that if the treatment is given to a pregnant woman it will harm the unborn 
child. Pregnant women must therefore not take part in this study; neither should women 
who plan to become pregnant during the study. Women who are at risk of pregnancy will be 
asked to have a pregnancy test before taking part, to exclude the possibility of pregnancy. 
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Women who could become pregnant must use an effective contraceptive during the course 
of this study. Any woman who finds that she has become pregnant while taking part in the 
study should immediately tell her research doctor. 
 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
 
The information that we get from this study will help us to better understand normal 
appetite regulation and may help us to better treat future patients who suffer from being 
overweight.  
If any of the screening questionnaires or blood tests reveal any medical problems (e.g. 
depression, diabetes, high cholesterol, thyroid, kidney or liver problems), your GP will be 
informed so that they can coordinate your further care, arrange any further tests, and refer 
you on to Hospital Doctors if necessary. 
 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE? 
 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied. If this happens, your research doctor will tell you 
about it and discuss with you whether you want to continue in the study. If you decide to 
continue in the study you will be asked to sign an updated consent form. Also, on receiving 
new information your research doctor might consider it to be in your best interests to 
withdraw you from the study.  
 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
 
Once the study has finished, the results of the study can be made available to you and/or 
your GP should you wish. If you have any problems immediately following the study, then 
you should contact one of the research doctors on the numbers provided below.  
 
 
WHAT IF SOMETHING GOES WRONG? 
 
Imperial College London holds insurance policies which apply to this study.  If you experience 
harm or injury as a result of taking part in this study, you may be eligible to claim 
compensation without having to prove that Imperial College is at fault.  This does not affect 
your legal rights to seek compensation. 
 
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of this study then you should immediately 
inform the Investigator (see contact details at the end).  The normal National Health Service 
complaint mechanisms are also available to you.  If you are still not satisfied with the 
response, you may contact the Imperial College Clinical Research Governance Office.   
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WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. 
It is a requirement that your GP is informed, with your consent, of your participation in this 
study, at the start of the study.     
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
 
The results are likely to be published in the year following the study. Your confidentiality will 
be ensured at all times and you will not be identified in any publication. At the end of the 
study, the results of the study can be made available to you and/or your GP should you wish.   
 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
This study is being organised and funded by the Department of Investigative Science of 
Imperial College School of Medicine. 
 
 
PAYMENT 
 
You will receive a fixed payment to cover expenses including travel costs. This sum of £100 
for each injection visit will be paid when you have completed your visits. 
 
 
WHO HAS REVIEWED THE STUDY? 
 
This study has been reviewed by the St Mary’s Hospitals Research Ethics Committee.  
Reference number 09/H0712/4um, 
 
 
CONTACT FOR FURTHER INFORMATION 
 
If you experience any problems during the study, you may withdraw at any stage. The 
doctors involved in the study, Dr Salem and Dr de Silva, will be available by telephone during 
working hours (020 8383 2820).  The hospital switchboard (020 8383 1000) has full contact 
details for all the doctors involved in the study and can reach them at any time outside 
normal working hours. 
 
If you agree to take part in the trial, you will also be given the mobile phone numbers of the 
doctors. 
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APPENDIX V – DETAILED NUTRITIONAL BREAKDOWN OF THE SET BREAKFAST 
SERVED ON ALL “FED” VISITS 
 
 
All participants were asked to eat the breakfast in its entirety and there was no 
instance (any subject on any “fed” visit) of this request not being complied with. 
 
 
 
 
 
 
 
 
Values for Breakfast portions 
     
       WEIGHT 
(g) MENU Protein Fat CHO Kcal KJ 
40 Bran Flakes (Kellogs) 4 0.8 26.8 130   
170 Semi-skimmed milk (Sainsburys) 5.78 2.89 8.5 83.3 350.2 
220 Orange Juice 1.1 0 20.02 92.4 391.6 
80 Wholmeal Bread (Hovis) 8 2.16 30.24 172.8 730.4 
20 Margarine (flora original) 0 11.8 0 106 436 
20 Jam (Robertson strawberry) 0 0 13.4 53.6 227.8 
25 
Cheese (2 x Leerdamer original 
slices) 6.75 7 0 89.5 372.5 
       
 
Total 25.63 24.65 98.96 727.6 2508.5 
 
% Composition 14.1 30.5 51.0 
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